

ABRYSVO

Products Affected

- ABRYSVO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | Non-pregnant individuals: 60 years of age or older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 months |
| Other Criteria | The patient has not already received an RSV vaccine. For Pregnant Individuals: patient is between 32 through 36 weeks gestational age |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ACTHAR

Products Affected

- ACTHAR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Coverage is not provided for diagnostic procedure. |
| Required Medical Information | Diagnosis, prescriber or consulting physician specialty, previous medications tried and response |
| Age Restrictions | Infantile spasms- less than 2yo. Acute MS exac-adult |
| Prescriber Restrictions | Infant spasms, prescr physician who consulted w/specializes in neurology. MS exacer, prescr/consult w/neuro/phys specializes MS.RA, JIA/JRA, AS, PsA, SLE, Systemic Dermatomyositis, prescr/consult w/rheum.Severe Erythema Multiforme, prescr/consult w/derm.Serum Sickness,prescr/consult w/allergist.Severe acute/chronic allergic/inflamm processes of eye and its adnexa, prescr/consult w/ ophthalmologist.Symptomatic Sarcoidosis, prescr/consult w/pulm/cardio.Nephrotic Syndrome, prescr/consult w/nephro. |
| Coverage Duration | All diagnoses-1 month |
| Other Criteria | For acute MS exacerbation, approve if Acthar is NOT being used as pulse therapy on a monthly basis. For all other FDA approved diagnoses (other than Infantile spasms or MS exacerbation), approve if the patient has tried a systemic corticosteroid for the current condition and patient has experienced a severe adverse effect or treatment failure with the corticosteroid (e.g., a psychotic reaction). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ACTIMMUNE

Products Affected

- ACTIMMUNE

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ADEMPAS

Products Affected

- ADEMPAS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent Use with Phosphodiesterase Inhibitors Used for Pulmonary Hypertension or Other Soluble Guanylate Cyclase Stimulators. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | PAH and CTEPH- must be prescribed by or in consultation with a cardiologist or a pulmonologist. |
| Coverage Duration | 1 year |
| Other Criteria | For PAH - must have PAH (WHO Group 1) and had a right heart catheterization to confirm the diagnosis of PAH (WHO Group 1). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

AIMOVIG

Products Affected

- AIMOVIG AUTOINJECTOR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Combination therapy with Ajoovy, Vyepti or Emgality |
| Required Medical Information | Diagnosis, number of migraine headaches per month, prior therapies tried |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Approve if the patient meets the following criteria (A and B): A) Patient has greater than or equal to 4 migraine headache days per month (prior to initiating a migraine-preventative medication), AND B) Patient has tried at least one standard prophylactic pharmacologic therapy (e.g., anticonvulsant, beta-blocker) and has had inadequate response or the patient has a contraindication to other prophylactic pharmacologic therapies according to the prescribing physician. A patient who has already tried an oral or injectable calcitonin gene-related peptide (CGRP) inhibitor indicated for the prevention of migraine or Botox (onabotulinumtoxinA injection) for the prevention of migraine is not required to try two standard prophylactic pharmacologic therapies. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

AJOVY

Products Affected

- AJOVY AUTOINJECTOR
- AJOVY SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Combination therapy with Aimovig, Vyepti or Emgality |
| Required Medical Information | Diagnosis, number of migraine headaches per month, prior therapies tried |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Approve if the patient meets the following criteria (A and B): A) Patient has greater than or equal to 4 migraine headache days per month (prior to initiating a migraine-preventative medication), AND B) Patient has tried at least one standard prophylactic pharmacologic therapy (e.g., anticonvulsant, beta-blocker) and has had inadequate response or the patient has a contraindication to other prophylactic pharmacologic therapies according to the prescribing physician. A patient who has already tried an oral or injectable calcitonin gene-related peptide (CGRP) inhibitor indicated for the prevention of migraine or Botox (onabotulinumtoxinA injection) for the prevention of migraine is not required to try two standard prophylactic pharmacologic therapies. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

AKEEGA

Products Affected

- AKEEGA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Prostate cancer- Approve if the patient meets the following (A, B, C, and D): A)Patient has metastatic castration-resistant prostate cancer, AND B)Patient has a BReast CAncer (BRCA) mutation, AND C)The medication is used in combination with prednisone, AND D)Patient meets one of the following (i or ii): i. The medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog, Note: Examples are leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant), Vantas (histrelin acetate subcutaneous implant), Firmagon (degarelix acetate subcutaneous injection), and Orgovyx (relugolix tablets).OR ii. Patient has had a bilateral orchiectomy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ALDURAZYME

Products Affected

- ALDURAZYME

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, genetic and lab test results |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders |
| Coverage Duration | 1 year |
| Other Criteria | Approve if the patient has a laboratory test demonstrating deficient alpha-L-iduronidase activity in leukocytes, fibroblasts, plasma, or serum OR has a molecular genetic test demonstrating alpha-L-iduronidase gene mutation |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ALECENSA

Products Affected

- ALECENSA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Non-small cell lung cancer-approve if the patient has advanced or metastatic disease and anaplastic lymphoma kinase (ALK)-positive disease as detected by an approved test. Anaplastic large cell lymphoma-approve if the patient has anaplastic lymphoma kinase (ALK)-positive disease and (i or ii): (i) the medication is used for palliative-intent therapy, or (ii) pt has relapsed or refractory disease. Erdheim-Chester disease-approve if the patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease. Inflammatory Myofibroblastic Tumor- pt has anaplastic lymphoma kinase (ALK)-positive disease AND (i or ii): (i) pt has advanced, recurrent or metastatic disease, or (ii) tumor is inoperable. Large B-Cell Lymphoma- pt has ALK-positive disease AND pt has relapsed or refractory disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Anaplastic large cell lymphoma, Erdheim Chester disease, Inflammatory Myofibroblastic Tumor, Large B-Cell Lymphoma |
| Part B Prerequisite | No |

ALOSETRON

Products Affected

- *alosetron*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Alosetron will not be approved for use in men, as safety and efficacy in men has not been established. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | Alosetron is considered medically necessary for the treatment of severe IBS-D. At least one of the following must be present for diarrhea to be considered severe: frequent and severe abdominal pain or discomfort, frequent bowel urgency or fecal incontinence, and disability or restriction of daily activities due to IBS. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ALPHA 1 PROTEINASE INHIBITORS

Products Affected

- ARALAST NP
- GLASSIA
- PROLASTIN-C
- ZEMAIRA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Alpha1-Antitrypsin Deficiency with Emphysema (or Chronic Obstructive Pulmonary Disease)-approve if the patient has a baseline (pretreatment) AAT serum concentration of less than 80 mg/dL or 11 micromol/L |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ALUNBRIG

Products Affected

- ALUNBRIG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | ALK status |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Erdheim-Chester disease-approve if the patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease. Inflammatory myofibroblastic tumor (IMT)-approve if the patient has ALK positive disease and has advanced, recurrent or metastatic disease or the tumor is inoperable. NSCLC, must be ALK-positive, as detected by an approved test, have advanced or metastatic disease and patients new to therapy must have a trial of Alecensa prior to approval of Alunbrig. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Erdheim-Chester disease, Inflammatory myofibroblastic tumor (IMT) |
| Part B Prerequisite | No |

AMBRISENTAN

Products Affected

- *ambrisentan*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Pulmonary arterial hypertension (PAH) WHO Group 1-results of right heart cath |
| Age Restrictions | N/A |
| Prescriber Restrictions | For treatment of pulmonary arterial hypertension, ambrisentan must be prescribed by or in consultation with a cardiologist or a pulmonologist. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Pulmonary arterial hypertension (PAH) WHO Group 1, are required to have had a right-heart catheterization to confirm diagnosis of PAH to ensure appropriate medical assessment. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ANTIBIOTICS (INJECTABLE)

Products Affected

- *amikacin injection solution 1,000 mg/4 ml, 500 mg/2 ml*
- *ampicillin sodium*
- *ampicillin-sulbactam*
- *azithromycin intravenous*
- *aztreonam*
- BICILLIN L-A
- CEFEPIME INTRAVENOUS
- *cefoxitin*
- *cefoxitin in dextrose, iso-osm*
- *ceftazidime*
- *cefuroxime sodium injection recon soln 750 mg*
- *cefuroxime sodium intravenous*
- *ciprofloxacin in 5 % dextrose*
- CLINDAMYCIN IN 0.9 % SOD CHLOR
- *clindamycin in 5 % dextrose*
- *clindamycin phosphate injection*
- *colistin (colistimethate na)*
- *doxy-100*
- *doxycycline hyclate intravenous*
- ERYTHROCIN INTRAVENOUS RECON SOLN 500 MG
- *gentamicin in nacl (iso-osm) intravenous piggyback 100 mg/100 ml, 60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml*
- GENTAMICIN IN NAACL (ISO-OSM) INTRAVENOUS PIGGYBACK 100 MG/50 ML, 120 MG/100 ML
- *gentamicin injection solution 40 mg/ml*
- *gentamicin sulfate (ped) (pf)*
- *levofloxacin in d5w*
- *levofloxacin intravenous*
- *lincomycin*
- *linezolid in dextrose 5%*
- *linezolid-0.9% sodium chloride*
- *metro i.v.*
- *metronidazole in nacl (iso-os)*
- MOXIFLOXACIN-SOD.ACE,SUL-WATER
- *moxifloxacin-sod.chloride(iso)*
- *nafcillin in dextrose iso-osm*
- *nafcillin injection*
- *nafcillin intravenous recon soln 2 gram*
- NUZYRA INTRAVENOUS
- ORBACTIV
- *oxacillin injection*
- *penicillin g potassium*
- *pfizerpen-g*
- *polymyxin b sulfate*
- SIVEXTRO INTRAVENOUS
- STREPTOMYCIN
- *sulfamethoxazole-trimethoprim intravenous*
- *tazicef*
- TEFLARO
- *tigecycline*
- *tobramycin sulfate*

| PA Criteria | Criteria Details |
|------------------------------|------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------------|
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 months |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ANTIFUNGALS (IV)

Products Affected

- *caspofungin*
- *fluconazole in nacl (iso-osm)*
- *voriconazole intravenous*

| PA Criteria | Criteria Details |
|------------------------------|-------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 months |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ANTIFUNGALS, POLYENE

Products Affected

- ABELCET
- *amphotericin b*
- *amphotericin b liposome*

| PA Criteria | Criteria Details |
|------------------------------|-------------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 6 months |
| Other Criteria | B vs D coverage determination |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ANTINEOPLASTICS, MONOCLONAL ANTIBODIES

Products Affected

- ABRAXANE
- ADCETRIS
- *adstiladrin*
- ALIQOPA
- BAVENCIO
- BESPONSA
- BLENREP
- BORTEZOMIB INJECTION RECON SOLN 1 MG, 2.5 MG
- *bortezomib injection recon soln 3.5 mg*
- BORTEZOMIB INTRAVENOUS RECON SOLN
- COLUMVI
- CYRAMZA
- DANYELZA
- DARZALEX
- DARZALEX FASPRO
- ELREXFIO
- ELZONRIS
- EMPLICITI
- ENHERTU
- EPKINLY
- EVOMELA
- FYARRO
- GAZYVA
- HALAVEN
- IMFINZI
- IMJUDO
- JEMPERLI
- KADCYLA
- KEYTRUDA
- KIMMTRAK
- LIBTAYO
- LUNSUMIO
- MARGENZA
- MONJUVI
- MYLOTARG
- ONIVYDE
- OPDIVO
- OPDUALAG
- PACLITAXEL PROTEIN-BOUND
- PADCEV
- *pemetrexed disodium intravenous recon soln*
- PERJETA
- PHESGO
- POLIVY
- POTELIGEO
- RUXIENCE
- RYBREVANT
- SARCLISA
- TALVEY
- TECENTRIQ
- TECVAYLI
- *thiotepa*
- TIVDAK
- TRAZIMERA
- TRODELVY
- UNITUXIN
- VECTIBIX
- YERVOY
- YONDELIS
- ZEPZELCA
- ZIRABEV
- ZYNLONTA
- ZYNYZ

| PA Criteria | Criteria Details |
|--------------------|------------------|
| Exclusion Criteria | N/A |

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | B vs D coverage determination |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ARANESP

Products Affected

- ARANESP (IN POLYSORBATE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML, 25 MCG/ML, 40 MCG/ML, 60 MCG/ML
- ARANESP (IN POLYSORBATE) INJECTION SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Anemia w/CRF not on dialysis. A hemoglobin (Hb) of less than 10.0 g/dL for adults and less than or equal to 11 g/dL for children required for start, Hb has to be less than or equal to 11.5 g/dL adults or less than or equal to 12 g/dL in children if previously receiving epoetin alfa (EA), Mircera or Aranesp. Anemia in a patient with cancer due to cancer chemotherapy, patients must be currently receiving myelosuppressive chemotherapy which is considered non-curative treatment, Hb is 10.0 g/dL or less to start or less than or equal to 12.0 g/dL if previously on EA or Aranesp. MDS, approve tx if Hb is 10 g/dL or less or serum erythropoietin level is 500 mU/mL or less to start. If the pt has previously been receiving Aranesp or EA, approve only if Hb is 12.0 g/dL or less. All conds, deny if Hb exceeds 12.0 g/dL. |
| Age Restrictions | MDS anemia = 18 years of age and older. |
| Prescriber Restrictions | MDS anemia, prescribed by or in consultation with, a hematologist or oncologist. |
| Coverage Duration | Anemia w/myelosupp=6 mos, Anemia CKD(dialysis)-3 years, no dialysis, MDS-1 year, Other=6 mos. |
| Other Criteria | For anemia associated with CRF in patients on dialysis deny under Medicare Part D (claim should be submitted under the ESRD bundled payment benefit). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Anemia due to myelodysplastic syndrome (MDS) |
| Part B Prerequisite | No |

ARCALYST

Products Affected

- ARCALYST

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent biologic therapy |
| Required Medical Information | N/A |
| Age Restrictions | Initial tx CAPS/Pericarditis-Greater than or equal to 12 years of age. |
| Prescriber Restrictions | Initial tx CAPS-prescribed by, or in consultation with, a rheumatologist, geneticist, allergist/immunologist, or dermatologist. DIRA initial-rheum, geneticist, dermatologist, or a physician specializing in the treatment of autoinflammatory disorders. Pericarditis-cardiologist or rheum |
| Coverage Duration | CAPS-3 mos initial, 1 yr cont. DIRA-6 mos initial, 1 yr cont. Pericard-3 mos initial, 1 yr cont |
| Other Criteria | CAPS renewal - approve if the patient has had a response as determined by the prescriber. DIRA initial-approve if the patient weighs at least 10 kg, genetic test confirms a mutation in the IL1RN gene and the patient has demonstrated a clinical benefit with anakinra subcutaneous injection. DIRA cont-approve if the patient has responded to therapy. Pericarditis initial-approve if the patient has recurrent pericarditis AND for the current episode, the patient is receiving standard treatment or standard treatment is contraindicated. Continuation-approve if the patient has had a clinical response. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

AREXVY

Products Affected

- AREXVY (PF)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 60 years of age or older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 months |
| Other Criteria | The patient has not already received an RSV vaccine |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ARIKAYCE

Products Affected

- ARIKAYCE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, previous medication history (as described in Other Criteria field) |
| Age Restrictions | MAC-18 years and older (initial therapy) |
| Prescriber Restrictions | MAC initial-Prescribed by a pulmonologist, infectious disease physician or a physician who specializes in the treatment of MAC lung infections. Cystic fibrosis-prescribed by or in consultation with a pulmonologist or physician who specializes in the treatment of cystic fibrosis |
| Coverage Duration | 1 year |
| Other Criteria | MAC Lung disease, initial-approve if the patient has a positive sputum culture for mycobacterium avium complex and the culture was collected within the past 3 months and was collected after the patient has completed a background multidrug regimen, the Mycobacterium avium complex isolate is susceptible to amikacin according to the laboratory report AND Arikayce will be used in conjunction to a background multidrug regimen. Note-a multidrug regimen typically includes a macrolide (azithromycin or clarithromycin), ethambutol and a rifamycin (rifampin or rifabutin). MAC Lung Disease, continuation-approve if Arikayce will be used in conjunction with a background multidrug regimen AND i. Patient meets ONE of the following criteria (a or b):a)patient has not achieved negative sputum cultures for Mycobacterium avium complex OR b) patient has achieved negative sputum cultures for Mycobacterium avium complex for less than 12 months. Cystic fibrosis-patient has pseudomonas aeruginosa in culture of the airway. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Cystic fibrosis pseudomonas aeruginosa infection |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

ARMODAFINIL

Products Affected

- *armodafinil*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | Excessive daytime sleepiness associated with narcolepsy-prescribed by or in consultation with a sleep specialist physician or neurologist |
| Coverage Duration | Authorization will be for 12 months. |
| Other Criteria | Excessive sleepiness associated with Shift Work Sleep Disorder (SWSD) - approve if the patient is working at least 5 overnight shifts per month. Excessive daytime sleepiness associated with obstructive sleep apnea/hypoapnea syndrome-approve. Excessive daytime sleepiness associated with Narcolepsy-approve if narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ATYPICAL ANTIPSYCHOTIC

Products Affected

- FANAPT
- LYBALVI
- *paliperidone*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Approve if the patient has tried two of the following: olanzapine, quetiapine fumarate, risperidone, ziprasidone. Approve requests for paliperidone ER in Schizoaffective Disorder without the trial of other treatment. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

AUBAGIO

Products Affected

- AUBAGIO
- *teriflunomide*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use of Aubagio (teriflunomide) with other disease-modifying agents used for multiple sclerosis (MS) |
| Required Medical Information | Relapsing form of MS, to include, clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist or MS specialist. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Cont tx - approve if the patient has been established on Aubagio (teriflunomide). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

AUGTYRO

Products Affected

- AUGTYRO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Non-Small Cell Lung Cancer-approve if the patient has locally advanced or metastatic disease, patient has ROS1-positive non-small cell lung cancer and the mutation was detected by an approved test. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

AUSTEDO

Products Affected

- AUSTEDO
- AUSTEDO XR
- AUSTEDO XR TITRATION KT(WK1-4)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | Chorea-prescribed by or in consult with a neuro. TD-Prescribed by or in consultation with a neurologist or a psychiatrist |
| Coverage Duration | 1 year |
| Other Criteria | Chorea associated with Huntington's Disease-approve if the diagnosis of Huntington's Disease is confirmed by genetic testing. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

AVONEX

Products Affected

- AVONEX

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use of other disease-modifying agent used for multiple sclerosis |
| Required Medical Information | Relapsing form of Multiple Sclerosis (MS), to include, clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or after consultation with a neurologist or an MS specialist. |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | Cont tx-approve if the patient has been established on Avonex. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

AYVAKIT

Products Affected

- AYVAKIT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | GIST-approve if the tumor is positive for platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation or if the patient has tried two of the following: Gleevec (imatinib), Sutent (sunitinib), Sprycel (dasatinib), Stivarga (regorafenib) or Qinlock (ripretinib). Myeloid/Lymphoid Neoplasms with eosinophilia-approve if the tumor is positive for PDGFRA D842V mutation. Systemic mastocytosis-Approve if the patient has a platelet count greater than or equal to 50,000/mcL and patient has either indolent systemic mastocytosis or one of the following subtypes of advanced systemic mastocytosis-aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm or mast cell leukemia. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Myeloid/Lymphoid neoplasms with Eosinophilia |
| Part B Prerequisite | No |

BALVERSA

Products Affected

- BALVERSA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, previous therapies, test results |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Urothelial Carcinoma, locally advanced or metastatic-approve if the patient has susceptible fibroblast growth factor receptor 3 or fibroblast growth factor receptor 2 genetic alterations AND the patient has progressed during or following prior platinum-containing chemotherapy or checkpoint inhibitor therapy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

BENLYSTA

Products Affected

- BENLYSTA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent Use with Other Biologics or Lupkynis |
| Required Medical Information | Diagnosis, medications that will be used in combination, autoantibody status |
| Age Restrictions | 18 years and older (initial). |
| Prescriber Restrictions | SLE-Prescribed by or in consultation with a rheumatologist, clinical immunologist, nephrologist, neurologist or dermatologist (initial and continuation). Lupus Nephritis-nephrologist or rheum. (Initial/cont) |
| Coverage Duration | SLE-Initial-4 months, cont-1 year, Lupus Nephritis-6 mo initial, 1 year cont |
| Other Criteria | <p>Lupus Nephritis Initial-approve if the patient has a diagnosis of lupus nephritis confirmed on biopsy (For example, World Health Organization class III, IV, or V lupus nephritis), AND the medication is being used concurrently with an immunosuppressive regimen (ex: azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate mofetil and/or a systemic corticosteroid). Cont-approve if the medication is being used concurrently with an immunosuppressive regimen (ex: azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate mofetil and/or a systemic corticosteroid) AND the patient has responded to the requested medication.</p> <p>SLE-Initial-The patient has autoantibody-positive SLE, defined as positive for antinuclear antibodies [ANA] and/or anti-double-stranded DNA antibody [anti-dsDNA] AND Benlysta is being used concurrently with at least one other standard therapy (i.e., antimalarials [e.g., hydroxychloroquine], a systemic corticosteroid [e.g., prednisone], and/or other immunosuppressants [e.g., azathioprine, mycophenolate mofetil, methotrexate]) unless the patient is determined to be intolerant due to a significant toxicity, as determined by the prescribing physician.</p> <p>Continuation-Benlysta is being used concurrently with at least one other standard therapy (i.e., antimalarials [e.g., hydroxychloroquine], a systemic corticosteroid [e.g., prednisone], and/or other immunosuppressants [e.g., azathioprine, mycophenolate mofetil, methotrexate]) unless the patient is</p> |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | determined to be intolerant due to a significant toxicity, as determined by the prescribing physician AND The patient has responded to Benlysta as determined by the prescriber. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

BESREMI

Products Affected

- BESREMI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use with other interferon products |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | Prescribed by or in consultation with a hematologist or an oncologist |
| Coverage Duration | 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

BETASERON

Products Affected

- BETASERON SUBCUTANEOUS KIT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with other disease-modifying agent used for multiple sclerosis |
| Required Medical Information | Relapsing form of Multiple Sclerosis (MS), to include, clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or after consultation with a neurologist or an MS specialist. |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

BEXAROTENE (ORAL)

Products Affected

- *bexarotene*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an oncologist or dermatologist (initial and continuation) |
| Coverage Duration | 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

BOSENTAN

Products Affected

- *bosentan*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Pulmonary arterial hypertension (PAH) WHO Group 1, results of right heart cath |
| Age Restrictions | N/A |
| Prescriber Restrictions | For treatment of pulmonary arterial hypertension, bosentan must be prescribed by or in consultation with a cardiologist or a pulmonologist. CTEPH-prescribed by or in consultation with a cardiologist or pulmonologist |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | CTEPH - pt must have tried Adempas, has a contraindication to Adempas, or is currently receiving bosentan for CTEPH. Pulmonary arterial hypertension (PAH) WHO Group 1, are required to have had a right-heart catheterization to confirm diagnosis of PAH to ensure appropriate medical assessment. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Chronic thromboembolic pulmonary hypertension (CTEPH) (bosentan) |
| Part B Prerequisite | No |

BOSULIF

Products Affected

- BOSULIF

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis. For CML/ALL, the Philadelphia chromosome (Ph) status of the leukemia must be reported. For ALL prior therapies tried. |
| Age Restrictions | CML- 1 year and older. ALL, myeloid/lymphoid neoplasms w eosinophilia- 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | For Ph-positive CML-patients new to therapy must have tried Sprycel and had an inadequate response or significant intolerance or have a contraindication or are not a candidate for Sprycel. For Ph-positive ALL, patients new to therapy must have tried Sprycel and had an inadequate response or significant intolerance or have a contraindication or are not a candidate for Sprycel. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients with Philadelphia chromosome positive Acute Lymphoblastic Leukemia, myeloid/lymphoid neoplasms with eosinophilia |
| Part B Prerequisite | No |

BOTOX

Products Affected

- BOTOX

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | cosmetic uses (eg, facial rhytides, frown lines, glabellar wrinkling, horizontal neck rhytides, mid and lower face and neck rejuvenation, platysmal bands, rejuvenation of the peri-orbital region) |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Migraine headache prevention if prescribed by, or after consultation with, a neurologist or HA specialist. |
| Coverage Duration | Authorization will be for 12 months |
| Other Criteria | Blepharospasm Associated with Dystonia, benign essential blepharospasm, seventh (VII) nerve disorder or Strabismus-approve. Cervial Dystonia (spasmodic torticollis)-approve. Hyperhidrosis, primary axillary-approve. Chronic low back pain after trial with at least 2 other pharmacologic therapies (eg, NSAID, antispasmodics, muscle relaxants, opioids, antidepressants) and if being used as part of a multimodal therapeutic pain management program. Essential tremor after a trial with at least 1 other pharmacologic therapy (eg, primidone, propranolol, benzodiazepines, gabapentin, topiramate). Migraine Headache prevention -must have 15 or more migraine headache days per month with headache lasting 4 hours per day or longer (prior to initiation of Botox therapy) AND have tried at least two other prophylactic pharmacologic therapies, each from a different pharmacologic class (e.g., beta-blocker, anticonvulsant, tricyclic antidepressant) and experienced inadequate efficacy or adverse events severe enough to warrant discontinuation of both therapies. If the patient is currently taking Botox for migraine headache prevention, patient must have had a significant clinical benefit. Urinary incontinence associated with a neurological condition (e.g., spinal cord injury, multiple sclerosis) approve after a trial with at least one other pharmacologic therapy (e.g., anticholinergic medication). Overactive Bladder with symptoms of Urge Urinary Incontinence, Urgency and Frequence-approve if the patient has |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | tried at least one other pharmacologic therapy. Spasticity, limb-approve. Pediatric Neurogenic Detrusor Overactivity (NDO)- approve if pt tried at least one other pharmacologic therapy. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Achalasia, Anal Fissure, Chronic facial pain/pain associated with TMJ dysfunction, Chronic low back pain, Hyperhidrosis (Palmar/Plantar, facial), Myofascial pain, Sialorrhea (chronic), Spasticity (other than lower and upper limb (eg, due to cerebral palsy, stroke, brain injury, spinal cord injury, MS, hemifacial spasm)), Essential tremor, Dystonia other than cervical (eg, focal dystonias, tardive dystonia, anismus, laryngeal dystonia/spasmodic dysphonia) Hyperhidrosis -Gustatory (Frey's Syndrome), Ophthalmic disorders (other than blepharospasm or Strabismus (eg, esotropia, exotropia, nystagmus, facial nerve paresis)) |
| Part B Prerequisite | No |

BRAFTOVI

Products Affected

- BRAFTOVI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, BRAF V600 status |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Melanoma - approve if the patient has unresectable, advanced or metastatic melanoma AND has a BRAF V600 mutation. Colon or Rectal cancer- approve if the patient meets the following (A, B, and C): A) The patient has BRAF V600E mutation-positive disease AND B) The patient has previously received a chemotherapy regimen for colon or rectal cancer AND C) The agent is prescribed as part of a combination regimen for colon or rectal cancer. NSCLC- approve if pt has BRAF V600E mutation-positive metastatic disease AND this medication will be taken in combination with Mektovi (binimetinib tablets). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

BRIUMVI

Products Affected

- BRIUMVI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with other Disease-Modifying Agents used for MS |
| Required Medical Information | N/A |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | Prescribed by, or in consultation with, a physician who specializes in the treatment of MS and/or a neurologist |
| Coverage Duration | 1 year |
| Other Criteria | For relapsing remitting disease - patient must have tried and failed two other MS therapies |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

BRUKINSA

Products Affected

- BRUKINSA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, prior therapies |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Mantle Cell Lymphoma - approve if the patient has tried at least one systemic regimen or patient is not a candidate for a systemic regimen (i.e., an elderly patient who is frail) . Chronic lymphocytic leukemia/small lymphocytic lymphoma-approve. Marginal zone lymphoma-approve if the patient has tried at least one systemic regimen. Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma-approve. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

CABOMETYX

Products Affected

- CABOMETYX

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, histology, RET gene rearrangement status for NSCLC |
| Age Restrictions | Thyroid carcinoma-12 years and older, other dx (except bone cancer)-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Renal Cell Carcinoma-Approve if the patient has relapsed or stage IV disease. Bone cancer-approve if the patient has Ewing sarcoma or osteosarcoma and has tried at least one previous systemic regimen. Thyroid carcinoma-approve if the patient has differentiated thyroid carcinoma, patient is refractory to radioactive iodine therapy and the patient has tried a vascular endothelial growth factor receptor (VEGFR)-targeted therapy. Endometrial carcinoma-approve if the patient has tried one systemic regimen. GIST-approve if the patient has tried two of the following- imatinib, Ayvakit, sunitinib, dasatinib, Stivarga or Qinlock. NSCLC-approve if the patient has RET rearrangement positive tumor. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients with Non-Small Cell Lung Cancer, Gastrointestinal stromal tumors (GIST), Bone cancer, Endometrial Carcinoma |
| Part B Prerequisite | No |

CALQUENCE

Products Affected

- CALQUENCE
- CALQUENCE (ACALABRUTINIB MAL)

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | CLL and SLL-approve. Mantle Cell Lymphoma- approve if the patient has tried at least one systemic regimen or is not a candidate for a systemic regimen (e.g., rituximab, dexamethasone, cytarabine, carboplatin, cisplatin, oxaliplatin, cyclophosphamide, doxorubicin, vincristine, prednisone, methotrexate, bendamustine, bortezomib, or lenalidomide). Marginal Zone Lymphoma-approve if patient has tried at least one systemic regimen (e.g., bendamustine, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, lenalidomide, or chlorambucil). Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma-approve if the patient has tried at least one systemic regimen (e.g., Brukinsa [zanubrutinib capsules], Imbruvica [ibrutinib tablets and capsules], rituximab, bendamustine, cyclophosphamide, dexamethasone, bortezomib, fludarabine, or cladribine) |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Marginal zone lymphoma. |
| Part B Prerequisite | No |

CAPRELSA

Products Affected

- CAPRELSA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | MTC - approve. DTC - approve if refractory to radioactive iodine therapy. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Differentiated (i.e., papillary, follicular, and Hurthle) Thyroid Carcinoma. |
| Part B Prerequisite | No |

CARGLUMIC ACID

Products Affected

- CARBAGLU
- *carglumic acid*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a metabolic disease specialist or a specialist who focuses in the treatment of metabolic diseases |
| Coverage Duration | NAGS-Pt meets criteria no genetic test-3 mo. Pt had genetic test-12 mo, other-approve 7 days |
| Other Criteria | N-Acetylglutamate synthase deficiency with hyperammonemia-Approve if genetic testing confirmed a mutation leading to N-acetylglutamate synthase deficiency or if the patient has hyperammonemia. Propionic Acidemia or Methylmalonic Acidemia with Hyperammonemia, Acute Treatment-approve if the patient's plasma ammonia level is greater than or equal to 50 micromol/L and the requested medication will be used in conjunction with other ammonia-lowering therapies. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA) (generic carglumic acid) |
| Part B Prerequisite | No |

CAYSTON

Products Affected

- CAYSTON

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a pulmonologist or a physician who specializes in the treatment of cystic fibrosis. |
| Coverage Duration | 1 year |
| Other Criteria | Approve if the patient has <i>Pseudomonas aeruginosa</i> in culture of the airway (e.g., sputum culture, oropharyngeal culture, bronchoalveolar lavage culture). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

CEREZYME

Products Affected

- CEREZYME INTRAVENOUS RECON
SOLN 400 UNIT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, genetic tests and lab results |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorder |
| Coverage Duration | 1 year |
| Other Criteria | Gaucher Disease, Type 1-approve if there is demonstration of deficient beta-glucocerebrosidase activity in leukocytes or fibroblasts OR molecular genetic testing documenting glucocerebrosidase gene mutation |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

CHEMET

Products Affected

- CHEMET

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Blood lead level |
| Age Restrictions | Approve in patients between the age of 12 months and 18 years |
| Prescriber Restrictions | Prescribed by or in consultation with a professional experienced in the use of chelation therapy (eg, a medical toxicologist or a poison control center specialist) |
| Coverage Duration | Approve for 2 months |
| Other Criteria | Approve if Chemet is being used to treat acute lead poisoning (not as prophylaxis) and prior to starting Chemet therapy the patient's blood lead level was greater than 45 mcg/dL. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

CHORIONIC GONADOTROPIN

Products Affected

- CHORIONIC GONADOTROPIN, HUMAN INTRAMUSCULAR
- NOVAREL INTRAMUSCULAR RECON SOLN 5,000 UNIT
- PREGNYL

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

CIALIS

Products Affected

- CIALIS ORAL TABLET 2.5 MG, 5 MG • *tadalafil oral tablet 2.5 mg, 5 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | Cialis (tadalafil) 2.5mg and 5mg are only covered under Part D for the treatment of benign prostatic hyperplasia (BPH). Cialis (tadalafil) can be approved with a non-D authorization for the indication of erectile dysfunction if the EGWP customer has the lifestyle buy-up |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

CIMZIA

Products Affected

- CIMZIA
- CIMZIA POWDER FOR RECONST
- CIMZIA STARTER KIT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with biologic therapy or targeted synthetic DMARD |
| Required Medical Information | Diagnosis, concurrent medications, previous therapies tried. |
| Age Restrictions | 18 years and older for CD and PP (initial therapy). |
| Prescriber Restrictions | All dx initial therapy only-RA/AS, prescribed by or in consultation with a rheumatologist. Crohn's disease, prescribed by or in consultation with a gastroenterologist. PsA prescribed by or in consultation with a rheumatologist or dermatologist. PP, prescribed by or in consultation with a dermatologist. nr-axSpA-prescribed by or in consultation with a rheumatologist |
| Coverage Duration | End of the plan year |
| Other Criteria | AS, approve if the patient has tried two of the following: TNF, JAK or biologic. RA, approve if the patient has tried two of the following: TNF, JAK or biologic. PsA, approve if the patient has tried two of the following: TNF, JAK or biologic. PP, approve if the patient has tried two of the following: TNF, JAK or biologic. CD, approve if patient has previously tried two of the following: TNF, JAK or biologic. Non-radiographic axial spondylitis (nr-axSpA)-approve if the patient has objective signs of inflammation, defined as at least one of the following: C-reactive protein (CRP) elevated beyond the upper limit of normal for the reporting laboratory OR sacroiliitis reported on MRI. Continuation-approve if the patient has had a response as determined by the prescriber. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

CLOBAZAM

Products Affected

- *clobazam*
- SYMPAZAN

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, other medications tried |
| Age Restrictions | 2 years and older (initial therapy) |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist (initial therapy) |
| Coverage Duration | 1 year |
| Other Criteria | Lennox-Gastaut Syndrome, initial therapy-patient has tried and/or is concomitantly receiving one of the following: lamotrigine, topiramate, rufinamide, felbamate, Fintepla, Epidiolex or valproic acid. Treatment refractory seizures/epilepsy, initial therapy-patient has tried and/or is concomitantly receiving at least two other antiepileptic drugs (e.g., valproic acid, lamotrigine, topiramate, clonazepam, levetiracetam, zonisamide, felbamate). Continuation-prescriber confirms patient is responding to therapy. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Dravet Syndrome and treatment-refractory seizures/epilepsy |
| Part B Prerequisite | No |

CLOMIPHENE

Products Affected

- *clomiphene citrate*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Clomiphene can be approved with a non-D authorization for the indication of infertility if the EGWP customer has the fertility buy-up |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

COMETRIQ

Products Affected

- COMETRIQ

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis. |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | MTC - approve. Non-Small Cell Lung Cancer with RET Gene Rearrangements - approve. Differentiated (i.e., papillary, follicular, and Hurthle) Thyroid Carcinoma-approve if the patient's carcinoma is refractory to radioactive iodine therapy and patient has tried a Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted therapy. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Non-Small Cell Lung Cancer with RET Gene Rearrangements, Differentiated (i.e., papillary, follicular, and Hurthle) Thyroid Carcinoma |
| Part B Prerequisite | No |

COPAXONE

Products Affected

- COPAXONE SUBCUTANEOUS SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with other disease-modifying agent used for multiple sclerosis |
| Required Medical Information | Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or after consultation with a neurologist or an MS specialist. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

COPIKTRA

Products Affected

- COPIKTRA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, previous therapies |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma - approve if the patient has tried one systemic regimen (e.g., Imbruvica (ibrutinib capsules, tablets and oral solution), Venclexta (venetoclax tablets), rituximab, Gazyva (obinutuzumab intravenous infusion), chlorambucil, fludarabine, cyclophosphamide, bendamustine, high-dose methylprednisolone, Campath (alemtuzumab intravenous infusion), Calquence (acalabrutinib capsules), Brukinsa (zanubrutinib capsules), or Arzerra (ofatumumab intravenous infusion). T-cell lymphoma- For peripheral T-cell lymphoma, approve. For breast implant-associated anaplastic large cell lymphoma, or hepatosplenic T-cell lymphoma, approve if the patient has relapsed or refractory disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | T-cell Lymphoma |
| Part B Prerequisite | No |

CORLANOR

Products Affected

- CORLANOR ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | CHF: Previous use of a Beta-blocker, LVEF. IST: Previous use of a Beta-blocker |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | Chronic HF, adults- must have LVEF of less than or equal 35 percent (currently or prior to initiation of Corlanor therapy) AND tried or is currently receiving a Beta-blocker for HF (e.g., metoprolol succinate sustained-release, carvedilol, bisoprolol, carvedilol ER) unless the patient has a contraindication to the use of beta blocker therapy (e.g., bronchospastic disease such as COPD and asthma, severe hypotension or bradycardia). Heart failure due to dilated cardiomyopathy, children-approve. IST - tried or is currently receiving a Beta-blocker unless the patient has a contraindication to the use of beta blocker therapy (e.g., bronchospastic disease such as COPD and asthma, severe hypotension or bradycardia). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | inappropriate sinus tachycardia (IST) |
| Part B Prerequisite | No |

COTELLIC

Products Affected

- COTELLIC

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Melanoma initial - must have BRAF V600 mutation. |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Melanoma (unresectable, advanced or metastatic) - being prescribed in combination with Zelboraf. CNS Cancer-approve if the patient has BRAF V600 mutation-positive disease AND medication is being used for one of the following situations (i, ii, or iii): i. Adjuvant treatment of one of the following conditions (a, b, or c): a) Pilocytic astrocytoma OR b) Pleomorphic xanthoastrocytoma OR c) Ganglioglioma OR ii. Recurrent or progressive disease for one of the following conditions (a, b, c or d): a) glioma OR b) isocitrate dehydrogenase-2 (IDH2)-mutant astrocytoma OR c) Glioblastoma or d) Oligodendroglioma OR iii. Melanoma with brain metastases AND medication with be taken in combination with Zelboraf (vemurafenib tablets). Histiocytic Neoplasm-approve if the patient meets one of the following (i, ii, or iii): i. Patient has Langerhans cell histiocytosis and one of the following (a, b, or c): a) Multisystem disease OR b) Pulmonary disease OR c) Central nervous system lesions OR ii. Patient has Erdheim Chester disease OR iii. Patient has Rosai-Dorfman disease AND C) Patient has BRAF V600 mutation-positive disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Central Nervous System Cancer |
| Part B Prerequisite | No |

CRINONE

Products Affected

- CRINONE VAGINAL GEL 8 %

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | Crinone can be approved with a non-D authorization for the indication of infertility if the EGWP customer has the fertility buy-up |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

CYSTEAMINE (OPHTHALMIC)

Products Affected

- CYSTARAN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an ophthalmologist or a metabolic disease specialist or specialist who focuses in the treatment of metabolic diseases |
| Coverage Duration | 1 year |
| Other Criteria | Approve if the patient has corneal cysteine crystal deposits confirmed by slit-lamp examination |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DALFAMPRIDINE

Products Affected

- *dalfampridine*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older (initial and continuation therapy) |
| Prescriber Restrictions | MS. If prescribed by, or in consultation with, a neurologist or MS specialist (initial and continuation). |
| Coverage Duration | Initial-4months, Continuation-1 year. |
| Other Criteria | Initial-approve if the patient is ambulatory, the requested medication is being used to improve or maintain mobility in a patient with MS and the patient has impaired ambulation as evaluated by an objective measure (e.g., timed 25 foot walk and multiple sclerosis walking scale-12). Continuation-approve if the patient is ambulatory, the requested medication is being used to improve or maintain mobility in a patient with MS and the patient has responded to or is benefiting from therapy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DAURISMO

Products Affected

- DAURISMO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, medications that will be used in combination, comorbidities |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | AML - approve if Daurismo will be used in combination with cytarabine. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DEFERIPRONE

Products Affected

- *deferiprone*
- FERRIPROX
- FERRIPROX (2 TIMES A DAY)

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Serum ferritin level |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a hematologist |
| Coverage Duration | 1 year |
| Other Criteria | Iron overload, chronic-transfusion related due to thalassemia syndrome or related to sickle cell disease or other anemias-Initial therapy - approve. Continuation therapy - approve is the patient is benefiting from therapy as confirmed by the prescribing physician. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DERMATOLOGICAL WOUND CARE AGENTS

Products Affected

- REGRANEX

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DICLOFENAC

Products Affected

- *diclofenac sodium topical solution in metered-dose pump*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DIMETHYL FUMARATE

Products Affected

- *dimethyl fumarate*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with other disease-modifying agents used for multiple sclerosis (MS) |
| Required Medical Information | Relapsing form of Multiple Sclerosis (MS), to include, clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist or MS specialist. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Initial treatment-approve if the patient has Vumerity. Cont tx-approve if the patient has been established on dimethyl fumarate |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DOPTELET

Products Affected

- DOPTELET (10 TAB PACK)
- DOPTELET (15 TAB PACK)
- DOPTELET (30 TAB PACK)

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, platelet count, date of procedure (Thrombocytopenia with chronic liver disease) |
| Age Restrictions | 18 years and older (for chronic ITP-initial therapy only) |
| Prescriber Restrictions | Chronic ITP-prescribed by or after consultation with a hematologist (initial therapy only) |
| Coverage Duration | Thrombo w/chronic liver disease-5 days, chronic ITP-initial-3 months, cont-1 year |
| Other Criteria | Thrombocytopenia with chronic liver disease-Approve if the patient has a current platelet count less than 50 x 10 ⁹ /L AND the patient is scheduled to undergo a procedure within 10 to 13 days after starting Doptelet therapy. Chronic ITP, initial-approve if the patient has a platelet count less than 30,000 microliters or less than 50,000 microliters and is at an increased risk of bleeding and has tried one other therapy or if the patient has undergone splenectomy. Continuation-approve if the patient demonstrates a beneficial clinical response and remains at risk for bleeding complications. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DROXIDOPA

Products Affected

- *droxidopa*
- NORTHERA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Medication history (as described in Other Criteria field) |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | Prescribed by or in consultation with a cardiologist or a neurologist |
| Coverage Duration | 12 months |
| Other Criteria | NOH, approve if the patient meets ALL of the following criteria: a) Patient has been diagnosed with symptomatic NOH due to primary autonomic failure (Parkinson's disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy, AND b) Patient has tried midodrine. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DUAVEE

Products Affected

- DUAVEE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | For the prevention of postmenopausal osteoporosis, trial, failure, or intolerance of raloxifene is required prior to the use of Duavee. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DUPIXENT

Products Affected

- DUPIXENT PEN
- DUPIXENT SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with Xolair or another Anti-interleukin (IL) Monoclonal Antibody (i.e., Adbry, Cinqair, Fasentra, Nucala, Tezspire, or Xolair). Concurrent use with Janus Kinase Inhibitors (JAKis) [oral or topical]. |
| Required Medical Information | Diagnosis, prescriber specialty, other medications tried and length of trials |
| Age Restrictions | AD-6 months and older, asthma-6 years of age and older, Esophagitis-1 yr and older, Chronic Rhinosinusitis/Prurigo nodularis-18 and older |
| Prescriber Restrictions | Atopic Dermatitis/prurigo nodularis-Prescribed by or in consultation with an allergist, immunologist or dermatologist, asthma-prescribed by or in consultation with an allergist, immunologist or pulmonologist. Rhinosinusitis-prescribed by or in consultation with an allergist, immunologist or otolaryngologist. Esophagitis-presc/consult-allergist or gastro |
| Coverage Duration | AD-Init-4mo, Cont-1 yr, asthma/Rhinosinusitis/esophagitis/prurigo nod- init-6 mo, cont 1 yr |
| Other Criteria | AD,Init-pt 2yrs and older-pt meets a and b:a.used at least 1 med,med-high,high, and/or super-high-potency rx top CS OR AD affecting ONLY face,eyes/lids,skin folds,and/or genitalia and tried tacrolimus oint AND b.Inadeq efficacy was demonstrated w/prev tx.AD,Init-pt between 6 mo and less than 2 yr-pt meets a and b:a.used at least 1 med,med-high,high, and/or super-high-potency rx top CS and b.inadeq efficacy was demonstrated w/prev tx OR AD affecting ONLY face,eyes/lids,skin folds,and/or genitalia.Cont-pt responded to Dupixent.Asthma,init-pt meets (i, ii, and iii):i.Pt meets (a or b):a)blood eosinophil greater than or equal to 150 cells per microliter w/in prev 6 wks or within 6 wks prior to tx with any IL tx or Xolair OR b)has oral CS-dependent asthma, AND ii.received combo tx w/following (a and b): a)ICS AND b)1 add asthma control/maint med(NOTE:exception to the requirement for a trial of 1 add asthma controller/maint med can be made if pt already received anti-IL-5 tx or Xolair used concomitantly w/an ICS AND iii.asthma uncontrolled or was uncontrolled prior to starting anti-IL tx or Xolair defined by 1 (a, b, c, d or |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | <p>e): a)exper 2 or more asthma exacer req tx with systemic CS in prev yr OR b)exper 1 or more asthma exacer requiring hosp or ED/urgent care visit in prev yr OR c)FEV1 less than 80percent predicted OR d)FEV1/FVC less than 0.80 OR e)asthma worsens w/tapering of oral CS tx. Cont-pt meets (i and ii): i.cont to receive tx with 1 ICS or 1 ICS-containing combo inhaler AND ii.has responded to Dupixent. Chronic rhinosinusitis w/nasal polyposis, init-pt receiving tx with an intranasal CS and experi rhinosinusitis symptoms like nasal obstruction, rhinorrhea, or reduction/loss of smell AND meets 1 (a or b): a)received tx w/syst CS w/in prev 2 yrs or has contraindication to systemic CS tx OR b)prior surgery for nasal polyps. Cont-pt cont to receive tx with an intranasal CS and responded to Dupixent. Eosino esoph, init- weighs greater than or equal to 15 kg, has dx of eosino esophagitis confirmed by endoscopic biopsy demonstrating greater than or equal to 15 intraepithelial eosinophils per high-power field, and does not have a secondary cause of eosino esophagitis, and has received at least 8 wks of tx with a Rx strength PPI. Cont-pt received at least 6mo of tx with Dupixent and has experi reduced intraepithelial eosinophil count or decreased dysphagia/pain upon swallowing or reduced frequency/severity of food impaction. Prurigo Nod, init-pt has greater than or equal to 20 nodular lesions and pt has experienced pruritus at least 6 wks, AND pt tried at least 1 high- or super-high-potency Rx topical CS. Cont-pt received at least 6 mo of tx with Dupixent and has experi reduced nodular lesion count, decreased pruritis or reduced nodular lesion size.</p> |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ELAPRASE

Products Affected

- ELAPRASE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, genetic and lab test results |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders |
| Coverage Duration | 1 year |
| Other Criteria | Approve if the patient has laboratory test demonstrating deficient iduronate-2-sulfatase activity in leukocytes, fibroblasts, or plasma OR a molecular genetic test demonstrating iduronate-2-sulfatase gene mutation |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ENBREL

Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION
- ENBREL SUBCUTANEOUS SYRINGE
- ENBREL SURECLICK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with biologic therapy or targeted synthetic DMARD. |
| Required Medical Information | Diagnosis, concurrent medications, previous therapies tried. |
| Age Restrictions | PP-4 years and older (initial therapy) |
| Prescriber Restrictions | Initial only-RA/AS/JIA/JRA,prescribed by or in consult w/ rheum. PsA, prescribed by or in consultation w/ rheumatologist or dermatologist.PP, prescribed by or in consult w/ dermatologist.GVHD,prescribed by or in consult w/ oncologist,hematologist,or physician affiliated w/ transplant center. Uveitis, prescribed by or in consultation with an ophthalmologist. |
| Coverage Duration | End of the plan year |
| Other Criteria | RA/PsA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic or JAK inhibitor for RA/PsA are not required to step back and try a conventional synthetic DMARD). JIA/JRA-initial-approve if the patient meets ONE of the following: patient has tried one other medication for this condition for at least 3 months (Note: Examples of other medications for JIA include methotrexate, sulfasalazine, or leflunomide, a nonsteroidal anti-inflammatory drug (NSAID), biologic or JAK inhibitor) OR patient has aggressive disease. PP initial, approve if the patient meets one of the following criteria: 1) pt has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (note: pts who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first) OR 2) pt has a contraindication to MTX as determined by the prescribing physician. Uveitis initial, tried one of the following: periocular, intraocular, or systemic corticosteroid, immunosuppressives or other biologic therapy. GVHD, approve. Continuation-approve if the patient has had a response as determined by the prescriber. Clinical criteria incorporated into the Enbrel |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | 25 mg quantity limit edit, approve additional quantity (to allow for 50 mg twice weekly dosing) if one of the following is met: 1) Patient has plaque psoriasis, OR 2) Patient has RA/JIA/PsA/AS and is started and stabilized on 50 mg twice weekly dosing, OR 3) Patient has RA and the dose is being increased to 50 mg twice weekly and patient has taken MTX in combination with Enbrel 50 mg once weekly for at least 2 months, unless MTX is contraindicated or intolerant, OR 4) Patient has JIA/PsA/AS and the dose is being increased to 50 mg twice weekly after taking 50 mg once weekly for at least 2 months. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Graft versus host disease (GVHD), Uveitis |
| Part B Prerequisite | No |

ENDARI

Products Affected

- ENDARI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, prescriber specialty |
| Age Restrictions | Greater than or equal to 5 years of age |
| Prescriber Restrictions | Prescribed by, or in consultation with, a physician who specializes in sickle cell disease (e.g., a hematologist) |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

EPCLUSA

Products Affected

- EPCLUSA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Combination use with other direct acting antivirals, excluding ribavirin. |
| Required Medical Information | Genotype (including unknown), prescriber specialty, other medications tried or used in combination with requested medication |
| Age Restrictions | 3 years or older |
| Prescriber Restrictions | Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician |
| Coverage Duration | Will be c/w AASLD guidance and inclusive of treatment already received for the requested drug |
| Other Criteria | Criteria will be applied consistent with current AASLD/IDSA guidance. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Indications consistent with current AASLD/IDSA guidance |
| Part B Prerequisite | No |

EPIDIOLEX

Products Affected

- EPIDIOLEX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, previous therapies |
| Age Restrictions | Patients 1 year and older (initial therapy) |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist (initial therapy) |
| Coverage Duration | 1 year |
| Other Criteria | Dravet Syndrome-approve if the patient has tried or is concomitantly receiving at least two other antiseizure drugs or if the patient has tried or is concomitantly receiving one of Diacomit or clobazam or Fintepla. Lennox Gastaut Syndrome-approve if the patient has tried or is concomitantly receiving at least two other antiseizure drugs. Tuberous Sclerosis Complex-approve if the patient has tried or is concomitantly receiving at least two other antiseizure drugs. Continuation of therapy-approve if the patient is responding to therapy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

EPOETIN ALFA

Products Affected

- PROCRIT
- RETACRIT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | <p>CRF anemia in patients not on dialysis.Hemoglobin (Hb) of less than 10.0 g/dL for adults or less than or equal to 11 g/dL for children to start.Hb less than or equal to 11.5 g/dL for adults or 12 g/dL or less for children if previously on epoetin alfa, Mircera or Aranesp. Anemia w/myelosuppressive chemotx.pt must be currently receiving myelosuppressive chemo as a non-curative treatment and Hb 10.0 g/dL or less to start.Hb less than or equal to 12.0 g/dL if previously on epoetin alfa or Aranesp.MDS, approve if Hb is 10 g/dL or less or serum erythropoietin level is 500 mU/mL or less to start.Previously receiving Aranesp or EA, approve if Hb is 12.0 g/dL or less. Anemia in HIV with zidovudine, Hb is 10.0 g/dL or less or endogenous erythropoietin levels are 500 mU/mL or less at tx start.Previously on EA approve if Hb is 12.0 g/dL or less.</p> <p>Surgical pts to reduce RBC transfusions - Hgb is less than or equal to 13, surgery is elective, nonvascular and non-cardiac and pt is unwilling or unable to donate autologous blood prior to surgery</p> |
| Age Restrictions | MDS anemia = 18 years of age and older. |
| Prescriber Restrictions | MDS anemia, myelofibrosis-prescribed by or in consultation with, a hematologist or oncologist. |
| Coverage Duration | Chemo-6m,Transfus-1m, CKD-1yr, Myelofibrosis-init-3 mo, cont-1 yr, all others-1 yr |
| Other Criteria | Myelofibrosis-Initial-patient has a Hb less than 10 or serum erythropoietin less than or equal to 500 Mu/mL. Cont-approve if according to the prescriber the patient has had a response. Anemia in patients with chronic renal failure on dialysis - deny under Medicare Part D (claim should be submitted under the ESRD bundled payment benefit). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Anemia due to myelodysplastic syndrome (MDS), myelofibrosis |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

ERIVEDGE

Products Affected

- ERIVEDGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | BCC (La or Met) - must not have had disease progression while on Odomzo. |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Basal cell carcinoma, locally advanced-patients new to therapy-approve if the patient has tried Odomzo. Central nervous system cancer (this includes brain and spinal cord tumors)-approve if the patient has medulloblastoma, the patient has tried at least one chemotherapy agent and according to the prescriber, the patient has a mutation of the sonic hedgehog pathway. Basal cell carcinoma, metastatic (this includes primary or recurrent nodal metastases and distant metastases)-approve. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Central nervous System Cancer |
| Part B Prerequisite | No |

ERLEADA

Products Affected

- ERLEADA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Prostate cancer-non-metastatic, castration resistant and prostate cancer-metastatic, castration sensitive-approve if the requested medication will be used in combination with a gonadotropin-releasing hormone (GnRH) agonist or the medication is concurrently used with Firmagon or if the patient has had a bilateral orchiectomy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ERLOTINIB

Products Affected

- *erlotinib*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | Advanced or Metastatic NSCLC, approve if the patient has sensitizing EGFR mutation positive non-small cell lung cancer as detected by an approved test. Note-Examples of sensitizing EGFR mutation-positive non-small cell lung cancer include the following mutations: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S768I. RCC, approve if the patient has recurrent or advanced non-clear cell histology RCC or if the patient had hereditary leiomyomatosis and renal cell carcinoma and erlotinib will be used in combination with bevacizumab. Bone cancer-chordoma-approve if the patient has chordoma and has tried at least one previous therapy. Pancreatic cancer-approve if the medication is used in combination with gemcitabine and if the patient has locally advanced, metastatic or recurrent disease. Vulvar cancer-approve if the patient has advanced, recurrent or metastatic disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Renal Cell Carcinoma, vulvar cancer and Bone Cancer-Chordoma. |
| Part B Prerequisite | No |

EVEROLIMUS

Products Affected

- AFINITOR
- AFINITOR DISPERZ
- *everolimus (antineoplastic)*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Breast Cancer-HER2 status, hormone receptor (HR) status. |
| Age Restrictions | All dx except TSC associated SEGA, renal angiomyolipoma or partial onset seizures-18 years and older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | Breast Cancer-approve if pt meets ALL the following (A, B, C, D, E, and F):A)pt has recurrent or metastatic,HR+ disease AND B)pt has HER2-negative breast cancer AND C)pt has tried at least 1 prior endocrine therapy AND D)pt meets 1 of the following conditions (i or ii):i.pt is a postmenopausal woman or man OR ii.pt is pre/perimenopausal woman AND is receiving ovarian suppression/ablation with a GnRH agonist, or has had surgical bilateral oophorectomy or ovarian irradiation AND E)pt meets 1 of the following conditions (i or ii): i. Afinitor will be used in combo with exemestane and pt meets 1 of the following:pt is male and is receiving a GnRH analog or pt is a woman or ii. Afinitor will be used in combo with fulvestrant or tamoxifen AND F)pt has not had disease progression while on Afinitor. RCC, relapsed or Stage IV disease-approve if using for non-clear cell disease or if using for clear cell disease, pt has tried 1 prior systemic therapy (e.g., Inlyta, Votrient, Sutent, Cabometyx, Nexavar).TSC Associated SEGA-approve if pt requires therapeutic intervention but cannot be curatively resected. Thymomas and Thymic Carcinomas-approve if pt has tried chemotherapy or cannot tolerate chemotherapy. TSC associated renal angiomyolipoma -approve. WM/LPL - approve if pt has progressive or relapsed disease or if pt has not responded to primary therapy. Thyroid Carcinoma, differentiated-approve if pt is refractory to radioactive iodine therapy. Endometrial Carcinoma- |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | <p>approve if Afinitor will be used in combo with letrozole. GIST-approve if pt has tried 2 of the following drugs: Sutent, Sprycel, Stivarga, Ayvakit, Qinlock or imatinib AND there is confirmation that Afinitor will be used in combo with 1 of these drugs (Sutent, Stivarga, or imatinib) in the treatment of GIST. TSC-associated partial-onset seizures-approve. NET tumors of the pancreas, GI Tract, Lung and Thymus (carcinoid tumors)-approve. Soft tissue sarcoma-approve if pt has perivascular epithelioid cell tumors (PEComa) or recurrent angiomyolipoma/lymphangiomyomatosis. Classic Hodgkin lymphoma-approve if pt has relapsed or refractory disease. Histiocytic neoplasm-approve if pt has Erdheim-Chester disease or, Rosai-Dorfman disease or Langerhans cell histiocytosis with bone disease, central nervous system lesions, multisystem disease or pulmonary disease. Patient must also have PIK3CA mutation. Uterine Sarcoma-approve if the patient has advanced, recurrent, metastatic, or inoperable disease, AND has a perivascular epithelioid cell tumor (PEComa), AND has tried at least one systemic regimen. Note: Examples of systemic regimen include doxorubicin, docetaxel, gemcitabine, ifosfamide, dacarbazine.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | <p>neuroendocrine tumors of the thymus (Carcinoid tumors). Soft tissue sarcoma, classical Hodgkin lymphoma, Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL), Thymomas and Thymic carcinomas, Differentiated Thyroid Carcinoma, Endometrial Carcinoma, Gastrointestinal Stromal Tumors (GIST), men with breast cancer, Pre-peri-menopausal women with breast cancer, Histiocytic Neoplasm, uterine sarcoma</p> |
| Part B Prerequisite | No |

EXKIVITY

Products Affected

- EXKIVITY

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Non-Small Cell Lung Cancer (NSCLC)-approve if the patient meets (A, B and C): A) Patient has locally advanced or metastatic NSCLC AND B) Patient has epidermal growth factor receptor (EGFR) exon 20 insertion mutation, as determined by an approved test AND C) Patient has previously tried at least one platinum-based chemotherapy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

EXTAVIA

Products Affected

- EXTAVIA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with other disease-modifying agent used for multiple sclerosis |
| Required Medical Information | Relapsing form of Multiple Sclerosis (MS) diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or after consultation with a neurologist or an MS specialist. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

EYLEA

Products Affected

- EYLEA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Administered by or under the supervision of an ophthalmologist |
| Coverage Duration | 3 years |
| Other Criteria | BvsD Coverage Determination |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

FARYDAK

Products Affected

- FARYDAK

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

FASENRA

Products Affected

- FASENRA
- FASENRA PEN

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with Xolair or another Anti-Interleukin (IL) Monoclonal Antibody |
| Required Medical Information | Diagnosis, severity of disease, peripheral blood eosinophil count, previous therapies tried and current therapies, FEV1/FVC |
| Age Restrictions | 12 years of age and older |
| Prescriber Restrictions | Prescribed by or in consultation with an allergist, immunologist, or pulmonologist |
| Coverage Duration | Authorization will be for 6 months initial, 12 months continuation. |
| Other Criteria | Initial - must have peripheral blood eosinophil count of greater than or equal to 150 cells per microliter within the previous 6 weeks or within 6 weeks prior to treatment with Fasenra or another monoclonal antibody therapy that may lower blood eosinophil levels AND meet both of the following criteria: 1) Patient has received combination therapy with an inhaled corticosteroid AND at least one additional asthma controller or asthma maintenance medication (Examples: LABA, LAMA, leukotrienes, monoclonal antibodies for asthma) AND 2) Patient's asthma is uncontrolled or was uncontrolled prior to receiving Fasenra or another monoclonal antibody therapy for asthma as defined by ONE of the following: a) patient experienced one or more asthma exacerbations requiring treatment with systemic corticosteroids in the previous year, OR b) patient experienced one or more asthma exacerbation requiring hospitalization, an urgent care visit or an Emergency Department (ED) visit in the previous year, OR c) patient has a FEV1 less than 80 percent predicted, OR d) Patient has an FEV1/FVC less than 0.80, OR e) Patient's asthma worsens upon tapering of oral corticosteroid therapy. Continuation - The patient has responded to Fasenra therapy as determined by the prescribing physician (e.g., decreased asthma exacerbations, decreased asthma symptoms, decreased hospitalizations, emergency department (ED)/urgent care, or physician visits due to asthma, decreased requirement for oral corticosteroid therapy) AND patient continues to receive therapy with an inhaled corticosteroid. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------------|
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

FINGOLIMOD

Products Affected

- *fingolimod*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with other disease-modifying agents used for multiple sclerosis (MS). |
| Required Medical Information | Relapsing form of Multiple Sclerosis (MS), to include, clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. |
| Age Restrictions | 10 years and older |
| Prescriber Restrictions | Prescribed by, or in consultation with, a neurologist or an MS specialist. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

FINTEPLA

Products Affected

- FINTEPLA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 2 years and older (initial therapy) |
| Prescriber Restrictions | Prescribed by or in consultation with an neurologist (initial therapy) |
| Coverage Duration | 1 year |
| Other Criteria | Dravet Syndrome-Initial therapy-approve if the patient has tried or is concomitantly receiving at least two other antiepileptic drugs or patient has tried or is concomitantly receiving Epidiolex, Clobazam or Diacomit. Dravet Syndrome-Continuation-approve if the patient is responding to therapy. Lennox-Gastaut Syndrome, initial-approve if the patient has tried or is concomitantly receiving at least two other antiepileptic drugs. Lennox-Gastaut Syndrome, continuation-approve if the patient is responding to therapy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

FIRDAPSE

Products Affected

- FIRDAPSE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | History of seizures (initial therapy) |
| Required Medical Information | Diagnosis, seizure history, lab and test results |
| Age Restrictions | 6 years and older (initial therapy) |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist or a neuromuscular specialist (initial therapy) |
| Coverage Duration | Initial-3 months, Cont-1 year |
| Other Criteria | Initial therapy-Diagnosis confirmed by at least one electrodiagnostic study (e.g., repetitive nerve stimulation) OR anti-P/Q-type voltage-gated calcium channels (VGCC) antibody testing according to the prescribing physician. Continuation-patient continues to derive benefit (e.g., improved muscle strength, improvements in mobility) from Firdapse, according to the prescribing physician. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

FORTEO

Products Affected

- FORTEO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concomitant use with other medications for osteoporosis |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | High risk for fracture-2 yrs, Not high risk-approve a max of 2 yrs of therapy (total)/lifetime. |
| Other Criteria | Treatment of PMO, approve if pt has tried one oral bisphosphonate OR pt cannot take an oral bisphosphonate because the pt cannot swallow or has difficulty swallowing or the pt cannot remain in an upright position post oral bisphosphonate administration or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried an IV bisphosphonate (ibandronate or zoledronic acid), OR pt has severe renal impairment (creatinine clearance less than 35 mL/min) or CKD or pt has had an osteoporotic fracture or fragility fracture. Increase bone mass in men (a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression) with primary or hypogonadal osteoporosis/Treatment of GIO, approve if pt tried one oral bisphosphonate OR pt cannot take an oral bisphosphonate because the patient cannot swallow or has difficulty swallowing or the patient cannot remain in an upright position post oral bisphosphonate administration or has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried zoledronic acid (Reclast), OR pt has severe renal impairment (CrCL less than 35 mL/min) or has CKD or has had an osteoporotic fracture or fragility fracture. Patients who |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | have already taken teriparatide for 2 years - approve if the patient is at high risk for fracture. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

FOTIVDA

Products Affected

- FOTIVDA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, other therapies |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Renal Cell Carcinoma (RCC)-approve if the patient has relapsed or Stage IV disease and has tried at least two other systemic regimens. Note: Examples of systemic regimens for renal cell carcinoma include axitinib tablets, axitinib + pembrolizumab injection, cabozantinib tablets, cabozantinib + nivolumab injection, sunitinib malate capsules, pazopanib tablets, sorafenib tablets, and lenvatinib capsules + everolimus. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

FRUZAQLA

Products Affected

- FRUZAQLA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Colon cancer, rectal cancer, or appendiceal cancer-Approve if the patient meets the following (A and B): A.Patient has advanced or metastatic disease, AND B.Patient has previously been treated with the following (i, ii, and iii): i.Fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, Note: Examples of fluoropyrimidine agents include 5-fluorouracil (5-FU) and capecitabine. AND ii.An anti-vascular endothelial growth factor (VEGF) agent, Note: Examples of anti-VEGF agents include bevacizumab. AND iii. If the tumor is RAS wild-type (KRAS wild-type and NRAS wild-type) [that is, the tumor or metastases are KRAS and NRAS mutation negative], the patient meets ONE of the following (a or b): a.According to the prescriber, anti-epidermal growth factor receptor (EGFR) therapy is NOT medically appropriate, OR b. The patient has received an anti-EGFR therapy. Note: Examples of anti-EGFR therapy includes Erbitux (cetuximab intravenous infusion) and Vectibix (panitumumab intravenous infusion). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Appendiceal cancer |
| Part B Prerequisite | No |

GATTEX

Products Affected

- GATTEX 30-VIAL
- GATTEX ONE-VIAL

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 1 year and older |
| Prescriber Restrictions | Prescribed by or in consultation with a gastroenterologist (initial and continuation) |
| Coverage Duration | 1 year |
| Other Criteria | Initial-approve if the patient is currently receiving parenteral nutrition on 3 or more days per week or according to the prescriber, the patient is unable to receive adequate total parenteral nutrition required for caloric needs. Continuation-approve if the patient has experienced improvement. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

GAVRETO

Products Affected

- GAVRETO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | NSCLC-18 years and older. thyroid cancer-12 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | NSCLC-approve if the patient has metastatic disease and rearranged during transfection (RET) fusion-positive disease detected by an Food and Drug Administration (FDA) approved test. Thyroid cancer-approve if the patient has rearranged during transfection (RET) fusion-positive disease or RET-mutation positive disease and has anaplastic thyroid cancer or the patient has medullary thyroid cancer or the disease is radioactive iodine-refractory. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Medullary Thyroid Cancer |
| Part B Prerequisite | No |

GILENYA

Products Affected

- GILENYA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use of Gilenya with other disease-modifying agents used for multiple sclerosis (MS). |
| Required Medical Information | Relapsing form of Multiple Sclerosis (MS), to include, clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. |
| Age Restrictions | 10 years and older |
| Prescriber Restrictions | Prescribed by, or in consultation with, a neurologist or an MS specialist. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Cont tx - approve if the patient has been established on Gilenya. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

GILOTRIF

Products Affected

- GILOTRIF

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For NSCLC - EGFR exon deletions or mutations or if NSCLC is squamous cell type |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | NSCLC EGFR pos - For the treatment of advanced or metastatic non small cell lung cancer (NSCLC)-approve if the patient has sensitizing EGFR mutation-positive NSCLC as detected by an approved test. Note: examples of sensitizing EGFR mutation-positive NSCLC include the following mutations : exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S768I. NSCLC metastatic squamous cell must have disease progression after treatment with platinum based chemotherapy. Head and neck cancer-approve if the patient has non-nasopharyngeal head and neck cancer and the patient has disease progression on or after platinum based chemotherapy (Part B before Part D Step Therapy - applies only to beneficiaries enrolled in an MA-PD plan) |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Head and neck cancer |
| Part B Prerequisite | Yes |

GLATIRAMER

Products Affected

- *glatiramer*
- *glatopa*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with other disease-modifying agent used for multiple sclerosis |
| Required Medical Information | Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or after consultation with a neurologist or an MS specialist. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

GLP-1 AGONISTS

Products Affected

- BYDUREON BCISE
- BYETTA
- MOUNJARO
- OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML)
- RYBELSUS
- TRULICITY
- VICTOZA 2-PAK
- VICTOZA 3-PAK
- WEGOVY

| PA Criteria | Criteria Details |
|------------------------------|----------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

GONADOTROPIN-RELEASING HORMONE AGONISTS - INJECTABLE LONG ACTING

Products Affected

- ELIGARD
- ELIGARD (3 MONTH)
- ELIGARD (4 MONTH)
- ELIGARD (6 MONTH)
- LEUPROLIDE (3 MONTH)
- *leuprolide subcutaneous kit*
- LUPRON DEPOT
- LUPRON DEPOT (3 MONTH)
- LUPRON DEPOT (4 MONTH)
- LUPRON DEPOT (6 MONTH)
- LUPRON DEPOT-PED
- LUPRON DEPOT-PED (3 MONTH)
- TRIPTODUR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | Premenstrual disorders - 18 years and older |
| Prescriber Restrictions | For the treatment of cancer diagnosis must be prescribed by or in consultation with an oncologist. A urologist may also prescribe for prostate cancer. |
| Coverage Duration | uterine leiomyomata 3 mo.All other=12 mo |
| Other Criteria | Premenstrual disorders including PMS and PMDD- approve if pt has severe refractory premenstrual symptoms AND pt has tried an SSRI or combined oral contraceptive. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Ovarian cancer including fallopian tube and primary peritoneal cancer, breast cancer, prophylaxis or treatment of uterine bleeding or menstrual suppression in patients with hematologic malignancy or undergoing cancer treatment or prior to bone marrow/stem cell transplantation, head and neck cancer-salivary gland tumors, premenstrual disorders including premenstrual syndrome and premenstrual dysphoric disorder, uterine cancer |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

GROWTH HORMONES - GENOTROPIN

Products Affected

- GENOTROPIN
- GENOTROPIN MINIQUICK

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | GHD in Children/Adolescents. Pt meets one of the following-1-had 2 GH stim tests with the following-levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon and both are inadequate as defined by a peak GH response which is below the normal reference range of the testing laboratory OR had at least 1 GH test and results show inadequate response and has at least one risk factor for GHD (e.g., ht for age curve deviated down across 2 major height percentiles [e.g., from above the 25 percentile to below the 10 percentile], growth rate is less than the expected normal growth rate based on age and gender, low IGF-1 and/or IGFBP-3 levels). 2.brain radiation or tumor resection and pt has 1 GH stim test and results is inadequate response or has def in at least 1 other pituitary hormone (that is, ACTH, TSH, gonadotropin deficiency [LH and/or FSH} are counted as 1 def], or prolactin).3. congenital hypopituitarism and has one GH stim test with inadequate response OR def in at least one other pituitary hormone and/or the patient has the imaging triad of ectopic posterior pituitary and pituitary hypoplasia with abnormal pituitary stalk 4.pt has multiple pituitary deficiencies and has 3 or more pituitary hormone deficiencies or pt has had one GH test and results were inadequate 5.pt had a hypophysectomy. Cont-pt responding to therapy |
| Age Restrictions | ISS 5 y/o or older, SGA 2 y/o or older, SBS 18 y/o or older |
| Prescriber Restrictions | GHD (Initial tx children or adolescents w/o hypophysectomy), GHD adults or transitional adolescents, Prader Willi (initial for child/adult and cont tx in adults), SHOX (initial), SGA (initial) - prescribed by or in consultation with an endocrinologist. CKD (initial) endocrinologist or nephrologist. |
| Coverage Duration | ISS - 6 mos initial, 12 months cont tx, SBS-1 month, others 12 mos |
| Other Criteria | GHD initial in adults and adolescents 1. endocrine must certify not being prescribed for anti-aging or to enhance athletic performance, 2. has either childhood onset or adult onset resulting from GHD alone, multiple hormone deficiency from pituitary dx, hypothalamic dz, pituitary surgery, |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | <p>cranial radiation tx, tumor treatment, TBI or subarachnoid hemorrhage, AND 3. meets one of the following - A. has known mutations, embryonic lesions, congenital or genetic defects or structural hypothalamic pituitary defects, B. 3 or more pituitary hormone def (ACTH, TSH, LH/FSH, or prolactin, IGF1 less than 84 mcg/L (Esoterix RIA), AND other causes of low serum IGF-1 have been excluded, C. Neg response to ONE preferred GH stim test (insulin peak response less than or equal to 5 mcg/L, Glucagon peak less than or equal to 3 mcg/L (BMI is less than or equal to 25), less than or equal to 3 and BMI is greater than or equal to 25 and less than or equal to 30 with a high pretest probability of GH deficiency, less than or equal to 1 and BMI is greater than or equal to 25 and less than or equal to 30 with a low pretest probability of GH deficiency or less than or equal to 1 mcg/L (BMI is greater than 30), if insulin and glucagon contraindicated then Arginine alone test with peak of less than or equal to 0.4 mcg/L, or Macrilen peak less than 2.8 ng/ml AND BMI is less than or equal to 40 AND if a transitional adolescent must be off tx for at least one month before retesting. Cont tx - endocrine must certify not being prescribed for anti-aging or to enhance athletic performance. ISS initial - baseline ht less than the 1.2 percentile or a standard deviation score (SDS) less than -2.25 for age and gender, open epiphyses, does not have CDGP and height velocity is either growth rate (GR) is a. less than 4 cm/yr for pts greater than or equal to 5 or b. growth velocity is less than 10th percentile for age/gender. Cont tx - prescriber confirms response to therapy. CKD initial - CKD defined by abnormal CrCl. Noonan initial - baseline height less than 5th percentile. PW cont tx in adults or adolescents who don't meet child requir - physician certifies not being used for anti-aging or to enhance athletic performance. SHOX initial - SHOX def by chromo analysis, open epiphyses, height less than 3rd percentile for age/gender. SGA initial -baseline ht less than 5th percentile for age/gender and born SGA (birth weight/length that is more than 2 SD below mean for gestational age/gender and didn't have sufficient catch up growth by 2-4 y/o). Cont tx - prescriber confirms response to therapy. Cont Tx for CKD, Noonan, PW in child/adolescents, SHOX, and TS - prescriber confirms response to therapy. SBS initial pt receiving specialized nutritional support. Cont tx - 2nd course if pt responded to tx with a decrease in the requirement for specialized nutritional support.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | SHOX, SBS, CKD |
| Part B Prerequisite | No |

HAEGARDA

Products Affected

- HAEGARDA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | prescribed by or in consultation with an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders |
| Coverage Duration | 1 year |
| Other Criteria | Hereditary Angioedema (HAE) Due to C1 Inhibitor (C1-INH) Deficiency [Type I or Type II], Prophylaxis, Initial Therapy: approve if the patient has HAE type I or type II confirmed by low levels of functional C1-INH protein (less than 50 percent of normal) at baseline and lower than normal serum C4 levels at baseline. Patient is currently taking for prophylaxis - approve if the patient meets the following criteria (i and ii): i) patient has a diagnosis of HAE type I or II, and ii) according to the prescriber, the patient has had a favorable clinical response since initiating prophylactic therapy compared with baseline. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HARVONI

Products Affected

- HARVONI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Combination use with other direct acting antivirals, excluding ribavirin |
| Required Medical Information | N/A |
| Age Restrictions | 3 years or older |
| Prescriber Restrictions | Prescribed by or in consultation w/ GI, hepatologist, ID, or a liver transplant MD |
| Coverage Duration | Will be c/w AASLD guidance and inclusive of treatment already received for the requested drug |
| Other Criteria | Criteria will be applied consistent with current AASLD/IDSA guidance. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Indications consistent with current AASLD/IDSA guidance |
| Part B Prerequisite | No |

HETLIOZ

Products Affected

- HETLIOZ
- *tasimelteon*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Non-24-patient is totally blind with no perception of light |
| Age Restrictions | Non-24-18 years or older (initial and continuation), SMS-3 years and older |
| Prescriber Restrictions | prescribed by, or in consultation with, a neurologist or a physician who specializes in the treatment of sleep disorders (initial and continuation) |
| Coverage Duration | 6 mos initial, 12 mos cont |
| Other Criteria | Initial - patient is totally blind with no perception of light, dx of Non-24 is confirmed by either assessment of one physiologic circadian phase marker (e.g., measurement of urinary melatonin levels, dim light melatonin onset, assessment of core body temperature), or if assessment of physiologic circadian phase marker cannot be done, the diagnosis must be confirmed by actigraphy plus evaluation of sleep logs. Cont - Approve if patient is totally blind with no perception of light and pt has achieved adequate results with Hetlizio therapy according to the prescribing physician (e.g., entrainment, clinically meaningful or significant increases in nighttime sleep, clinically meaningful or significant decreases in daytime sleep). Nighttime sleep disturbances in Smith-Magenis Syndrome (SMS)-approve. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HIGH RISK MEDICATIONS - BENZTROPINE

Products Affected

- *benztropine oral*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | For all medically-accepted indications, approve if the prescriber confirms he/she has assessed risk versus benefit in prescribing benztropine for the patient and he/she would still like to initiate/continue therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HIGH RISK MEDICATIONS - CARISOPRODOL

Products Affected

- *carisoprodol*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects. For patients concurrently taking multiple anticholinergic medications, the physician has assessed the risk. |
| Age Restrictions | Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HIGH RISK MEDICATIONS - CYCLOBENZAPRINE

Products Affected

- *cyclobenzaprine oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | Patients aged less than 65 years, approve. |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months. |
| Other Criteria | The physician has assessed risk versus benefit in using this High Risk Medication (HRM) in this patient and has confirmed that he/she would still like to initiate/continue therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HIGH RISK MEDICATIONS - FIRST GENERATION ANTIHISTAMINES

Products Affected

- *promethazine oral*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply. |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months. |
| Other Criteria | For hydroxyzine hydrochloride, authorize use without a previous drug trial for all FDA-approved indications other than anxiety. Approve hydroxyzine hydrochloride if the patient has tried at least two other FDA-approved products for the management of anxiety. Prior to approval of promethazine and hydroxyzine, approve if the physician must have assessed risk versus benefit in prescribing the requested HRM for the patient and must confirm that he/she would still like to initiate/continue therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HIGH RISK MEDICATIONS - PHENOBARBITAL

Products Affected

- *phenobarbital*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Coverage is not provided for use in sedation/insomnia. |
| Required Medical Information | N/A |
| Age Restrictions | Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply. |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | For the treatment of seizures, approve only if the patient is currently taking phenobarbital. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HRM - ANTIDEMENTIA AGENTS

Products Affected

- *ergoloid*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects, AND the physician has documented that the patient has tried and failed two (2) safer formulary alternatives or provided clinical rationale why two safer formulary alternatives are not appropriate for the patient. |
| Age Restrictions | Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | The patient has tried two of the following: donepezil, galantamine and rivastigmine. The physician has assessed risk versus benefit in using this High Risk medication (HRM) in this patient and has confirmed that he/she would still like to initiate/continue therapy |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HRM - BUTALBITAL COMBINATIONS

Products Affected

- *ascomp with codeine*
- *butalbital-acetaminop-caf-cod*
- *butalbital-acetaminophen oral tablet*
- *butalbital-acetaminophen-caff*
- *butalbital-aspirin-caffeine oral capsule*
- *tencon*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects, AND the physician has documented that the patient has tried and failed two (2) safer formulary alternatives or provided clinical rationale why two safer formulary alternatives are not appropriate for the patient. |
| Age Restrictions | Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | The patient has tried two of the following: naproxen sodium and ibuprofen. The physician has assessed risk versus benefit in using this High Risk medication (HRM) in this patient and has confirmed that he/she would still like to initiate/continue therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HRM - GLYBURIDE

Products Affected

- *glyburide*
- *glyburide micronized*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects, AND the physician has documented that the patient has tried and failed glipizide or provided clinical rationale as to why that safer formulary alternative is not appropriate for the patient. |
| Age Restrictions | Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | The patient has tried glipizide. The physician has assessed risk versus benefit in using this High Risk medication (HRM) in this patient and has confirmed that he/she would still like to initiate/continue therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HRM - GLYBURIDE/METFORMIN

Products Affected

- *glyburide-metformin*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects, AND the physician has documented that the patient has tried and failed glipizide-metformin or provided clinical rationale why that safer formulary alternative is not appropriate for the patient. |
| Age Restrictions | Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | The patient has tried glipizide-metformin. The physician has assessed risk versus benefit in using this High Risk medication (HRM) in this patient and has confirmed that he/she would still like to initiate/continue therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HRM - SKELETAL MUSCLE RELAXANTS

Products Affected

- *chlorzoxazone oral tablet 500 mg*
- *cyclobenzaprine oral tablet*
- *metaxalone*
- *methocarbamol oral tablet 500 mg, 750 mg*
- *orphenadrine citrate oral*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects. For patients concurrently taking multiple anticholinergic medications, the physician has assessed the risk. |
| Age Restrictions | Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | The physician has assessed risk versus benefit in using this High Risk Medication (HRM) in this patient and has confirmed that he/she would still like to initiate/continue therapy. For patients concurrently taking multiple anticholinergic medications, the physician has assessed this risk as well. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HRM - TRIHEXYPHENIDYL

Products Affected

- *trihexyphenidyl*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects. For patients concurrently taking multiple anticholinergic medications, the physician has assessed the risk. |
| Age Restrictions | Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | The physician has assessed risk versus benefit in using this High Risk Medication (HRM) in this patient and has confirmed that he/she would still like to initiate/continue therapy. For patients concurrently taking multiple anticholinergic medications, the physician has assessed this risk as well. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HUMIRA

Products Affected

- ADALIMUMAB-ADAZ
- ADALIMUMAB-ADBAM
- ADALIMUMAB-ADBAM(CF) PEN CROHNS
- ADALIMUMAB-ADBAM(CF) PEN PS-UV
- CYLTEZO(CF)
- CYLTEZO(CF) PEN
- CYLTEZO(CF) PEN CROHN'S-UC-HS
- CYLTEZO(CF) PEN PSORIASIS-UV
- HUMIRA PEN (PREFERRED NDCS STARTING WITH 00074)
- HUMIRA PEN CROHNS-UC-HS START (PREFERRED NDCS STARTING WITH 00074)
- HUMIRA PEN PSOR-UV-ADOL HS (PREFERRED NDCS STARTING WITH 00074)
- HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML (PREFERRED NDCS STARTING WITH 00074)
- HUMIRA(CF) (PREFERRED NDCS STARTING WITH 00074)
- HUMIRA(CF) PEDI CROHNS STARTER (PREFERRED NDCS STARTING WITH 00074)
- HUMIRA(CF) PEN (PREFERRED NDCS STARTING WITH 00074)
- HUMIRA(CF) PEN CROHNS-UC-HS (PREFERRED NDCS STARTING WITH 00074)
- HUMIRA(CF) PEN PEDIATRIC UC (PREFERRED NDCS STARTING WITH 00074)
- HUMIRA(CF) PEN PSOR-UV-ADOL HS (PREFERRED NDCS STARTING WITH 00074)
- HYRIMOZ PEN CROHN'S-UC STARTER (PREFERRED NDCS STARTING WITH 61314)
- HYRIMOZ PEN PSORIASIS STARTER (PREFERRED NDCS STARTING WITH 61314)
- HYRIMOZ(CF) (PREFERRED NDCS STARTING WITH 61314)
- HYRIMOZ(CF) PEDI CROHN STARTER (PREFERRED NDCS STARTING WITH 61314)
- HYRIMOZ(CF) PEN (PREFERRED NDCS STARTING WITH 61314)

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with biologic therapy or targeted synthetic DMARD. |
| Required Medical Information | Diagnosis, concurrent medications, previous therapies tried. |
| Age Restrictions | Crohn's disease (CD), 6 or older (initial therapy). Ulcerative colitis (UC), 5 or older (initial therapy), PP-18 or older (initial therapy) |
| Prescriber Restrictions | Initial therapy only all dx-RA/JIA/JRA/Ankylosing spondylitis, prescribed by or in consultation with rheumatologist. Psoriatic arthritis (PsA), prescribed by or in consultation with a rheumatologist or dermatologist. |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | Plaque psoriasis (PP), prescribed by or in consultation with a dermatologist. UC/ CD, prescribed by or in consultation with a gastroenterologist. HS - dermatologist.UV-ophthalmologist |
| Coverage Duration | End of the plan year |
| Other Criteria | RA/PsA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic or JAK inhibitor for RA/PsA are not required to step back and try a conventional synthetic DMARD). JIA/JRA-initial-approve if the patient meets ONE of the following: patient has tried one other medication for this condition for at least 3 months (Note: Examples of other medications for JIA include methotrexate, sulfasalazine, or leflunomide, a nonsteroidal anti-inflammatory drug (NSAID), biologic or JAK inhibitor) OR patient has aggressive disease. PP initial, approve if the patient meets one of the following criteria: 1) pt has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (note: pts who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first) OR 2) pt has a contraindication to MTX as determined by the prescribing physician. CD initial, approve if the patient has tried or is currently taking corticosteroids or patient has tried one other agent for CD for at least 3 months. UC initial, approve if the patient has had a trial of one systemic agent for at least 3 months (e.g., 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, biologic, JAK inhibitor or a corticosteroid such as prednisone or methylprednisolone). Uveitis initial, tried one of the following: periocular, intraocular, or systemic corticosteroid, immunosuppressives or other biologic therapy. HS initial, tried ONE other therapy (e.g., intralesional or oral corticosteroids, systemic antibiotics, isotretinoin). Continuation-approve if the patient has had a response as determined by the prescriber. Clinical criteria incorporated into the Humira 40 mg quantity limit edit allow for approval of additional quantities to accommodate induction dosing. The allowable quantity is dependent upon the induction dosing regimen for the applicable FDA-labeled indications as outlined in product labeling. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

IBRANCE

Products Affected

- IBRANCE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Breast cancer - approve recurrent or metastatic, hormone receptor positive (HR+) [i.e., estrogen receptor positive- {ER+} and/or progesterone receptor positive {PR+}] disease, and HER2-negative breast cancer when the pt meets ONE of the following 1. Pt is postmenopausal and Ibrance will be used in combination with anastrozole, exemestane, or letrozole 2, pt is premenopausal or perimenopausal and is receiving ovarian suppression/ablation with GnRH agonists, or has had surgical bilateral oophorectomy, or ovarian irradiation AND meets one of the following conditions: Ibrance will be used in combination with anastrozole, exemestane, or letrozole or Ibrance will be used in combination with fulvestrant 3. pt is a man (a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression) who is receiving GnRH analog AND Ibrance will be used in combination with anastrozole, exemestane or letrozole or Ibrance will be used in combination with fulvestrant 4. Pt is postmenopausal and Ibrance will be used in combination with fulvestrant. In addition, patients new to therapy must have a trial of Kisqali, Kisqali Femara Co-Pack or Verzenio prior to approval of Ibrance. Liposarcoma-approve if the patient has well-differentiated/dedifferentiated liposarcoma (WD-DDLS). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Liposarcoma |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

ICATIBANT

Products Affected

- *icatibant*
- *sajazir*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by, or in consultation with, an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Hereditary Angioedema (HAE) Due to C1 Inhibitor (C1-INH) Deficiency [Type I or Type II] - Treatment of Acute Attacks, Initial Therapy-the patient has HAE type I or type II as confirmed by the following diagnostic criteria (i and ii): i. the patient has low levels of functional C1-INH protein (less than 50 percent of normal) at baseline, as defined by the laboratory reference values AND ii. the patient has lower than normal serum C4 levels at baseline, as defined by the laboratory reference values. Patients who have treated previous acute HAE attacks with icatibant-the patient has treated previous acute HAE type I or type II attacks with icatibant AND according to the prescribing physician, the patient has had a favorable clinical response (e.g., decrease in the duration of HAE attacks, quick onset of symptom relief, complete resolution of symptoms, decrease in HAE acute attack frequency or severity) with icatibant treatment. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ICLUSIG

Products Affected

- ICLUSIG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, the Philadelphia chromosome (Ph) status of the leukemia must be reported. T315I status |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Patients new to therapy with Acute lymphoblastic leukemia, Philadelphia chromosome positive or chronic myeloid leukemia-approve if the patient has tried Sprycel and had an inadequate response or significant intolerance or have a contraindication or are not a candidate for Sprycel. GIST - approve if the patient tried all of the FDA-approved therapies first to align with NCCN recommendations which include: Imatinib or Ayvakit (avapritinib tablets) AND Sunitinib or Sprycel (dasatinib tablets) AND Stivarga (regorafenib tablets) AND Qinlock (ripretinib tablets). Myeloid/Lymphoid Neoplasms with Eosinophilia - approve if the tumor has ABL1 rearrangement or FGFR1 rearrangement. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Gastrointestinal Stromal Tumor, Myeloid/Lymphoid Neoplasms with Eosinophilia |
| Part B Prerequisite | No |

IDHIFA

Products Affected

- IDHIFA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | IDH2-mutation status |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | AML - approve if the patient is IDH2-mutation status positive as detected by an approved test |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

IMATINIB

Products Affected

- *imatinib*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis. For indications of CML and ALL, the Philadelphia chromosome (Ph) status of the leukemia must be reported. |
| Age Restrictions | ASM, DFSP, HES, MDS/MPD/Myeloid/Lymphoid Neoplasms-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | For ALL/CML, must have Ph-positive for approval of imatinib. Kaposi's Sarcoma-approve if the patient has tried at least one regimen AND has relapsed or refractory disease. Pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)-patient has tried Turalio or according to the prescriber, the patient cannot take Turalio. Myelodysplastic/myeloproliferative disease-approve if the condition is associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements.Graft versus host disease, chronic-approve if the patient has tried at least one conventional systemic treatment (e.g., imbruvica). Metastatic melanoma-approve if the patient has c-Kit-positive advanced/recurrent or metastatic melanoma. Myeloid/lymphoid neoplasms with eosinophilia-approve if the tumor has an ABL1 rearrangement or an FIP1L1-PDGFR or PDGFRB rearrangement. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Chordoma, advanced, aggressive or unresectable fibromatosis (desmoid tumors), cKit positive advanced/recurrent or metastatic melanoma, Kaposi's Sarcoma and pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor, myeloid/lymphoid neoplasms with eosinophilia, GVHD, chronic. |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

IMBRUVICA

Products Affected

- IMBRUVICA ORAL CAPSULE
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | GVHD-1 year and older, other-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | <p>CLL- Approve. GVHD-Approve if the patient has tried one conventional systemic treatment for graft versus host disease (e.g., corticosteroids [methylprednisolone, prednisone], imatinib, low-dose methotrexate, sirolimus, mycophenolate mofetil, Jakafi [ruxolitinib tablets]). Mantle Cell Lymphoma - approve if the patient has tried one systemic regimen or is not a candidate for a systemic regimen (e.g., bendamustine, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, cytarabine, carboplatin, cisplatin, oxaliplatin, or lenalidomide) or if Imbruvica is being used in combination with rituximab prior to induction therapy (e.g., rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone) or if Imbruvica is being used as induction or maintenance therapy in combination with chemotherapy. Marginal Zone Lymphoma - approve if the patient has tried at least one systemic regimen (e.g., bendamustine, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, or lenalidomide). B-cell lymphoma-approve if the patient has tried at least one systemic regimen (e.g., cisplatin, cytarabine, rituximab, oxaliplatin, gemcitabine, ifosfamide, carboplatin, etoposide, or rituximab). Central nervous system Lymphoma (primary)- approve if the patient is not a candidate for or is intolerant to high-dose methotrexate OR has tried at least one therapy (e.g., methotrexate, rituximab, vincristine, procarbazine, cytarabine, thiotepa, carmustine, intrathecal methotrexate, cytarabine, or</p> |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | rituximab). Hairy Cell Leukemia - approve if the patient has tried at least two systemic regimens (cladribine, Nipent [pentostatin injection], rituximab, or Pegasys [peginterferon alfa-2a subcutaneous injection]). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Central Nervous System Lymphoma (Primary), Hairy Cell Leukemia, B-Cell Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma |
| Part B Prerequisite | No |

INCRELEX

Products Affected

- INCRELEX

| PA Criteria | Criteria Details |
|-------------------------------------|----------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | Patients 2 years of age or older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

INFLECTRA

Products Affected

- INFLECTRA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with Biologic DMARD or Targeted Synthetic. |
| Required Medical Information | Diagnosis, concurrent medication, previous medications tried |
| Age Restrictions | CD and UC- Pts aged 6 years or more (initial therapy). PP-18 years and older (initial therapy) |
| Prescriber Restrictions | All dx Initial therapy only -prescribed by or in consultation with: RA/AS/Still's disease/JIA/JRA-rheumatologist, PP/Pyoderma gangrenosum/Hidradenitis suppurativa-dermatologist, Psoriatic Arthritis-rheum or derm, CD/UC-gastroenterologist, Uveitis ophthalmologist, GVHD-a physician affiliated with a transplant center, oncologist, or hematologist, Behcet's Disease- rheum, derm, ophthalmologist, gastroenterologist, or neurologist, Sarcoidosis-pulmonol, ophthalmol, cardio, neuro, or derm |
| Coverage Duration | GVHD intl-1 mo, cont-3 mo.Pyoderma Gangrenosum-intl 4 mo, cont 1 yr.all others-intl 6 mo, cont-12 mo |
| Other Criteria | RA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic or JAK inhibitor for RA are not required to step back and try a conventional synthetic DMARD). JIA/JRA-initial-approve if the patient meets ONE of the following: patient has tried one other medication for this condition for at least 3 months (Note: Examples of other medications for JIA include methotrexate, sulfasalazine, or leflunomide, a nonsteroidal anti-inflammatory drug (NSAID), biologic or JAK inhibitor OR Patient has aggressive disease. PP initial, approve if the patient meets one of the following criteria: 1) pt has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (note: pts who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first) OR 2) pt has a contraindication to MTX as determined by the prescribing physician. Uveitis initial, tried one of the following: periocular, intraocular, or |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | <p>systemic corticosteroid, immunosuppressives or other biologic therapy. GVHD, approve. CD initial, approve if the patient has tried or is currently taking corticosteroids or patient has tried one other agent for CD. UC initial, approve if the patient has had a trial of one systemic agent for at least 3 months (e.g., 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, biologic, JAK inhibitor or a corticosteroid such as prednisone or methylprednisolone). HS initial, tried ONE other therapy (e.g., intralesional or oral corticosteroids, systemic antibiotics, isotretinoin). Behcet's initial, patient has tried at least one conventional tx (eg, systemic CSs, immunosuppressants [e.g., AZA, MTX, MM, CSA, tacrolimus, chlorambucil, cyclophosphamide] or interferon alfa) or at least one tumor necrosis factor for Behcet's disease OR has ophthalmic manifestations. Still's Disease initial, tried CS AND 1 conventional synthetic DMARD (eg, MTX) for 2 mos, or was intolerant. Prev trial of one biologic other than requested drug or biosimilar of the requested drug also counts. Sarcoidosis initial, tried CS and immunosuppressant (eg, MTX, AZA, CSA, chlorambucil), or chloroquine, or thalidomide. Pyoderma gangrenosum (PG) initial, tried one systemic CS or immunosuppressant (eg, mycophenolate, CSA) for 2 mos or was intolerant to one of these agents. Continuation-approve if the patient has had a response as determined by the prescriber.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients already started on infliximab for a covered use, Behcet's disease, Still's disease, Uveitis, Pyoderma gangrenosum, Hidradenitis suppurativa,, Graft-versus-host disease, Juvenile Idiopathic Arthritis (JIA)/JRA, Sarcoidosis |
| Part B Prerequisite | No |

INFLIXIMAB

Products Affected

- AVSOLA
- RENFLEXIS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with Biologic DMARD or Targeted Synthetic. |
| Required Medical Information | Diagnosis, concurrent medication, previous medications tried |
| Age Restrictions | CD and UC- Pts aged 6 years or more (initial therapy). PP-18 years and older (initial therapy) |
| Prescriber Restrictions | All dx Initial therapy only -prescribed by or in consultation with: RA/AS/Still's disease/JIA/JRA-rheumatologist, PP/Pyoderma gangrenosum/Hidradenitis suppurativa-dermatologist, Psoriatic Arthritis-rheum or derm, CD/UC-gastroenterologist, Uveitis ophthalmologist, GVHD-a physician affiliated with a transplant center, oncologist, or hematologist, Behcet's Disease- rheum, derm, ophthalmologist, gastroenterologist, or neurologist, Sarcoidosis-pulmonol, ophthalmol, cardio, neuro, or derm |
| Coverage Duration | GVHD intl-1 mo, cont-3 mo.Pyoderma Gangrenosum-intl 4 mo, cont 1 yr.all others-intl 6 mo, cont-12 mo |
| Other Criteria | RA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic or JAK inhibitor for RA are not required to step back and try a conventional synthetic DMARD). JIA/JRA-initial-approve if the patient meets ONE of the following: patient has tried one other medication for this condition for at least 3 months (Note: Examples of other medications for JIA include methotrexate, sulfasalazine, or leflunomide, a nonsteroidal anti-inflammatory drug (NSAID), biologic or JAK inhibitor OR Patient has aggressive disease. PP initial, approve if the patient meets one of the following criteria: 1) pt has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (note: pts who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first) OR 2) pt has a contraindication to MTX as determined by the prescribing physician. Uveitis initial, tried one of the following: periocular, intraocular, or |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | <p>systemic corticosteroid, immunosuppressives or other biologic therapy. GVHD, approve. CD initial, approve if the patient has tried or is currently taking corticosteroids or patient has tried one other agent for CD. UC initial, approve if the patient has had a trial of one systemic agent for at least 3 months (e.g., 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, biologic, JAK inhibitor or a corticosteroid such as prednisone or methylprednisolone). HS initial, tried ONE other therapy (e.g., intralesional or oral corticosteroids, systemic antibiotics, isotretinoin). Behcet's initial, patient has tried at least one conventional tx (eg, systemic CSs, immunosuppressants [e.g., AZA, MTX, MM, CSA, tacrolimus, chlorambucil, cyclophosphamide] or interferon alfa) or at least one tumor necrosis factor for Behcet's disease OR has ophthalmic manifestations. Still's Disease initial, tried CS AND 1 conventional synthetic DMARD (eg, MTX) for 2 mos, or was intolerant. Prev trial of one biologic other than requested drug or biosimilar of the requested drug also counts. Sarcoidosis initial, tried CS and immunosuppressant (eg, MTX, AZA, CSA, chlorambucil), or chloroquine, or thalidomide. Pyoderma gangrenosum (PG) initial, tried one systemic CS or immunosuppressant (eg, mycophenolate, CSA) for 2 mos or was intolerant to one of these agents. Continuation-approve if the patient has had a response as determined by the prescriber.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients already started on infliximab for a covered use, Behcet's disease, Still's disease, Uveitis, Pyoderma gangrenosum, Hidradenitis suppurativa,, Graft-versus-host disease, Juvenile Idiopathic Arthritis (JIA)/JRA, Sarcoidosis |
| Part B Prerequisite | No |

INGREZZA

Products Affected

- INGREZZA
- INGREZZA INITIATION PACK

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | TD-Prescribed by or in consultation with a neurologist or psychiatrist. Chorea HD - prescribed by or in consultation with a neurologist |
| Coverage Duration | 1 year |
| Other Criteria | Chorea associated with Huntington's Disease- approve if diagnosis is confirmed by genetic testing (for example, an expanded HTT CAG repeat sequence of at least 36). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

INLYTA

Products Affected

- INLYTA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Advanced Renal cell carcinoma-approve. Differentiated thyroid cancer, approve if patient is refractory to radioactive iodine therapy. Soft tissue sarcoma-approve if the patient has alveolar soft part sarcoma and the medication will be used in combination with Keytruda (pembrolizumab). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Differentiated (i.e., papillary, follicular, and Hurthle) Thyroid Carcinoma, Soft tissue sarcoma |
| Part B Prerequisite | No |

INQOVI

Products Affected

- INQOVI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Neoplasms |
| Part B Prerequisite | No |

INREBIC

Products Affected

- INREBIC

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Myelofibrosis (MF), including Primary MF, Post-Polycythemia Vera MF, and Post-Essential Thrombocythemia MF-approve if the patient has intermediate-2 or high-risk disease. Myeloid/Lymphoid Neoplasms with Eosinophilia-approve if the tumor has a JAK2 rearrangement. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Myeloid/Lymphoid Neoplasms with Eosinophilia |
| Part B Prerequisite | No |

INTRAROSA

Products Affected

- INTRAROSA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

IRESSA

Products Affected

- *gefitinib*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | NSCLC-approve if the patient has advanced or metastatic disease and the patient has sensitizing EGFR mutation-positive NSCLC as detected by an approved test. Note: Examples of sensitizing EGFR mutation-positive NSCLC include the following mutations: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S768I. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

IVERMECTIN

Products Affected

- *ivermectin oral*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 month |
| Other Criteria | Pediculosis-approve if the patient has infection caused by pediculus humanus capitis (head lice), pediculus humanus corporis (body lice), or has pediculosis pubis caused by phthirus pubis (pubic lice). Scabies-approve if the patient has classic scabies, treatment resistant scabies, is unable to tolerate topical treatment, has crusted scabies or is using ivermectin tablets for prevention and/or control of scabies. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Ascariasis, Enterobiasis (pinworm infection), Hookworm-related cutaneous larva migrans, Mansonella ozzardi infection, Mansonella streptocerca infection, Pediculosis, Scabies. Trichuriasis, Wucheria bancrofti infection |
| Part B Prerequisite | No |

IWILFIN

Products Affected

- IWILFIN

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Neuroblastoma-Approve if the patient meets the following (A, B and C): A) Patient has high-risk disease, AND B) The medication is being used to reduce the risk of relapse, AND C) Patient has had at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. Note:Examples of anti-GD2 immunotherapy includes Unituxin (dinutuximab intravenous infusion). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

JAKAFI

Products Affected

- JAKAFI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | ALL-less than 21 years of age, GVHD-12 and older, MF/PV/CMML-2/essential thrombo/myeloid/lymphoid neoplasm-18 and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | For polycythemia vera patients must have tried hydroxyurea or peginterferon alfa-2a. ALL-approve if the mutation/pathway is Janus associated kinase (JAK)-related. GVHD, chronic-approve if the patient has tried one conventional systemic treatment for graft versus host disease (for example: prednisone, ibrutinib capsules/tablets). GVHD, acute-approve if the patient has tried one systemic corticosteroid. Polycythemia vera-approve if the patient has tried hydroxyurea. Atypical chronic myeloid leukemia-approve if the patient has a CSF3R mutation or a janus associated kinase 2 (JAK2) mutation. Chronic monomyelocytic leukemia-2 (CMML-2)-approve if the patient is also receiving a hypomethylating agent. Essential thrombocythemia-approve if the patient has tried hydroxyurea, peginterferon alfa-2a or anagrelide. Myeloid/lymphoid neoplasms-approve if the patient has eosinophilia and the tumor has a janus associated kinase 2 (JAK2) rearrangement. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Acute lymphoblastic leukemia, atypical chronic myeloid leukemia, chronic monomyelocytic leukemia-2 (CMML-2), essential thrombocythemia, myeloid/lymphoid neoplasms |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

JAYPIRCA

Products Affected

- JAYPIRCA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | <p>Mantle cell lymphoma-approve if the patient has tried at least one systemic regimen or patient is not a candidate for a systemic regimen (i.e., an elderly patient who is frail), AND the patient has tried one Bruton tyrosine kinase inhibitor (BTK) for mantle cell lymphoma. Note: Examples of a systemic regimen contain one or more of the following products: rituximab, dexamethasone, cytarabine, carboplatin, cisplatin, oxaliplatin, cyclophosphamide, doxorubicin, vincristine, prednisone, methotrexate, bendamustine, Velcade (bortezomib intravenous or subcutaneous injection), lenalidomide, gemcitabine, and Venclexta (venetoclax tablets). Note: Examples of BTK inhibitors indicated for mantle cell lymphoma include Brukinsa (zanubrutinib capsules), Calquence (acalabrutinib capsules), and Imbruvica (ibrutinib capsules, tablets, and oral suspension). CLL/SLL-patient meets (A or B): A) patient has resistance or intolerance to Imbruvica (ibrutinib tablets, capsules, or oral solution), Calquence (acalabrutinib tablets), or Brukinsa (zanubrutinib capsules) or B) patient has relapsed or refractory disease and has tried a Bruton tyrosine kinase (BTK) inhibitor and Venclexta (venetoclax tablet)-based regimen. Examples of BTK inhibitor include: Imbruvica (ibrutinib tablets, capsules, or oral solution), Calquence (acalabrutinib tablets), or Brukinsa (zanubrutinib capsules). Richter's Transformation to DLBCL- pt has tried at least one chemotherapy regimen or is not a candidate for a chemotherapy regimen.</p> |

| PA Criteria | Criteria Details |
|----------------------------|--|
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Richter's Transformation to Diffuse Large B-Cell Lymphoma |
| Part B Prerequisite | No |

KALYDECO

Products Affected

- KALYDECO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Combination use with Orkambi, Trikafta or Symdeko |
| Required Medical Information | N/A |
| Age Restrictions | 1 month of age and older |
| Prescriber Restrictions | prescribed by or in consultation with a pulmonologist or a physician who specializes in CF |
| Coverage Duration | 1 year |
| Other Criteria | CF - must have one mutation in the CFTR gene that is responsive to the requested medication. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

KERENDIA

Products Affected

- KERENDIA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concomitant use with spironolactone or eplerenone |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older (initial and continuation therapy) |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Diabetic kidney disease, initial-approve if the patient meets the following criteria (i, and ii): i. Patient has a diagnosis of type 2 diabetes, AND ii. Patient meets one of the following (a or b): a)Patient is currently receiving a maximally tolerated labeled dosage of an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) OR b)According to the prescriber, patient has a contraindication to ACE inhibitor or ARB therapy. Diabetic kidney disease, continuation-approve if the patient meets the following criteria (i, and ii): i. Patient has a diagnosis of type 2 diabetes, AND ii. Patient meets one of the following (a or b): a. Patient is currently receiving a maximally tolerated labeled dosage of an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) OR b. According to the prescriber, patient has a contraindication to ACE inhibitor or ARB therapy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

KESIMPTA

Products Affected

- KESIMPTA PEN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with other disease-modifying agents used for multiple sclerosis (MS) |
| Required Medical Information | Relapsing form of Multiple Sclerosis (MS), to include, clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

KISQALI

Products Affected

- KISQALI
- KISQALI FEMARA CO-PACK

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | <p>Breast cancer - approve recurrent or metastatic hormone receptor positive (HR+) [i.e., estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+)]disease, and HER2-negative breast cancer when the pt meets ONE of the following</p> <ol style="list-style-type: none"> 1. Pt is postmenopausal and Kisqali will be used in combination with anastrozole, exemestane, or letrozole 2. pt is premenopausal or perimenopausal and is receiving ovarian suppression/ablation with GnRH agonist, or has had surgical bilateral oophorectomy, or ovarian irradiation AND Kisqali will be used in combination with anastrozole, exemestane, or letrozole 3. pt is a man (a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression) who is receiving GnRH analog AND Kisqali with be used in combination with anastrozole, exemestane or letrozole. 4. Patient is postmenopausal, pre/perimenopausal (patient receiving ovarian suppression/ablation with a GnRH agonist or has had surgical bilateral oophorectomy or ovarian irradiation) or a man, and Kisqali (not Co-Pack) will be used in combination with fulvestrant. If the request is for Kisqali Femara, patients do not need to use in combination with anastrozole, exemestane or letrozole. <p>Endometrial cancer - approve if pt meets all of (A, B and C): A) pt has recurrent or metastatic disease, and B) has estrogen receptor (ER)-positive tumors, and C) if request is for Kisqali (not Co-Pack), Kisqali will be used in combination with letrozole.</p> |

| PA Criteria | Criteria Details |
|----------------------------|--|
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Pre/peri-menopausal women with breast cancer in combination with fulvestrant, and endometrial cancer |
| Part B Prerequisite | No |

KORLYM

Products Affected

- KORLYM
- *mifepristone oral tablet 300 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, prior surgeries |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | Prescribed by or in consultation with an endocrinologist or a physician who specializes in the treatment of Cushing's syndrome. |
| Coverage Duration | Endogenous Cushing's Synd-1 yr. Pt awaiting surgery or response after radiotherapy-4 months |
| Other Criteria | Pending CMS Review |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients with Endogenous Cushing's Syndrome, awaiting surgery. Patients with Endogenous Cushing's syndrome, awaiting a response after radiotherapy |
| Part B Prerequisite | No |

KOSELUGO

Products Affected

- KOSELUGO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | <p>Neurofibromatosis Type 1-approve if prior to starting Koselugo, the patient has symptomatic, inoperable plexiform neurofibromas and if the patient is 2 to 18 years old OR if the patient is 19 years or older if the patient started on therapy with Koselugo prior to becoming 19. Circumscribed Glioma-approve if the patient has recurrent, refractory or progressive disease AND the tumor is BRAF fusion positive OR BRAF V600E activating mutation positive OR patient has neurofibromatosis type 1 mutated glioma AND this medication will be used as a single agent AND the patient is 3-21 years of age OR is greater 21 and has been previously started on therapy with Koselugo prior to becoming 21 years of age. Langerhans Cell Histiocytosis- approve if the patient meets the following criteria (A and B):</p> <p>A) Patient meets one of the following (i, ii, iii, or iv): i. Patient meets both of the following (a and b): a) Patient has multisystem Langerhans cell histiocytosis, AND b) Patient has symptomatic disease or impending organ dysfunction, OR ii. Patient has single system lung Langerhans cell histiocytosis, OR iii. Patient meets all of the following (a, b, and c): a) Patient has single system bone disease, AND b) Patient has not responded to treatment with a bisphosphonate, AND c) Patient has more than 2 bone lesions, OR iv. Patient has central nervous system disease, AND B) The medication is used as a single agent.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |

| PA Criteria | Criteria Details |
|----------------------------|---|
| Off-Label Uses | Circumscribed Glioma, Langerhans Cell Histiocytosis |
| Part B Prerequisite | No |

KRAZATI

Products Affected

- KRAZATI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Non-Small Cell Lung Cancer (NSCLC)-approve if the patient has KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an approved test AND has been previously treated with at least one systemic regimen. Note: Examples of systemic regimens include those containing one or more of the following products: Keytruda (pembrolizumab intravenous infusion), Opdivo (nivolumab intravenous infusion), Tecentriq (atezolizumab intravenous infusion), Alimta (pemetrexed intravenous infusion), Yervoy (ipilimumab intravenous infusion), Abraxane (albumin-bound paclitaxel intravenous infusion), bevacizumab, cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine. Colon or Rectal Cancer-approve if pt has unresectable, advanced, or metastatic disease AND pt has KRAS G12C mutation-positive disease AND medication is prescribed as part of a combination regimen or the patient is unable to tolerate combination therapy AND pt has previously received a chemotherapy regimen for colon or rectal cancer. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Colon or Rectal cancer |
| Part B Prerequisite | No |

LAPATINIB

Products Affected

- *lapatinib*
- TYKERB

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis for which lapatinib is being used. Metastatic breast cancer, HER2 status or hormone receptor (HR) status. |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | HER2-positive recurrent or metastatic breast cancer, approve if lapatinib will be used in combination with capecitabine OR trastuzumab and the patient has tried at least two prior anti-HER2 based regimens OR the medication will be used in combination with an aromatase inhibitor and and the patient has HR+ disease and the patient is a postmenopausal woman or the patient is premenopausal or perimenopausal woman and is receiving ovarian suppression/ablation with a GnRH agonist, surgical bilateral oophorectomy or ovarian irradiation OR the patient is a man and is receiving a GnRH analog. Colon or rectal cancer-approve if the patient has unresectable advanced or metastatic disease that is human epidermal receptor 2 (HER2) amplified and with wild-type RAS and BRAF disease and the patient has tried at least one chemotherapy regimen or is not a candidate for intensive therapy and the medication is used in combination with trastuzumab (Part B before Part D Step Therapy - applies only to beneficiaries enrolled in an MA-PD plan) and the patient has not been previously treated with a HER2-inhibitor. Bone Cancer-approve if the patient has recurrent chordoma and if the patient has epidermal growth-factor receptor (EGFR)-positive disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Bone cancer-chordoma, colon or rectal cancer, breast cancer in pre/perimenopausal women and men |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

LENALIDOMIDE

Products Affected

- *lenalidomide*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis and previous therapies or drug regimens tried. |
| Age Restrictions | 18 years and older (except Kaposi's Sarcoma, Castleman's Disease, CNS Lymphoma) |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | Follicular lymphoma-approve if the patient is using lenalidomide in combination with rituximab or has tried at least one prior therapy. MCL-approve -if the patient is using lenalidomide in combination with rituximab or has tried at least two other therapies or therapeutic regimens. MZL-approve if the patient is using lenalidomide in combination with rituximab or has tried at least one other therapy or therapeutic regimen. Multiple myeloma-approve. MDS-approve if the patient meets one of the following: 1) Pt has symptomatic anemia, OR 2) Pt has transfusion-dependent anemia, OR 3) Pt has anemia that is not controlled with an erythroid stimulating agent (eg, Epogen, Procrit [epoetin alfa injection], Aranesp [darbepoetin alfa injection]). B-cell-lymphoma (other)-approve if the pt has tried at least one prior therapy. Myelofibrosis-approve if according to the prescriber the patient has anemia and the pt has serum erythropoietin levels greater than or equal to 500 mU/mL or according to the prescriber the patient has anemia, has serum erythropoietin levels less than 500 mU/mL and patient has experienced no response or loss of response to erythropoietic stimulating agents. Peripheral T-Cell Lymphoma or T-Cell Leukemia/Lymphoma-approve if the pt has tried at least one other therapy or regimen. CNS lymphoma-approve if according to the prescriber the patient has relapsed or refractory disease. Hodgkin lymphoma, classical-approve if the patient has tried at least three other I222 regimens. |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | Castleman's disease-approve if the patient has relapsed/refractory or progressive disease. Kaposi's Sarcoma-approve if the patient has tried at least one regimen or therapy and the patient has relapsed or refractory disease. Systemic light chain amyloidosis-approve if lenalidomide is used in combination with dexamethasone. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Off label uses for lenalidomide include-Systemic Amyloidosis Light Chain, Diffuse Large B Cell Lymphoma (Non-Hodgkin's Lymphoma), Myelofibrosis. Castleman's Disease, Hodgkin lymphoma (Classical), Peripheral T-Cell Lymphoma, T-Cell Leukemia/Lymphoma, Central nervous system lymphoma, Kaposi's sarcoma. Off label uses for lenalidomide include-follicular lymphoma, marginal zone lymphoma and multiple myeloma following autologous hematopoietic stem cell transplantation. |
| Part B Prerequisite | No |

LENVIMA

Products Affected

- LENVIMA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | <p>DTC - must be refractory to radioactive iodine treatment for approval.</p> <p>RCC, advanced disease- approve if the pt meets i or ii: i. Lenvima is being used in combination with pembrolizumab OR ii. Lenvima is used in combination with everolimus and the patient meets a or b - a. Patient has clear cell histology and patient has tried one antiangiogenic therapy or b. patient has non-clear cell histology. New starts for all RCC must have tried Cabometyx. MTC-approve if the patient has tried at least one systemic therapy. Endometrial Carcinoma-Approve if the patient meets the following criteria (A, B, C, and D): A) The patient has advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) AND B) The medication is used in combination with Keytruda (pembrolizumab for intravenous injection) AND C)the disease has progressed on at least one prior systemic therapy AND D) The patient is not a candidate for curative surgery or radiation.</p> <p>Thymic carcinoma-approve if the patient has tried at least one chemotherapy regimen. New starts for Hepacocellular Carnicoma: For first line systemic therapy, sorafenib must be tried first. For subsequent-line system therapy if disease progression, Cabometyx must be tried first.</p> <p>Melanoma - approve if the patient has unresectable or metastatic melanoma AND the medication will be used in combination with Keytruda (pembrolizumab intravenous injection) AND the patient has disease</p> |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | progression on anti-programmed death receptor-1 (PD-1)/programmed death-ligand 1 (PD-L1)-based therapy. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients with Medullary Thyroid Carcinoma (MTC), thymic carcinoma, Renal cell carcinoma with non-clear cell histology and Melanoma |
| Part B Prerequisite | No |

LONSURF

Products Affected

- LONSURF

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Gastric or Gastroesophageal Junction Adenocarcinoma, approve if the patient has been previously treated with at least two chemotherapy regimens for gastric or gastroesophageal junction adenocarcinoma. Colon and rectal cancer-approve per labeling if the patient has been previously treated with a fluopyrimidine, oxaliplatin, irinotecan and if the patient's tumor or metastases are wild-type RAS (KRAS wild type and NRAS wild type) they must also try Erbitux or Vectibix. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

LOQTORZI

Products Affected

- LOQTORZI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | Prescribed by or in consultation with an oncologist |
| Coverage Duration | 1 year |
| Other Criteria | Nasopharyngeal carcinoma-approve if the patient has recurrent, unresectable, oligometastatic, or metastatic disease AND the patient meets ONE of the following (i or ii): i. Patient meets BOTH of the following (a and b): a) Loqtorzi is used for first-line treatment AND b) Loqtorzi is used in combination with cisplatin and gemcitabine, OR ii. Patient meets both of the following (a and b): a) Loqtorzi is used for subsequent treatment AND b) Loqtorzi is used as a single agent. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

LORBRENA

Products Affected

- LORBRENA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, ALK status, ROS1 status, previous therapies |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Erdheim Chester disease-approve if the patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease. Inflammatory myofibroblastic tumor (IMT)-approve if the patient has IMT with ALK translocation. NSCLC - Approve if the patient has ALK-positive advanced or metastatic NSCLC, as detected by an approved test. In addition, patients new to therapy must also have a trial of Alecensa prior to approval of Lorbrena. NSCLC-ROS1 Rearrangement-Positive, advanced or metastatic NSCLC-approve if the patient has tried at least one of crizotinib, entrectinib or ceritinib. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Non-small cell lung cancer (NSCLC)-ROS1 Rearrangement-Positive, Erdheim Chester Disease, Inflammatory Myofibroblastic Tumor (IMT) |
| Part B Prerequisite | No |

LUMAKRAS

Products Affected

- LUMAKRAS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | Non-Small Cell Lung Cancer (NSCLC)-approve if the patient has KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test AND has been previously treated with at least one systemic regimen. Pancreatic Adenocarcinoma- approve if patient has KRAS G12C-mutated disease, as determined by an approved test AND either (i or ii): (i) patient has locally advanced or metastatic disease and has been previously treated with at least one systemic regimen OR (ii) patient has recurrent disease after resection. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Pancreatic Adenocarcinoma |
| Part B Prerequisite | No |

LUMIZYME

Products Affected

- LUMIZYME

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, genetic and lab test results |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a geneticist, neurologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders |
| Coverage Duration | 1 year |
| Other Criteria | Approve if the patient has a laboratory test demonstrating deficient acid alpha-glucosidase activity in blood, fibroblasts, or muscle tissue OR patient has a molecular genetic test demonstrating acid alpha-glucosidase gene mutation |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

LYNPARZA

Products Affected

- LYNPARZA

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | <p>Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - Maintenance monotherapy-Approve if the patient meets one of the following criteria (A or B): A) The patient meets both of the following criteria for first-line maintenance therapy (i and ii): i. The patient has a germline or somatic BRCA mutation-positive disease as confirmed by an approved test AND ii. The patient is in complete or partial response to first-line platinum-based chemotherapy regimen (e.g., carboplatin with paclitaxel, carboplatin with doxorubicin, docetaxel with carboplatin) OR B) The patient is in complete or partial response after at least two platinum-based chemotherapy regimens (e.g., carboplatin with gemcitabine, carboplatin with paclitaxel, cisplatin with gemcitabine). Ovarian, fallopian tube, or primary peritoneal cancer-maintenance, combination therapy-approve if the medication is used in combination with bevacizumab, the patient has homologous recombination deficiency (HRD)-positive disease, as confirmed by an approved test and the patient is in complete or partial response to first-line platinum-based chemotherapy regimen. Breast cancer, adjuvant-approve if the patient has germline BRCA mutation-positive, HER2-negative breast cancer and the patient has tried neoadjuvant or adjuvant therapy. Breast cancer, recurrent or metastatic disease-approve if the patient has recurrent or metastatic disease and has germline BRCA mutation-positive breast cancer. Pancreatic Cancer-maintenance therapy-approve if the patient has a germline BRCA mutation-positive metastatic disease and the disease has</p> |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | <p>not progressed on at least 16 weeks of treatment with a first-line platinum-based chemotherapy regimen. Prostate cancer-castration resistant-approve if the patient has metastatic disease, the medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog or the pateint has had a bilateral orchiectomy, and the patient meets either (i or ii): i) the patient has germline or somatic homologous recombination repair (HRR) gene-mutated disease, as confirmed by an approved test and the patient has been previously treated with at least one androgen receptor directed therapy or ii) the patient has a BRCA mutation and the medication is used in combination with abiraterone plus one of prednisone or prednisolone. Uterine Leiomyosarcoma-approve if the patient has BRCA2-altered disease and has tried one systemic regimen.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Uterine Leiomyosarcoma |
| Part B Prerequisite | No |

LYTGOBI

Products Affected

- LYTGOBI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Cholangiocarcinoma-approve if the patient has unresectable locally advanced or metastatic disease, tumor has fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements as detected by an approved test and if the patient has been previously treated with at least one systemic regimen. Note: Examples of systemic regimens include gemcitabine + cisplatin, 5-fluorouracil + oxaliplatin or cisplatin, capecitabine + cisplatin or oxaliplatin, gemcitabine + Abraxane (albumin-bound paclitaxel) or capecitabine or oxaliplatin, and gemcitabine + cisplatin + Abraxane. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

MAVYRET

Products Affected

- MAVYRET

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Genotype (including unknown), prescriber specialty, other medications tried or used in combination with requested medication |
| Age Restrictions | 3 years or older |
| Prescriber Restrictions | Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician |
| Coverage Duration | Criteria will be applied consistent with current AASLD/IDSA guidance. |
| Other Criteria | Criteria will be applied consistent with current AASLD/IDSA guidance. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Indications consistent with current AASLD/IDSA guidance |
| Part B Prerequisite | No |

MEGESTROL

Products Affected

- *megestrol oral suspension 400 mg/10 ml (10 ml), 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml), 800 mg/20 ml (20 ml)*
- *megestrol oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Coverage is not provided for weight gain for cosmetic reasons. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

MEKINIST

Products Affected

- MEKINIST

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis for which Mekinist is being used. For melanoma, thyroid cancer and NSCLC must have documentation of BRAF V600 mutations |
| Age Restrictions | 1 year and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Melanoma must be used in patients with BRAF V600 mutation, and patient has unresectable, advanced (including Stage III or Stage IV disease), or metastatic melanoma. Note-This includes adjuvant treatment in patients with Stage III disease with no evidence of disease post-surgery. For NSCLC requires BRAF V600E Mutation and use in combination with Tafenlar. Thyroid cancer, anaplastic-patient has locally advanced or metastatic anaplastic disease AND Mekinist will be taken in combination with Tafenlar, unless intolerant AND the patient has BRAF V600-positive disease. Ovarian/fallopian tube/primary peritoneal cancer-approve if the patient has recurrent disease and the medication is used for low-grade serous carcinoma or the patient has BRAF V600 mutation positive disease and the medication will be taken in combination with Tafenlar. Biliary Tract Cancer-approve if the patient has tried at least one systemic chemotherapy regimen, patient has BRAF V600 mutation positive disease and the medication will be taken in combination with Tafenlar. Central Nervous System Cancer-approve if the medication is being used for one of the following situations (i, ii, or iii): i. Adjuvant treatment of one of the following conditions (a, b, or c): a) Pilocytic astrocytoma OR b) Pleomorphic xanthoastrocytoma OR c) Ganglioglioma OR ii. Recurrent or progressive disease for one of the following conditions (a, b, c or d): a) glioma OR b) Isocitrate dehydrogenase-2 (IDH2)-mutant astrocytoma OR c) Glioblastoma or d) Oligodendroglioma OR iii. Melanoma with brain |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | <p>metastases AND patient has BRAF V600 mutation-positive disease AND medication will be taken in combination with Tafinlar (dabrafenib). Histiocytic neoplasm-approve if patient has Langerhans cell histiocytosis and one of the following (a, b, or c): a) Multisystem disease OR b) Pulmonary disease OR c) Central nervous system lesions OR patient has Erdheim Chester disease or Rosai-Dorfman disease. Metastatic or Solid Tumors-Approve if the patient meets the following (A, B, and C): A) Patient has BRAF V600 mutation-positive disease, AND B) The medication will be taken in combination with Tafinlar (dabrafenib capsules), AND C) Patient has no satisfactory alternative treatment options.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Histiocytic Neoplasm |
| Part B Prerequisite | No |

MEKTOVI

Products Affected

- MEKTOVI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, BRAF V600 status, concomitant medications |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Melanoma - approve if the patient has unresectable, advanced or metastatic melanoma AND has a BRAF V600 mutation AND Mektovi will be used in combination with Braftovi. Histiocytic neoplasm-approve if the patient has Langerhans cell histiocytosis and one of the following (i, ii, or iii): i. multisystem disease OR, ii. pulmonary disease or, iii. central nervous system lesions. NSCLC-approve if pt has BRAF V600E mutation-positive metastatic disease AND this medication will be taken in combination with Braftovi (encorafenib capsules). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Histiocytic Neoplasms |
| Part B Prerequisite | No |

MODAFINIL

Products Affected

- *modafinil*
- PROVIGIL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | Excessive daytime sleepiness associated with narcolepsy-prescribed by or in consultation with a sleep specialist physician or neurologist |
| Coverage Duration | Authorization will be for 12 months. |
| Other Criteria | Excessive sleepiness associated with Shift Work Sleep Disorder (SWSD) - approve if the patient is working at least 5 overnight shifts per month. Adjunctive/augmentation treatment for depression in adults if the patient is concurrently receiving other medication therapy for depression. Excessive daytime sleepiness associated with obstructive sleep apnea/hypoapnea syndrome-approve. Excessive daytime sleepiness associated with Narcolepsy-approve if narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Excessive daytime sleepiness (EDS) associated with myotonic dystrophy. Adjunctive/augmentation for treatment of depression in adults. |
| Part B Prerequisite | No |

NAGLAZYME

Products Affected

- NAGLAZYME

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, genetic and lab test results |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders |
| Coverage Duration | 1 year |
| Other Criteria | Approve if the patient has a laboratory test demonstrating deficient N-acetylgalactosamine 4-sulfatase (arylsulfatase B) activity in leukocytes or fibroblasts OR has a molecular genetic test demonstrating arylsulfatase B gene mutation. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NAYZILAM

Products Affected

- NAYZILAM

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, other medications used at the same time |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist |
| Coverage Duration | 1 year |
| Other Criteria | Intermittent Episodes of Frequent Seizure Activity (i.e., seizure clusters, acute repetitive seizures)-approve if the patient is currently receiving maintenance antiepileptic medication(s). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NERLYNX

Products Affected

- NERLYNX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Stage of cancer, HER2 status, previous or current medications tried |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Breast cancer adjuvant therapy - approve if the patient meets all of the following criteria: patient will not be using this medication in combination with HER2 antagonists, Patient has HER2-positive breast cancer AND patient has completed one year of adjuvant therapy with trastuzumab OR could not tolerate one year of therapy. Breast cancer, recurrent or metastatic disease-approve if the patient has HER-2 positive breast cancer, Nerlynx will be used in combination with capecitabine and the patient has tried at least two prior anti-HER2 based regimens. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NEXLETOL

Products Affected

- NEXLETOL

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Patient has tried and failed or has a contraindication to a statin or the patient is determined to be statin intolerant defined by experiencing statin related rhabdomyolysis or pt experienced skeletal-related muscle symptoms while receiving separate trials of two statins and during both trials the skeletal-related symptoms resolved during discontinuation. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NEXLIZET

Products Affected

- NEXLIZET

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Patient has tried and failed or has a contraindication to a maximally tolerated statin or the patient is determined to be statin intolerant defined by experiencing statin related rhabdomyolysis or pt experienced skeletal-related muscle symptoms while receiving separate trials of two statins and during both trials the skeletal-related symptoms resolved during discontinuation. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NINLARO

Products Affected

- NINLARO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | MM - be used in combination with lenalidomide or cyclophosphamide OR pt had received at least ONE previous therapy for multiple myeloma OR the agent will be used following autologous stem cell transplantation (ASCT). Systemic light chain amyloidosis-approve if the patient has tried at least one other regimen for this condition. Waldenstrom Macroglobulinemia/lymphoplasmacytic lymphoma-approve if used in combination with a rituximab product and dexamethasone |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients with systemic light chain amyloidosis, Waldenstrom Macroglobulinemia/lymphoplasmacytic lymphoma |
| Part B Prerequisite | No |

NMDA RECEPTOR ANTAGONIST

Products Affected

- *memantine*
- NAMENDA TITRATION PAK
- NAMENDA XR ORAL CAPSULE,SPRINKLE,ER 24HR
- NAMZARIC

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | Automatic approval if member is greater than 26 years of age. Prior Authorization is required for age 26 or younger. |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NUBEQA

Products Affected

- NUBEQA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Prostate cancer - non-metastatic, castration resistant-approve if the requested medication will be used concurrently with a gonadotropin-releasing hormone (GnRH) agonist or if the patient has had a bilateral orchiectomy or if the medication is used concurrently with Firmagon. Prostate cancer-metastatic, castration sensitive-approve if (A and B): A) the medication is used in combination with docetaxel or patient has completed docetaxel therapy, and B) the medication will be used in combination with a GnRH agonist or in combination with Firmagon or if the patient had a bilateral orchiectomy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NUCALA

Products Affected

- NUCALA SUBCUTANEOUS AUTO-INJECTOR
- NUCALA SUBCUTANEOUS SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with another monoclonal antibody therapy |
| Required Medical Information | N/A |
| Age Restrictions | Asthma-6 years of age and older. EGPA/Polyps-18 years of age and older. HES-12 years and older. |
| Prescriber Restrictions | Asthma-Prescribed by or in consultation with an allergist, immunologist, or pulmonologist. EGPA-prescribed by or in consultation with an allergist, immunologist, pulmonologist or rheumatologist. HES-prescribed by or in consultation with an allergist, immunologist, hematologist, pulmonologist or rheumatologist. Polyps-prescribed by or in consult with allergist, immunologist or Otolaryngologist. |
| Coverage Duration | Initial-Asthma/EGPA/polyps-6 months, HES-8 months. 12 months continuation. |
| Other Criteria | Asthma initial - must have blood eosinophil level of greater than or equal to 150 cells per microliter within the previous 6 wks (prior to tx with Nucala or another monoclonal antibody therapy that may lower blood eosinophil levels) AND has received combo tx w/inhaled corticosteroid AND at least 1 additional asthma controller/maintenance med (Examples: LAMA, LABA, leukotriene receptor antagonist, monoclonal antibody) AND pt's asthma cont to be uncontrolled, or was uncontrolled prior to starting Nucala or another monoclonal antibody therapy for asthma as defined by 1 of following-pt experi 2 or more asthma exacer req tx w/systemic corticosteroids in prev yr, pt experienced 1 or more asthma exacer requiring hospitalization, urgent care visit or ED visit in the prev yr, pt has a FEV1 less than 80 percent predicted, Pt has FEV1/FVC less than 0.80, or Pt's asthma worsens upon taper of oral (systemic) corticosteroid therapy. Cont-pt responded to Nucala tx as determined by the prescribing physician AND Pt cont to receive tx with an inhaled corticosteroid. EGPA initial-approve if pt has active, non-severe disease, has/had a blood eosinophil level of greater than or equal to 150 cells per microliter within |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | <p>the previous 6 wks or within 6 wks prior to any monoclonal antibody that may lower blood eosinophil levels. Cont-pt responded to Nucala tx as determined by the prescribing physician.HES initial-pt has had hypereosinophilic synd for greater than or equal to 6 months AND has FIP1L1-PDGFRalpha-negative dis AND pt does NOT have identifiable non-hematologic secondary cause of hypereosinophilic synd AND prior to initiating tx with monoclonal antibody that may lower blood eosinophil levels, pt has/had a blood eosinophil level of greater than or equal to 1,000 cells per microliter. Cont-approve if the patient has responded to Nucala tx. Nasal polyps, initial-approve if pt meets ALL of the following criteria(A, B, C and D):A) pt has chronic rhinosinusitis w/nasal polyposis as evidenced by direct examination, endoscopy, or sinus CT scan AND B)pt experienced 2 or more of the following sympt for at least 6 months:nasal congest/obstruct/discharge, and/or reduction/loss of smell AND C)pt meets BOTH of the following (a and b): a)Pt has received tx with intranasal corticosteroid AND b)Pt will continue to receive tx with intranasal corticosteroid concomitantly with Nucala AND D)pt meets 1 of the following (a, b or c): a)Pt has received at least 1 course of tx with a systemic corticosteroid for 5 days or more within the previous 2 years, OR b)Pt has a contraindication to systemic corticosteroid tx, OR c)Pt had prior surgery for nasal polyps.Cont-approve if the pt has received at least 6 months of therapy, continues to receive tx with an intranasal corticosteroid and has responded to tx.</p> |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NUEDEXTA

Products Affected

- NUEDEXTA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NUPLAZID

Products Affected

- NUPLAZID

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist |
| Coverage Duration | 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NURTEC

Products Affected

- NURTEC ODT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with another calcitonin gene-related peptide (CGRP) inhibitor being prescribed for migraine headache prevention if Nurtec ODT is being taking for the preventive treatment of episodic migraine. |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Migraine, Acute treatment-approve if the patient has tried at least one triptan or has a contraindication to triptans. Preventive treatment of episodic migraine-approve if the patient has greater than or equal to 4 but less than 15 migraine headache days per month (prior to initiating a migraine preventive medication and has tried at least two standard prophylactic pharmacologic therapies, at least one drug each from a different pharmacologic class (e.g., anticonvulsant, beta-blocker), and has had inadequate responses to those therapies or the patient has experienced adverse events severe enough to warrant discontinuation. In addition, if the patient is currently taking Nurtec ODT, the patient has had a significant clinical benefit from the medication. A patient who has already tried an oral or injectable calcitonin gene-related peptide (CGRP) inhibitor indicated for the prevention of migraine or Botox (onabotulinumtoxinA injection) for the prevention of migraine is not required to try two standard prophylactic pharmacologic therapies. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

OCALIVA

Products Affected

- OCALIVA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Patient does not have cirrhosis or has compensated cirrhosis without evidence of portal hypertension |
| Required Medical Information | Prescriber specialty, lab values, prior medications used for diagnosis and length of trials |
| Age Restrictions | 18 years and older (initial) |
| Prescriber Restrictions | Prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant physician (initial) |
| Coverage Duration | 6 months initial, 1 year cont. |
| Other Criteria | Initial treatment of PBC-Patient must meet both 1 and 2-1. Patient has a diagnosis of PBC as defined by TWO of the following:a)Alkaline phosphatase (ALP) elevated above the upper limit of normal as defined by normal laboratory reference values b)Positive anti-mitochondrial antibodies (AMAs) or other PBC-specific auto-antibodies, including sp100 or gp210, if AMA is negative c)Histologic evidence of primary biliary cholangitis (PBC) from a liver biopsy 2. Patient meets ONE of the following: a) Patient has been receiving ursodiol therapy for greater than or equal to 1 year and has had an inadequate response. b) Patient is unable to tolerate ursodiol therapy. Cont tx - approve if the patient has responded to Ocaliva therapy as determined by the prescribing physician (e.g., improved biochemical markers of PBC (e.g., alkaline phosphatase [ALP], bilirubin, gamma-glutamyl transpeptidase [GGT], aspartate aminotransferase [AST], alanine aminotransferase [ALT] levels)). Patients new to therapy and continuing therapy must not have cirrhosis or must have compensated cirrhosis without evidence of portal hypertension. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

OCREVUS

Products Affected

- OCREVUS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with other Disease-Modifying Agents used for MS |
| Required Medical Information | N/A |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | Prescribed by, or in consultation with, a physician who specializes in the treatment of MS and/or a neurologist |
| Coverage Duration | 1 year |
| Other Criteria | For relapsing remitting disease new starts - patient must have tried and failed two other MS therapies |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

OCTREOTIDE INJECTABLE

Products Affected

- *octreotide acetate*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Acromegaly-prescr/consult w/endocrinologist. NETs-prescr/consult w/oncologist, endocrinologist, or gastroenterologist. Pheochromocytoma/paraganglioma-prescr/consult w/endo/onc/neuro.Meningioma-prescr/consult w/oncologist, radiologist, neurosurg/thymoma/thymic carcinoma-presc/consult with oncologist |
| Coverage Duration | 1 year |
| Other Criteria | Acromegaly-approve if patient meets ONE of the following (i, ii, or iii): i. Patient has had an inadequate response to surgery and/or radiotherapy OR ii. Patient is NOT an appropriate candidate for surgery and/or radiotherapy OR iii. Patient is experiencing negative effects due to tumor size (e.g., optic nerve compression) AND Patient has (or had) a pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender for the reporting laboratory. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Meningioma, thymoma and thymic carcinoma, pheochromocytoma and paraganglioma |
| Part B Prerequisite | No |

ODOMZO

Products Affected

- ODOMZO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | BCC - Must not have had disease progression while on Erivedge (vismodegib). |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Locally advanced BCC approve if the BCC has recurred following surgery/radiation therapy or if the patient is not a candidate for surgery AND the patient is not a candidate for radiation therapy, according to the prescribing physician. Metastatic BCC - approve, if the disease is limited to nodal metastases. (Note-This includes primary or recurrent nodal metastases. A patient with distant metastasis does not meet this requirement.) |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Metastatic BCC |
| Part B Prerequisite | No |

OFEV

Products Affected

- OFEV

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | IPF-Prescribed by or in consultation with a pulmonologist. Interstitial lung disease associated with systemic sclerosis-prescribed by or in consultation with a pulmonologist or rheumatologist. |
| Coverage Duration | 1 year |
| Other Criteria | IPF - must have FVC greater than or equal to 40 percent of the predicted value AND IPF must be diagnosed with either findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP. Interstitial lung disease associated with systemic sclerosis-approve if the FVC is greater than or equal to 40 percent of the predicted value and the diagnosis is confirmed by high-resolution computed tomography. Chronic fibrosing interstitial lung disease-approve if the forced vital capacity is greater than or equal to 45 percent of the predicted value AND according to the prescriber the patient has fibrosing lung disease impacting more than 10 percent of lung volume on high-resolution computed tomography AND according to the prescriber the patient has clinical signs of progression. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

OJJAARA

Products Affected

- OJJAARA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Myelofibrosis-approve if the patient has intermediate-risk or high-risk disease and (a or b): a) the patient has anemia, defined as hemoglobin less than 10g/dL or b) the patient has platelet count greater than or equal to 50x10 ⁹ /L. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ONUREG

Products Affected

- ONUREG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | AML - Approve if the medication is used for post-remission maintenance therapy AND the patient has intermediate or poor-risk cytogenetics OR has complete response to previous intensive induction chemotherapy AND the patient has declined or is not fit or eligible for allogeneic hematopoietic stem cell transplant. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

OPSUMIT

Products Affected

- OPSUMIT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | PAH WHO group, right heart catheterization |
| Age Restrictions | N/A |
| Prescriber Restrictions | PAH - must be prescribed by or in consultation with a cardiologist or a pulmonologist. |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | Pulmonary arterial hypertension (PAH) WHO Group 1 patients are required to have had a right-heart catheterization to confirm the diagnosis of PAH to ensure appropriate medical assessment. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ORENCIA

Products Affected

- ORENCIA
- ORENCIA CLICKJECT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with a Biologic DMARD or Targeted Synthetic DMARD |
| Required Medical Information | Diagnosis, concurrent medications, previous therapies tried. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Initial therapy only-RA and JIA/JRA prescribed by or in consultation with a rheumatologist. PsA-prescribed by or in consultation with a rheumatologist or dermatologist. |
| Coverage Duration | End of the plan year |
| Other Criteria | Pending CMS review |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ORENITRAM

Products Affected

- *orenitram*
- ORENITRAM MONTH 1 TITRATION KT
- ORENITRAM MONTH 2 TITRATION KT
- ORENITRAM MONTH 3 TITRATION KT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent Use with Other Inhaled or Parenteral Prostacyclin Agents Used for Pulmonary Hypertension. |
| Required Medical Information | Diagnosis, results of right heart cath |
| Age Restrictions | N/A |
| Prescriber Restrictions | PAH must be prescribed by or in consultation with a cardiologist or a pulmonologist. |
| Coverage Duration | 1 year |
| Other Criteria | For PAH - must have PAH (WHO Group 1) and had a right heart catheterization to confirm the diagnosis of PAH (WHO Group 1). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ORGOVYX

Products Affected

- ORGOVYX

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Prostate Cancer-approve |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ORKAMBI

Products Affected

- ORKAMBI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Combination use with Kalydeco, Trikafta or Symdeko. |
| Required Medical Information | N/A |
| Age Restrictions | 1 year of age and older |
| Prescriber Restrictions | prescribed by or in consultation with a pulmonologist or a physician who specializes in CF |
| Coverage Duration | 1 year |
| Other Criteria | CF - homozygous for the Phe508del (F508del) mutation in the CFTR gene (meaning the patient has two copies of the Phe508del mutation) |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ORSERDU

Products Affected

- ORSERDU

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Breast cancer in postmenopausal women or Men-approve if the patient meets the following criteria (A, B, C, D, and E): A) Patient has recurrent or metastatic disease, AND B) Patient has estrogen receptor positive (ER+) disease, AND C) Patient has human epidermal growth factor receptor 2 (HER2)-negative disease, AND D) Patient has estrogen receptor 1 gene (ESR1)-mutated disease, AND E) Patient has tried at least one endocrine therapy. Note: Examples of endocrine therapy include fulvestrant, anastrozole, exemestane, letrozole, and tamoxifen. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

OSPHENA

Products Affected

- OSPHENA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

OTEZLA EGWP

Products Affected

- OTEZLA
- OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent Use with a Biologic or with a Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARD). |
| Required Medical Information | Diagnosis, previous drugs tried |
| Age Restrictions | 18 years and older (initial) |
| Prescriber Restrictions | All dx, initial only-PsA - Prescribed by or in consultation with a dermatologist or rheumatologist. PP - prescribed by or in consultation with a dermatologist. Behcet's-prescribed by or in consultation with a dermatologist or rheumatologist |
| Coverage Duration | End of the plan year |
| Other Criteria | PP, approve if the patient has tried two of the following: traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA), TNF, JAK or biologic. PsA, approve if the patient has tried one of the following: traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA), TNF, JAK or biologic. Behcet's-patient has oral ulcers or other mucocutaneous involvement AND patient has tried one conventional tx (eg, systemic CSs, immunosuppressants [e.g., AZA, MTX, MM, CSA, tacrolimus, chlorambucil, cyclophosphamide] or interferon alfa) or a tumor necrosis factor. PsA/PP/Behcet's cont - pt has received 4 months of therapy and had a response, as determined by the prescribing physician. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

OXERVATE

Products Affected

- OXERVATE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Treatment duration greater than 16 weeks per affected eye(s) |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by an ophthalmologist or an optometrist |
| Coverage Duration | Initial-8 weeks, continuation-approve for an additional 8 weeks |
| Other Criteria | Patients who have already received Oxervate-approve if the patient has previously received less than or equal to 8 weeks of treatment per affected eye(s) and the patient has a recurrence of neurotrophic keratitis. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PEGASYS

Products Affected

- PEGASYS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, previous medications tried, liver disease compensation status, concomitant medications for HCV |
| Age Restrictions | HCV - patients 5 years of age or older, HBV - patients 3 years of age or older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PEMAZYRE

Products Affected

- PEMAZYRE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, prior therapies |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Cholangiocarcinoma-approve if the patient has unresectable locally advanced or metastatic disease and the tumor has a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an approved test AND the patient has been previously treated with at least one systemic therapy regimen. Myeloid/lymphoid neoplasms-approve if the patient has eosinophilia and the cancer has fibroblast growth factor receptor 1 (FGFR1) rearrangement, as detected by an approved test and the cancer is in chronic phase or blast phase. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PHENYL BUTYRATE

Products Affected

- *sodium phenylbutyrate*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concomitant therapy with more than one phenylbutyrate product |
| Required Medical Information | Diagnosis, genetic tests and lab results (as specified in the Other Criteria field) |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases) |
| Coverage Duration | Pt meets criteria with no genetic test - 3 mo approval. Pt had genetic test - 12 mo approval |
| Other Criteria | Urea cycle disorders-approve if genetic testing confirmed a mutation resulting in a urea cycle disorder or if the patient has hyperammonemia diagnosed with an ammonia level above the upper limit of the normal reference range for the reporting laboratory. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PHEOCHROMOCYTOMA

Products Affected

- *metyrosine*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, prior medication trials |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an endocrinologist or a physician who specializes in the management of pheochromocytoma (initial and continuation therapy for metyrosine) |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | If the requested drug is metyrosine for initial therapy, approve if the patient has tried a selective alpha blocker (e.g., doxazosin, terazosin or prazosin). If the requested drug is metyrosine for continuation therapy, approve if the patient is currently receiving metyrosine or has received metyrosine in the past. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PHOSPHODIESTERASE-5 INHIBITORS FOR PAH

Products Affected

- *alyq*
- *sildenafil (pulm.hypertension) oral tablet*
- *tadalafil (pulm. hypertension)*
- TADLIQ

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent Use With Guanylate Cyclase Stimulators. |
| Required Medical Information | Diagnosis, right heart cath results |
| Age Restrictions | N/A |
| Prescriber Restrictions | For PAH, if prescribed by, or in consultation with, a cardiologist or a pulmonologist. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Pulmonary arterial hypertension (PAH) WHO Group 1, are required to have had a right-heart catheterization to confirm diagnosis of PAH to ensure appropriate medical assessment. Clinical criteria incorporated into the quantity limit edits for sildenafil 20 mg tablets require confirmation that the indication is PAH (ie, FDA labeled use) prior to reviewing for quantity exception. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PIQRAY

Products Affected

- PIQRAY

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, prior therapies |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Breast Cancer. Approve if the patient meets the following criteria (A, B, C, D, E and F): A) The patient is a postmenopausal female, male or pre/perimenopausal and is receiving ovarian suppression with a gonadotropin-releasing hormone (GnRH) agonist or has had surgical bilateral oophorectomy or ovarian irradiation AND B) The patient has advanced or metastatic hormone receptor (HR)-positive disease AND C) The patient has human epidermal growth factor receptor 2 (HER2)-negative disease AND D) The patient has PIK3CA-mutated breast cancer as detected by an approved test AND E) The patient has progressed on or after at least one prior endocrine-based regimen (e.g., anastrozole, letrozole, exemestane, tamoxifen, toremifene or fulvestrant) AND F) Piqray will be used in combination with fulvestrant injection. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Treatment of breast cancer in premenopausal women |
| Part B Prerequisite | No |

PIRFENIDONE

Products Affected

- *pirfenidone oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | Prescribed by or in consultation with a pulmonologist |
| Coverage Duration | 1 year |
| Other Criteria | IPF - must have FVC greater than or equal to 40 percent of the predicted value AND IPF must be diagnosed with either findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

POMALYST

Products Affected

- POMALYST

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | Kaposi Sarcoma/MM-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Kaposi Sarcoma-Approve if the patient meets one of the following (i or ii): i. patient is Human Immunodeficiency Virus (HIV)-negative OR ii. patient meets both of the following (a and b): a) The patient is Human Immunodeficiency Virus (HIV)-positive AND b) The patient continues to receive highly active antiretroviral therapy (HAART). CNS Lymphoma-approve if the patient has relapsed or refractory disease. MM-approve if the patient has received at least one other Revlimid (lenalidomide tablets)-containing regimen. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Systemic Light Chain Amyloidosis, Central Nervous System (CNS) Lymphoma |
| Part B Prerequisite | No |

PROMACTA

Products Affected

- PROMACTA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Cause of thrombocytopenia. Thrombocytopenia due to HCV-related cirrhosis, platelet counts. Severe aplastic anemia, platelet counts and prior therapy. MDS-platelet counts. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Immune Thrombocytopenia or Aplastic Anemia, approve if prescribed by, or after consultation with, a hematologist (initial therapy). Thrombocytopenia in pt with chronic Hep C, approve if prescribed by, or after consultation with, a gastroenterologist, hematologist, hepatologist, or a physician who specializes in infectious disease (initial therapy). MDS-presc or after consult with heme/onc (initial therapy). |
| Coverage Duration | Immune Thrombo/MDS initial-3 mo, cont 1yr, AA-initial-4 mo, cont-1 yr, Thrombo/Hep C-1 yr |
| Other Criteria | Thrombocytopenia in patients with immune thrombocytopenia, initial-approve if the patient has a platelet count less than 30, 000 microliters or less than 50, 000 microliters and the patient is at an increased risk for bleeding AND the patient has tried ONE other therapy or has undergone a splenectomy. Cont-approve if the patient demonstrates a beneficial clinical response and remains at risk for bleeding complications. Treatment of thrombocytopenia in patients with Chronic Hepatitis C initial-approve if the patient will be receiving interferon-based therapy for chronic hepatitis C AND to allow for initiation of antiviral therapy if the patient has low platelet counts at baseline (eg, less than 75,000 microliters). Aplastic anemia initial - approve if the patient has low platelet counts at baseline/pretreatment (e.g., less than 30,000 microliters) AND tried one immunosuppressant therapy (e.g., cyclosporine, mycophenolate mofetil, sirolimus) OR patient will be using Promacta in combination with standard immunosuppressive therapy. Cont-approve if the patient demonstrates a beneficial clinical response. MDS initial-approve if patient has low- to intermediate-risk MDS AND the patient has a platelet count less than 30, 000 microliters or less than 50, 000 microliters and is at an increased risk |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | for bleeding. Cont-approve if the patient demonstrates a beneficial clinical response and remains at risk for bleeding complications. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Thrombocytopenia in Myelodysplastic Syndrome (MDS) |
| Part B Prerequisite | No |

PYRIMETHAMINE

Products Affected

- *pyrimethamine*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Patient's immune status (Toxoplasma gondii Encephalitis, chronic maintenance and prophylaxis, primary) |
| Age Restrictions | N/A |
| Prescriber Restrictions | Toxoplasma gondii Encephalitis, Chronic Maintenance and Prophylaxis (Primary)-prescribed by or in consultation with an infectious diseases specialist. Toxoplasmosis Treatment-prescribed by or in consultation with an infectious diseases specialist, a maternal-fetal medicine specialist, or an ophthalmologist. |
| Coverage Duration | 12 months |
| Other Criteria | Toxoplasma gondii Encephalitis, Chronic Maintenance, approve if the patient is immunosuppressed. Toxoplasma gondii Encephalitis Prophylaxis (Primary), approve if the patient is immunosuppressed. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Chronic maintenance and prophylaxis of Toxoplasma Gondii encephalitis |
| Part B Prerequisite | No |

PYRUKYND

Products Affected

- PYRUKYND

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older (initial and continuation) |
| Prescriber Restrictions | Prescribed by or in consultation with a hematologist (initial and continuation) |
| Coverage Duration | Initial-6 months, continuation-1 year |
| Other Criteria | <p>Initial therapy-Approve if the patient has the presence of at least two variant/mutant alleles in the pyruvate kinase liver and red blood cell (PKLR) gene and at least one of the variant/mutant alleles was a missense variant AND the patient has a current hemoglobin level less than or equal to 10g/dL or patient is currently receiving red blood cell transfusions regularly, defined as at least six transfusion within the last year.</p> <p>Continuation of therapy-Approve if the patient has the presence of at least two variant/mutant alleles in the pyruvate kinase liver and red blood cell (PKLR) gene and at least one of the variant/mutant alleles was a missense variant AND the patient has experienced a benefit from therapy, defined as increase in or maintenance of hemoglobin levels, or improvement in or maintenance of hemolysis laboratory parameters, OR decrease in or maintenance of transfusion requirements.</p> |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

QINLOCK

Products Affected

- QINLOCK

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, other therapies tried |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Gastrointestinal stromal tumor (GIST)-approve if the patient has tried imatinib or avapritinib tablets, AND the patient meets one of the following criteria (i, ii, or iii): i. Patient has tried sunitinib and regorafenib tablets, OR ii. Patient has tried dasatinib tablets, OR iii. Patient is intolerant of sunitinib. Melanoma, cutaneous-approve if the patient has metastatic or unresectable disease, AND the patient has an activating KIT mutation, AND the patient has tried at least one systemic regimen. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Melanoma, cutaneous |
| Part B Prerequisite | No |

QUILLICHEW ER

Products Affected

- QUILLICHEW ER

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | Patients must try and fail methylphenidate ER tablets and dextroamphetamine-amphetamine ER capsules. For patients who cannot swallow whole tablets/capsules, trial is not required. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

QUININE SULFATE

Products Affected

- *quinine sulfate*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Excluded if used for treatment or prevention of nocturnal leg cramps. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 month |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Babesiosis, uncomplicated Plasmodium vivax malaria. |
| Part B Prerequisite | No |

RADICAVA IV

Products Affected

- RADICAVA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist, a neuromuscular disease specialist, or a physician specializing in the treatment of ALS (initial and continuation). |
| Coverage Duration | Initial, 6 months. Continuation, 6 months. |
| Other Criteria | ALS, initial therapy-approve if the patient meets ALL of the following criteria: 1. According to the prescribing physician, the patient has a definite or probable diagnosis of ALS, based on the application of the El Escorial or the revised Airlie house diagnostic criteria 2. The patient has a score of two points or more on each item of the ALS Functional Rating Scale-Revised (ALSFRS-R) [ie, has retained most or all activities of daily living], AND 3. The patient has a percent predicted FVC greater than or equal to 80% (ie, has normal respiratory function), AND 4. The Patient has been diagnosed with ALS for less than or equal to 2 years 5. Patient has received or is currently receiving riluzole tablets. Note-a trial of Tiglutik or Exservan would also count. ALS, continuation therapy: approve if, according to the prescribing physician, the patient continues to benefit from therapy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

REBIF

Products Affected

- REBIF (WITH ALBUMIN)
- REBIF TITRATION PACK
- REBIF REBIDOSE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with other disease-modifying agent used for multiple sclerosis |
| Required Medical Information | Relapsing form of Multiple Sclerosis (MS), to include, clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or after consultation with a neurologist or an MS specialist. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | For patients requesting Rebif, approve if the patient has tried Betaseron |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

REMICADE

Products Affected

- REMICADE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with Biologic DMARD or Targeted Synthetic. |
| Required Medical Information | Diagnosis, concurrent medication, previous medications tried |
| Age Restrictions | CD and UC- Pts aged 6 years or more (initial therapy). PP-18 years and older (initial therapy) |
| Prescriber Restrictions | All dx Initial therapy only -prescribed by or in consultation with: RA/AS/Still's disease/JIA/JRA-rheumatologist, PP/Pyoderma gangrenosum/Hidradenitis suppurativa-dermatologist, Psoriatic Arthritis-rheum or derm, CD/UC-gastroenterologist, Uveitis ophthalmologist, GVHD-a physician affiliated with a transplant center, oncologist, or hematologist, Behcet's Disease- rheum, derm, ophthalmologist, gastroenterologist, or neurologist, Sarcoidosis-pulmonol, ophthalmol, cardio, neuro, or derm |
| Coverage Duration | GVHD intl-1 mo, cont-3 mo.Pyoderma Gangrenosum-intl 4 mo, cont 1 yr.all others-intl 3 mo, cont-12 m |
| Other Criteria | RA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic or JAK inhibitor for RA are not required to step back and try a conventional synthetic DMARD). JIA/JRA-initial-approve if the patient meets ONE of the following: patient has tried one other medication for this condition for at least 3 months (Note: Examples of other medications for JIA include methotrexate, sulfasalazine, or leflunomide, a nonsteroidal anti-inflammatory drug (NSAID), biologic or JAK inhibitor OR Patient has aggressive disease. PP initial, approve if the patient meets one of the following criteria: 1) pt has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (note: pts who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first) OR 2) pt has a contraindication to MTX as determined by the prescribing physician. Uveitis initial, tried one of the following: periocular, intraocular, or |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | <p>systemic corticosteroid, immunosuppressives or other biologic therapy. GVHD, approve. CD initial, approve if the patient has tried or is currently taking corticosteroids or patient has tried one other agent for CD. UC initial, approve if the patient has had a trial of one systemic agent for at least 3 months (e.g., 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, biologic, JAK inhibitor or a corticosteroid such as prednisone or methylprednisolone). HS initial, tried ONE other therapy (e.g., intralesional or oral corticosteroids, systemic antibiotics, isotretinoin). Behcet's initial, patient has tried at least one conventional tx (eg, systemic CSs, immunosuppressants [e.g., AZA, MTX, MM, CSA, tacrolimus, chlorambucil, cyclophosphamide] or interferon alfa) or at least one tumor necrosis factor for Behcet's disease OR has ophthalmic manifestations. Still's Disease initial, tried CS AND 1 conventional synthetic DMARD (eg, MTX) for 2 mos, or was intolerant. Prev trial of one biologic other than requested drug or biosimilar of the requested drug also counts. Sarcoidosis initial, tried CS and immunosuppressant (eg, MTX, AZA, CSA, chlorambucil), or chloroquine, or thalidomide. Pyoderma gangrenosum (PG) initial, tried one systemic CS or immunosuppressant (eg, mycophenolate, CSA) for 2 mos or was intolerant to one of these agents. Continuation-approve if the patient has had a response as determined by the prescriber.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients already started on infliximab for a covered use, Behcet's disease, Still's disease, Uveitis, Pyoderma gangrenosum, Hidradenitis suppurativa, Graft-versus-host disease, Juvenile Idiopathic Arthritis (JIA)/JRA, Sarcoidosis |
| Part B Prerequisite | No |

REPATHA

Products Affected

- REPATHA PUSHTRONEX
- REPATHA SURECLICK
- REPATHA SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use of Leqvio or Praluent. |
| Required Medical Information | LDL-C and response to other agents, prior therapies tried, medication adverse event history, medical history (as specified in the Other Criteria field) |
| Age Restrictions | ASCVD/Primary Hyperlipidemia - 18 yo and older, HoFH/HeFH - 10 yo and older. |
| Prescriber Restrictions | Prescribed by, or in consultation with, a cardiologist, endocrinologist, or a physician who focuses in the treatment of CV risk management and/or lipid disorders |
| Coverage Duration | Approve for 1 year |
| Other Criteria | <p>Hyperlipidemia with HeFH - approve if: 1) diagnosis of HeFH AND 2) tried ONE high intensity statin (i.e. atorvastatin greater than or equal to 40 mg daily or rosuvastatin greater than or equal to 20 mg daily) and LDL remains 70 mg/dL or higher unless pt is statin intolerant defined by experiencing statin related rhabdomyolysis or skeletal-related muscle symptoms while receiving separate trials of atorvastatin and rosuvastatin and during both trials the symptoms resolved upon discontinuation.</p> <p>Hyperlipidemia with ASCVD -approve if: 1) has one of the following conditions: prior MI, h/o ACS, diagnosis of angina, h/o CVA or TIA, CAD, PAD, undergone a coronary or other arterial revascularization procedure, AND 2) tried ONE high intensity statin (defined above) and LDL remains 70 mg/dL or higher unless pt is statin intolerant (defined above). HoFH - approve if: 1) has one of the following: a) genetic confirmation of two mutant alleles at the LDLR, APOB, PCSK9, or LDLRAP1 gene locus, OR b) untreated LDL greater than 500 mg/dL (prior to treatment), OR c) treated LDL greater than or equal to 300 mg/dL (after treatment but prior to agents such as Repatha or Juxtapid), OR d) has clinical manifestations of HoFH (e.g., cutaneous xanthomas, tendon xanthomas, arcus cornea, tuberous xanthomas or xanthelasma), AND 2) tried ONE high intensity statin (defined above) for 8 weeks or longer and</p> |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | LDL remains 70 mg/dL or higher unless statin intolerant (defined above). Primary hyperlipidemia (not associated with ASCVD, HeFH, or HoFH)-approve if the patient has tried one high-intensity statin therapy (defined above) and ezetimibe for 8 weeks or longer and LDL remains 100 mg/dL or higher unless statin intolerant (defined above). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

RETEVMO

Products Affected

- RETEVMO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | Medullary Thyroid Cancer/Thyroid Cancer-12 years and older, all others 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Non-Small Cell Lung Cancer (NSCLC)-Approve if the patient has recurrent, advanced or metastatic disease AND the tumor is RET fusion-positive. Thyroid cancer-approve if the patient has rearranged during transfection (RET) fusion positive or RET mutation positive disease AND the patient meets i or ii: i. patient has anaplastic thyroid cancer OR ii. the disease requires treatment with systemic therapy and patient has medullary thyroid cancer or the disease is radioactive iodine-refractory. Solid tumors-approve if the patient has recurrent, advanced or metastatic disease and the tumor is rearranged during transfection (RET) fusion-positive. Histiocytic neoplasm-approve if the patient has a rearranged during transfection (RET) fusion and has Langerhans cell histiocytosis or Erdheim Chester disease or Rosai-Dorfman disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Anaplastic thyroid carcinoma, histiocytic neoplasm |
| Part B Prerequisite | No |

REVLIMID

Products Affected

- REVLIMID

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis and previous therapies or drug regimens tried. |
| Age Restrictions | 18 years and older (except Kaposi's Sarcoma, Castleman's Disease, CNS Lymphoma) |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | Follicular lymphoma-approve if the patient is using lenalidomide (brand or generic) in combination with rituximab or has tried at least one prior therapy. MCL-approve if the patient is using lenalidomide (brand or generic) in combination with rituximab or has tried at least two other therapies or therapeutic regimens. MZL-approve if the patient is using lenalidomide (brand or generic) in combination with rituximab or has tried at least one other therapy or therapeutic regimen. Multiple myeloma-approve. MDS-approve if the patient meets one of the following: 1) Pt has symptomatic anemia, OR 2) Pt has transfusion-dependent anemia, OR 3) Pt has anemia that is not controlled with an erythroid stimulating agent (eg, Procrit [epoetin alfa injection], Aranesp [darbepoetin alfa injection]). B-Cell-Lymphoma (other)-approve if the pt has tried at least one prior therapy. Myelofibrosis-approve if according to the prescriber the patient has anemia and the pt has serum erythropoietin levels greater than or equal to 500 mU/mL or according to the prescriber the patient has anemia, has serum erythropoietin levels less than 500 mU/mL and patient has experienced no response or loss of response to erythropoietic stimulating agents. Peripheral T-Cell Lymphoma or T-Cell Leukemia/Lymphoma-approve if the pt has tried at least one other therapy or regimen. CNS lymphoma-approve if according to the prescriber the patient has relapsed or refractory disease. Hodgkin lymphoma, classical-approve if the patient has |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | <p>tried at least one other therapy or therapeutic regimen. Castleman's disease-approve if the patient has relapsed/refractory or progressive disease. Kaposi's Sarcoma-approve if the patient has tried at least one regimen or therapy and the patient has relapsed or refractory disease. Systemic light chain amyloidosis-approve if lenalidomide (brand or generic) is used in combination with dexamethasone.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | <p>Off label uses for Revlimid include-Systemic Amyloidosis Light Chain, Diffuse Large B Cell Lymphoma (Non-Hodgkin's Lymphoma), Myelofibrosis. Castleman's Disease, Hodgkin lymphoma (Classical), Peripheral T-Cell Lymphoma, T-Cell Leukemia/Lymphoma, Central nervous system lymphoma, Kaposi's sarcoma.</p> |
| Part B Prerequisite | No |

REZLIDHIA

Products Affected

- REZLIDHIA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Acute myeloid leukemia-approve if the patient has relapsed or refractory disease and the patient has isocitrate dehydrogenase-1 (IDH1) mutation positive disease as detected by an approved test. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

REZUROK

Products Affected

- REZUROCK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 12 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Graft-versus-host disease-approve if the patient has chronic graft-versus-host disease and has tried at least two conventional systemic treatments (e.g., ibrutinib, cyclosporine) for chronic graft-versus-host disease. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

RINVOQ

Products Affected

- RINVOQ

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with biologic therapy or targeted synthetic DMARD. |
| Required Medical Information | Diagnosis, concurrent medications, previous therapies tried. |
| Age Restrictions | PsA/RA/UC/AS/CD-18 years and older (initial therapy), AD-12 years and older (Initial therapy) |
| Prescriber Restrictions | RA/AS/Non-Radiographic Spondy, prescribed by or in consultation with a rheumatologist. PsA-prescribed by or in consultation with a rheumatologist or a dermatologist. AD-prescr/consult with allergist, immunologist or derm. UC/CD-prescribed by or in consultation with a gastroenterologist. |
| Coverage Duration | End of the plan year |
| Other Criteria | RA/PsA/UC/AS/CD initial - patient has tried a TNF blocker for at least 3 months. AD - patient has tried at one systemic agent for at least 3 months. Examples of traditional systemic therapies include methotrexate, azathioprine, cyclosporine, and mycophenolate mofetil. Non-Radiographic Axial Spondyloarthritis-approve if the patient has objective signs of inflammation defined as at least one of the following: C-reactive protein (CRP) elevated beyond the upper limit of normal for the reporting laboratory OR sacroiliitis reported on MRI and patient has had a 3 month trial of at least one tumor necrosis factor inhibitor or was unable to tolerate a 3- month trial. Continuation-approve if the patient has had a response as determined by the prescriber. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ROMIDEPSIN

Products Affected

- *romidepsin intravenous recon soln*
- ROMIDEPSIN INTRAVENOUS SOLUTION

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis and past medication history. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | Use of romidepsin is considered medically necessary for the treatment of cutaneous T-cell lymphoma in patients that have tried and failed at least 1 prior therapy. B vs D coverage determination. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ROZLYTREK

Products Affected

- ROZLYTREK

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | NSCLC-18 years and older, Solid Tumors-1 month and older, Pediatric Diffuse High-Grade Glioma-less than 18 years old |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Solid Tumors-Approve if the patients tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion AND the tumor is metastatic OR surgical resection of tumor will likely result in severe morbidity. Non-Small Cell Lung Cancer-Approve if the patient has ROS1-positive metastatic disease and the mutation was detected by an approved test. Pediatric Diffuse High-Grade Glioma- approve if the tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion AND the medication is used either as adjuvant therapy or for recurrent or progressive disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Pediatric Diffuse High-Grade Glioma |
| Part B Prerequisite | No |

RUBRACA

Products Affected

- RUBRACA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis for which Rubraca is being used. BRCA-mutation (germline or somatic) status. Other medications tried for the diagnosis provided |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Maintenance Therapy of Ovarian, Fallopian tube or Primary peritoneal cancer-Approve if the patient is in complete or partial response after a platinum-based chemotherapy regimen and the patient is in complete or partial response to first-line primary treatment or if the patient has recurrent disease and has a BRCA mutation. Castration-Resistant Prostate Cancer - Approve if the patient meets the following criteria (A, B, C, and D): A) The patient has metastatic disease that is BRCA-mutation positive (germline and/or somatic) AND B) The patient meets one of the following criteria (i or ii): i. The medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog OR ii. The patient has had a bilateral orchiectomy AND C) The patient has been previously treated with at least one androgen receptor-directed therapy AND D) The patient meets one of the following criteria (i or ii): i. The patient has been previously treated with at least one taxane-based chemotherapy OR ii. The patient is not a candidate or is intolerant to taxane-based chemotherapy. Pancreatic adenocarcinoma-approve if pt has a BRCA mutation or PALB2 mutation AND pt has tried platinum-based chemotherapy AND has not had disease progression following the most recent platinum-based chemotherapy. Uterine leiomyosarcoma-approve if the patient has BRCA2-altered disease and has tried one systemic regimen. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |

| PA Criteria | Criteria Details |
|----------------------------|---|
| Off-Label Uses | Uterine Leiomyosarcoma, Pancreatic Adenocarcinoma |
| Part B Prerequisite | No |

RYDAPT

Products Affected

- RYDAPT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For AML, FLT3 status |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | AML-approve if the patient is FLT3-mutation positive as detected by an approved test. Myeloid or lymphoid Neoplasms with eosinophilia-approve if the patient has an FGFR1 rearrangement or has an FLT3 rearrangement. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Myeloid or lymphoid Neoplasms with eosinophilia |
| Part B Prerequisite | No |

SANDOSTATIN

Products Affected

- SANDOSTATIN LAR DEPOT INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, previous treatments/therapies |
| Age Restrictions | N/A |
| Prescriber Restrictions | Acromegaly-prescr/consult w/endocrinologist. NETs-prescr/consult w/oncologist, endocrinologist, or gastroenterologist. Pheochromocytoma/paraganglioma-prescr/consult w/endo/onc/neuro.Meningioma-prescr/consult w/oncologist, radiologist, neurosurg/thymoma/thymic carcinoma-presc/consult with oncologist |
| Coverage Duration | 1 year |
| Other Criteria | Acromegaly-approve if patient meets ONE of the following (i, ii, or iii): i. Patient has had an inadequate response to surgery and/or radiotherapy OR ii. Patient is NOT an appropriate candidate for surgery and/or radiotherapy OR iii. Patient is experiencing negative effects due to tumor size (e.g., optic nerve compression) AND Patient has (or had) a pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender for the reporting laboratory. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Meningioma, thymoma and thymic carcinoma, pheochromocytoma and paraganglioma |
| Part B Prerequisite | No |

SAPROPTERIN

Products Affected

- *javygtor*
- *sapropterin*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with Palynziq |
| Required Medical Information | Diagnosis, Phe concentration |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a specialist who focuses in the treatment of metabolic diseases (initial therapy) |
| Coverage Duration | Initial-12 weeks, Continuation-1 year |
| Other Criteria | Initial - approve. Continuation (Note-if the patient has received less than 12 weeks of therapy or is restarting therapy with sapropterin should be reviewed under initial therapy) - approve if the patient has had a clinical response (e.g., cognitive and/or behavioral improvements) as determined by the prescribing physician OR patient had a 20 percent or greater reduction in blood Phe concentration from baseline OR treatment with sapropterin has resulted in an increase in dietary phenylalanine tolerance. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SCSEMBLIX

Products Affected

- SCSEMBLIX

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Chronic Myeloid Leukemia (CML)-approve if the patient meets the following (A and B): A) Patient has Philadelphia chromosome-positive chronic myeloid leukemia, AND B) Patient meets one of the following (i or ii): i. The chronic myeloid leukemia is T315I-positive, OR ii. Patient has tried at least two other tyrosine kinase inhibitors indicated for use in Philadelphia chromosome-positive chronic myeloid leukemia. Note: Examples of tyrosine kinase inhibitors include imatinib tablets, Bosulif (bosutinib tablets), Iclusig (ponatinib tablets), Sprycel (dasatinib tablets), and Tasisa (nilotinib capsules). Myeloid/Lymphoid Neoplasms with Eosinophilia - approve if the tumor has an ABL1 rearrangement. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Myeloid/Lymphoid Neoplasms with Eosinophilia |
| Part B Prerequisite | No |

SIGNIFOR

Products Affected

- SIGNIFOR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older (initial therapy) |
| Prescriber Restrictions | Prescribed by or in consultation with an endocrinologist or a physician or specializes in the treatment of Cushing's syndrome (initial therapy) |
| Coverage Duration | Cushing's disease/syndrome-Initial therapy - 4 months, Continuation therapy - 1 year. |
| Other Criteria | Cushing's disease, initial therapy - approve if, according to the prescribing physician, the patient is not a candidate for surgery, or surgery has not been curative. Cushing's disease, continuation therapy - approve if the patient has already been started on Signifor/Signifor LAR and, according to the prescribing physician, the patient has had a response and continuation of therapy is needed to maintain response. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SIMPONI

Products Affected

- SIMPONI
- SIMPONI ARIA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with biologic therapy or targeted synthetic DMARD |
| Required Medical Information | Diagnosis, concurrent medications, previous therapies tried. |
| Age Restrictions | UC-18 years and older (initial therapy) |
| Prescriber Restrictions | All dx-initial only-RA/Ankylosing spondylitis, prescribed by or in consultation with a rheumatologist. Psoriatic arthritis, prescribed by or in consultation with a rheumatologist or dermatologist. UC-prescribed by or in consultation with a gastroenterologist |
| Coverage Duration | End of the plan year |
| Other Criteria | AS, approve if the patient has tried two of the following: TNF, JAK or biologic. RA, approve if the patient has tried two of the following: TNF, JAK or biologic. PsA, approve if the patient has tried two of the following: TNF, JAK or biologic. UC, approve if the patient has tried two of the following: TNF, JAK or biologic. Continuation-approve if the patient has had a response as determined by the prescriber. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SIRTURO

Products Affected

- SIRTURO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Patients weighing less than 15 kg |
| Required Medical Information | Diagnosis, concomitant therapy |
| Age Restrictions | Patients 5 years of age or older |
| Prescriber Restrictions | Prescribed by, or in consultation with an infectious diseases specialist |
| Coverage Duration | 9 months |
| Other Criteria | Tuberculosis (Pulmonary) - Approve if the patient has multidrug-resistant tuberculosis and the requested medication is prescribed as part of a combination regimen with other anti-tuberculosis agents |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SKYRIZI

Products Affected

- SKYRIZI INTRAVENOUS
- SKYRIZI SUBCUTANEOUS PEN INJECTOR
- SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML
- SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with biologic therapy or targeted synthetic DMARD. |
| Required Medical Information | Diagnosis, concurrent medications, previous therapies tried. |
| Age Restrictions | PP-18 years of age and older (initial therapy) |
| Prescriber Restrictions | PP-Prescribed by or in consultation with a dermatologist (initial therapy). Psoriatic arthritis (PsA), prescribed by or in consultation with a rheumatologist or dermatologist. CD, prescribed by or in consultation with a gastroenterologist. |
| Coverage Duration | End of the plan year |
| Other Criteria | PP initial, approve if the patient meets one of the following criteria: 1) pt has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (note: pts who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first) OR 2) pt has a contraindication to MTX as determined by the prescribing physician. PsA initial - peripheral disease, patient has tried one conventional synthetic DMARD for at least 3 months, unless intolerant. (note: patients who have already had a 3-month trial of a biologic or JAK inhibitor are not required to step back and try a conventional synthetic DMARD) PsA initial - axial disease (sacroiliitis), patient has tried one conventional synthetic DMARD or NSAID for at least 3 months, unless intolerant. (note: patients who have already had a 3-month trial of a biologic or JAK inhibitor are not required to step back and try a conventional synthetic DMARD or NSAID). CD initial, approve if the patient has tried or is currently taking corticosteroids, or patient has tried one other agent for at least 3 months. Continuation-approve if the patient has had a response as determined by the prescriber. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------------|
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SOMATULINE

Products Affected

- SOMATULINE DEPOT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, previous treatments/therapies |
| Age Restrictions | N/A |
| Prescriber Restrictions | Acromegaly-prescribed by or in consultation with an endocrinologist. Carcinoid syndrome-prescribed by or in consultation with an oncologist, endocrinologist or gastroenterologist. All neuroendocrine tumors-prescribed by or in consultation with an oncologist, endocrinologist, or gastroenterologist. Pheochromocytoma/paraganglioma-prescribed by or in consultation with an endo/onc/neuro. |
| Coverage Duration | 1 year |
| Other Criteria | Acromegaly-approve if the patient has a pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender for the reporting laboratory AND the patient meets i., ii., or iii: i. has had an inadequate response to surgery and/or radiotherapy or ii. is not an appropriate candidate for surgery and/or radiotherapy or iii. the patient is experiencing negative effects due to tumor size (e.g., optic nerve compression). Neuroendocrine Tumor(s) [NETs] of the Gastrointestinal Tract, Lung, Thymus (Carcinoid Tumors), and Pancreas (including glucagonomas, gastrinomas, vasoactive intestinal peptide-secreting tumors [VIPomas], insulinomas)-approve. Carcinoid Syndrome-approve. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Pheochromocytoma/paraganglioma, Neuroendocrine tumors of the gastrointestinal tract, lung, thymus (carcinoid tumor) and pancreas (including glucagonomas, gastrinomas, vasoactive intestinal peptide-secreting tumors [VIPomas], insulinomas) |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

SOMAVERT

Products Affected

- SOMAVERT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, previous therapy, concomitant therapy |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an endocrinologist |
| Coverage Duration | 1 year |
| Other Criteria | Acromegaly-approve if patient meets ONE of the following (i, ii, or iii): i. patient has had an inadequate response to surgery and/or radiotherapy OR ii. The patient is NOT an appropriate candidate for surgery and/or radiotherapy OR iii. The patient is experiencing negative effects due to tumor size (e.g., optic nerve compression) AND patient has (or had) a pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal (ULN) based on age and gender for the reporting laboratory. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SORAFENIB

Products Affected

- NEXAVAR
- *sorafenib*

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | <p>Bone cancer, approve if the patient has recurrent chordoma or has osteosarcoma and has tried one standard chemotherapy regimen. GIST, approve if the patient has tried TWO of the following: imatinib mesylate, avapritinib, sunitinib, dasatinib, ripretinib or regorafenib. Differentiated (ie, papillary, follicular, Hurthle) thyroid carcinoma (DTC), approve if the patient is refractory to radioactive iodine treatment. Medullary thyroid carcinoma, approve if the patient has tried at least one systemic therapy. AML - Approve if disease is FLT3-ITD mutation positive as detected by an approved test and the medication is used in combination with azacitidine or decitabine or patient has had an allogeneic stem cell transplant and is in remission. Renal cell carcinoma (RCC)-approve if the patient has relapsed or advanced clear cell histology and the patient has tried at least one systemic therapy (e.g., Inlyta, Votrient, Sutent Cabometyx). Ovarian, fallopian tube, primary peritoneal cancer-approve if the patient has platinum resistant disease and sorafenib is used in combination with topotecan. HCC-approve if the patient has unresectable or metastatic disease. Soft tissue sarcoma-approve if the patient has angiosarcoma or desmoid tumors (aggressive fibromatosis) or solitary fibrous tumor/hemangiopericytoma. Myeloid/lymphoid neoplasms with eosinophilia-approve if the tumor has an FLT3 rearrangement. Please note for all diagnoses: Part B before Part D Step Therapy applies only to beneficiaries enrolled in an MA-PD plan.</p> |

| PA Criteria | Criteria Details |
|----------------------------|---|
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Bone cancer, Soft tissue sarcoma, gastrointestinal stromal tumors (GIST), medullary thyroid carcinoma, Acute Myeloid Leukemia, ovarian, fallopian tube, primary peritoneal cancer, myeloid/lymphoid neoplasms with eosinophilia |
| Part B Prerequisite | Yes |

SPRAVATO

Products Affected

- SPRAVATO NASAL SPRAY, NON-AEROSOL 56 MG (28 MG X 2), 84 MG (28 MG X 3)

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | Psychiatrist |
| Coverage Duration | MDD with Acute Suicidal Ideation or Behavior: 2 mo. Treatment-Resistant Depression: 6 mo |
| Other Criteria | Major Depressive Disorder with Acute Suicidal Ideation or Behavior-approve if the patient meets the following criteria (A, B and C): A) Patient has major depressive disorder that is considered to be severe, according to the prescriber, AND B) Patient is concomitantly receiving at least one oral antidepressant (Note: Antidepressants may include, but are not limited to, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), mirtazapine, and bupropion), AND C) Patient has one of the following (i or ii): i. No history of psychosis, OR ii. History of psychosis and the prescriber believes that the benefits of Spravato outweigh the risks. Treatment-Resistant Depression-approve if the patient meets the following criteria (A, B, C and D): A) Patient meets both of the following (i and ii): i. Patient has demonstrated nonresponse (less than or equal to 25 percent improvement in depression symptoms or scores) to at least two different antidepressants, each from a different pharmacologic class, according to the prescriber (Note: Different pharmacologic classes of antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), bupropion, mirtazapine, etc.) AND ii. Each antidepressant was used at therapeutic dosages for at least 6 weeks in the current episode of depression, according |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | to the prescriber, AND C) Patient is concomitantly receiving at least one oral antidepressant, AND D) Patient has one of the following (i or ii): i. No history of psychosis, OR ii. History of psychosis and the prescriber believes that the benefits of Spravato outweigh the risks, AND E) The patient history of controlled substance prescriptions has been checked using the state prescription drug monitoring program (PDMP), according to the prescriber. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SPRYCEL

Products Affected

- SPRYCEL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis for which Sprycel is being used. For indications of CML and ALL, the Philadelphia chromosome (Ph) status of the leukemia must be reported. For melanoma, cutaneous- KIT mutation and previous therapies. |
| Age Restrictions | GIST/chondrocarcoma or chordoma/ melanoma, cutaneous-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | For CML, patient must have Ph-positive CML. For ALL, patient must have Ph-positive ALL. GIST - approve if the patient has tried imatinib or avapritinib. For melanoma, cutaneous - approve if patient has metastatic or unresectable disease AND has an activating KIT mutation AND has tried at least one systemic regimen. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | GIST, chondrosarcoma, chordoma, melanoma cutaneous |
| Part B Prerequisite | No |

STELARA

Products Affected

- STELARA SUBCUTANEOUS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with biologic therapy or targeted synthetic DMARD. |
| Required Medical Information | Diagnosis, concurrent medications, previous therapies tried. |
| Age Restrictions | 18 years and older CD/UC (initial therapy). PP/PsA-6 years and older (initial therapy). |
| Prescriber Restrictions | PP-Prescr/consult w/derm.PsA-prescr/consult w/rheum or derm.CD/UC-prescr/consult w/gastro. |
| Coverage Duration | End of the plan year |
| Other Criteria | PsA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic or JAK inhibitor for PsA are not required to step back and try a conventional synthetic DMARD). PP initial, approve if the patient meets one of the following criteria: 1) pt has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (note: pts who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first) OR 2) pt has a contraindication to MTX as determined by the prescribing physician. CD initial, approve if the patient has tried or is currently taking corticosteroids, or patient has tried one other agent for at least 3 months. UC initial, approve if the patient has had a trial of one systemic agent for at least 3 months (e.g., 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, biologic, JAK inhibitor or a corticosteroid such as prednisone or methylprednisolone) |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

STIVARGA

Products Affected

- STIVARGA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis for which Stivarga is being used. Prior therapies tried. For metastatic CRC, KRAS/NRAS mutation status. |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | <p>For GIST, patient must have previously been treated with imatinib or Ayvakit and sunitinib or Sprycel. For HCC, patient must have previously been treated with at least one systemic regimen. Soft tissue sarcoma, advanced or metastatic disease-approve if the patient has non-adipocytic sarcoma, angiosarcoma, or pleomorphic rhabdomyosarcoma.</p> <p>Osteosarcoma-approve if the patient has relapsed/refractory or metastatic disease and the patient has tried one systemic chemotherapy regimen.</p> <p>Colon and Rectal cancer/Appendiceal cancer-approve if the patient has advanced or metastatic disease, has been previously treated with a fluoropyrimidine, oxaliplatin, irinotecan and if the patient meets one of the following (i or ii): i. patient's tumor or metastases are wild-type RAS (KRAS wild type and NRAS wild type), the patient has tried Erbitux or Vectibix or the patient's tumor did not originate on the left side of the colon (from the splenic fixture to rectum) or ii. the patient's tumor or metastases has a RAS mutation (either KRAS mutation or NRAS mutation).</p> <p>Glioblastoma-approve if the patient has recurrent disease.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Soft tissue Sarcoma, Osteosarcoma, Glioblastoma, Appendiceal cancer |
| Part B Prerequisite | No |

SUCRAID

Products Affected

- SUCRAID

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, genetic and lab test results (as specified in the Other Criteria field) |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a geneticist, gastroenterologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of congenital diarrheal disorders |
| Coverage Duration | 1 year |
| Other Criteria | Approve if the patient meets the following criteria (A and B): A) The diagnosis is established by one of the following (i or ii): i. Patient has endoscopic biopsy of the small bowel with disaccharidase levels consistent with congenital sucrose-isomaltase deficiency as evidenced by ALL of the following (a, b, c, and d): a) Decreased (usually absent) sucrase (normal reference: greater than 25 U/g protein), b) Decreased to normal isomaltase (palatinase) [normal reference: greater than 5 U/g protein], c) Decreased maltase (normal reference: greater than 100 U/g protein), d) Decreased to normal lactase (normal reference: greater than 15 U/g protein) OR ii. Patient has a molecular genetic test demonstrating homozygous or compound heterozygous pathogenic or likely pathogenic sucrase-isomaltase gene variant AND B) Patient has symptomatic congenital sucrose-isomaltase deficiency (e.g., diarrhea, bloating, abdominal cramping). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SUNITINIB

Products Affected

- *sunitinib malate*
- SUTENT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Gastrointestinal stromal tumors (GIST), approve if the patient has tried imatinib or Ayvakit or if the patient has succinate dehydrogenase (SDH)-deficient GIST. Chordoma, approve if the patient has recurrent disease. Differentiated thyroid carcinoma, approve if the patient is refractory to radioactive iodine therapy. Medullary thyroid carcinoma, approve if the patient has tried at least one systemic therapy. Meningioma, approve if the patient has recurrent or progressive disease. Thymic carcinoma - has tried at least one systemic chemotherapy. Renal Cell Carcinoma (RCC), clear cell or non-clear cell histology-approve if the patient is at high risk of recurrent clear cell RCC following nephrectomy and Sutent is used for adjuvant therapy or if the patient has relapsed or advanced disease. Neuroendocrine tumors of the pancreas-approve for advanced or metastatic disease. Pheochromocytoma/paraganglioma-approve if the patient has unresectable or metastatic disease. Myeloid/lymphoid neoplasms with eosinophilia-approve if the tumor has an FLT3 rearrangement. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Chordoma, angiosarcoma, solitary fibrous tumor/hemangiopericytoma, alveolar soft part sarcoma (ASPS), differentiated (ie, papillary, follicular, and Hurthle) thyroid carcinoma, medullary thyroid carcinoma, meningioma, thymic carcinoma, pheochromocytoma/paraganglioma, |

| | |
|----------------------------|---|
| PA Criteria | Criteria Details |
| | myeloid/lymphoid neoplasms with eosinophilia, GIST-unresectable succinate dehydrogenase (SDH)-deficient GIST, or use after avapritinib. |
| Part B Prerequisite | No |

SYMDEKO

Products Affected

- SYMDEKO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Patients with unknown CFTR gene mutations, Combination therapy with Orkambi, Kalydeco or Trikafta |
| Required Medical Information | Diagnosis, specific CFTR gene mutations |
| Age Restrictions | Six years of age and older |
| Prescriber Restrictions | Prescribed by or in consultation with a pulmonologist or a physician who specializes in CF |
| Coverage Duration | 1 year |
| Other Criteria | CF - must be homozygous for the F508del mutation or have at least one mutation in the CFTR gene that is responsive to the requested medication. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SYMLIN

Products Affected

- SYMLINPEN 120
- SYMLINPEN 60

| PA Criteria | Criteria Details |
|-------------------------------------|----------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SYNAGIS

Products Affected

- SYNAGIS

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of diagnosis. |
| Age Restrictions | 24 months or younger |
| Prescriber Restrictions | N/A |
| Coverage Duration | 6 months |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TABRECTA

Products Affected

- TABRECTA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Non-Small Cell Lung Cancer (NSCLC)-Approve if the patient has advanced or metastatic disease AND the tumor is positive for a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping or high-level MET amplification, as detected by an approved test. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Non-small cell lung cancer with high-level MET amplification. |
| Part B Prerequisite | No |

TAFAMIDIS

Products Affected

- VYNDAMAX
- VYNDAQEL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concomitant use with Onpattro or Tegsedi. Concurrent use of Vyndaqel and Vyndamax. |
| Required Medical Information | Diagnosis, genetic tests and lab results (as specified in the Other Criteria field) |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | Prescribed by or in consultation with a cardiologist or a physician who specializes in the treatment of amyloidosis |
| Coverage Duration | 1 year |
| Other Criteria | Cardiomyopathy of Wild-Type or Hereditary Transthyretin Amyloidosis-approve if the diagnosis was confirmed by one of the following (i, ii or iii): i. A technetium pyrophosphate scan (i.e., nuclear scintigraphy),ii. Amyloid deposits are identified on cardiac biopsy OR iii. patient had genetic testing which, according to the prescriber, identified a TTR mutation AND Diagnostic cardiac imaging (e.g., echocardiogram, cardiac magnetic imaging) has demonstrated cardiac involvement (e.g., increased thickness of the ventricular wall or interventricular septum). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TAFINLAR

Products Affected

- TAFINLAR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis for which Tafinlar is being used. BRAF V600 mutations |
| Age Restrictions | 1 year and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | <p>Melanoma with BRAF V600 mutation AND patient has unresectable, advanced (including Stage III or Stage IV disease) or metastatic melanoma. Note-This includes adjuvant treatment in patients with Stage III disease with no evidence of disease post-surgery. For NSCLC, must have BRAF V600E mutation. Thyroid Cancer, anaplastic-must have BRAF V600-positive disease AND Tafinlar will be taken in combination with Mekinist, unless intolerant AND the patient has locally advanced or metastatic anaplastic disease. Thyroid Cancer, differentiated (i.e., papillary, follicular, or Hurthle cell) AND the patient has disease that is refractory to radioactive iodine therapy AND the patient has BRAF-positive disease. Biliary Tract Cancer-approve if the patient has tried at least one systemic chemotherapy regimen, patient has BRAF V600 mutation positive disease and the medication will be taken in combination with Mekinist. Central Nervous System Cancer-approve if the medication is being used for one of the following situations (i, ii, or iii): i. Adjuvant treatment of one of the following conditions (a, b, or c): a) Pilocytic astrocytoma OR b) Pleomorphic xanthoastrocytoma OR c) Ganglioglioma OR ii. Recurrent or progressive disease for one of the following conditions (a, b, c, or d): a) glioma OR b) Isocitrate dehydrogenase-2 (IDH2)-mutant astrocytoma OR c) Glioblastoma OR d)Oligodendroglioma OR iii. Melanoma with brain metastases AND patient has BRAF V600 mutation-positive disease AND medication will be taken in combination with Mekinist (trametinib tablets).</p> |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | <p>Histiocytic neoplasm-approve if patient has Langerhans cell histiocytosis and one of the following (a, b, or c): a) Multisystem disease OR b) Pulmonary disease OR c) Central nervous system lesions OR patient has Erdheim Chester disease AND patient has BRAF V600-mutation positive disease. Metastatic or solid tumors-approve if BRAF V600 mutation-positive disease AND medication will be taken in combination with Mekinist (trametinib tablets) AND patient has no satisfactory alternative treatment options. Ovarian, Fallopian Tube, or Primary Peritoneal Cancer-approve if the patient meets the following (A, B, and C): A) Patient has recurrent disease, AND B) Patient has BRAF V600 mutation-positive disease, AND C) The medication will be taken in combination with Mekinist (trametinib tablets).</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients with Differentiated Thyroid Cancer, Biliary tract cancer, central nervous system cancer, histiocytic neoplasm, Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| Part B Prerequisite | No |

TAGRISSO

Products Affected

- TAGRISSO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | NSCLC-EGFR Mutation Positive (other than EGFR T790M-Positive Mutation)- approve if the patient has advanced or metastatic disease, has sensitizing EGFR mutation-positive NSCLC as detected by an approved test. Note-examples of sensitizing EGFR mutation-positive NSCLC include the following mutations: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S7681. NSCLC-EGFR T790M mutation positive-approve if the patient has metastatic EGFR T790M mutation-positive NSCLC as detected by an approved test and has progressed on treatment with at least one of the EGFR tyrosine kinase inhibitors. NSCLC-Post resection-approve if the patient has completely resected disease and has received previous adjuvant chemotherapy or if the patient is ineligible to receive platinum based chemotherapy and the patient has EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an approved test. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TALTZ

Products Affected

- TALTZ AUTOINJECTOR
- TALTZ SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with a Biologic DMARD or Targeted Synthetic DMARD. |
| Required Medical Information | Diagnosis, Previous medication use |
| Age Restrictions | PP-6 years and older (initial therapy), all other dx-18 years of age and older (initial therapy) |
| Prescriber Restrictions | All dx initial therapy only-PP-Prescribed by or in consultation with a dermatologist. PsA prescribed by or in consultation with a rheumatologist or a dermatologist. AS-prescribed by or in consultation with a rheum. |
| Coverage Duration | End of the plan year |
| Other Criteria | PP initial, approve if the patient meets one of the following criteria: 1) pt has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (note: pts who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first) OR 2) pt has a contraindication to MTX as determined by the prescribing physician. PsA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic or JAK inhibitor for RA/PsA are not required to step back and try a conventional synthetic DMARD). Non-Radiographic Axial Spondyloarthritis-approve if the patient has objective signs of inflammation defined as at least one of the following: C-reactive protein (CRP) elevated beyond the upper limit of normal for the reporting laboratory OR sacroiliitis reported on MRI and patient has had a 3 month trial of at least one tumor necrosis factor inhibitor or was unable to tolerate a 3- month trial. Continuation-approve if the patient has had a response as determined by the prescriber. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

TALZENNA

Products Affected

- TALZENNA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Recurrent or metastatic breast cancer-approve if the patient has germline BRCA mutation-positive disease. Prostate cancer - approve if the patient has metastatic castration resistant prostate cancer, AND is using this medication concurrently with a gonadotropin-releasing hormone (GnRH) analog or has had a bilateral orchiectomy AND the patient has homologous recombination repair (HRR) gene-mutated disease [Note: HRR gene mutations include ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C] AND the medication is used in combination with Xtandi (enzalutamide capsules and tablets). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TARGRETIN TOPICAL

Products Affected

- *bexarotene*

- TARGRETIN TOPICAL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an oncologist or dermatologist (initial and continuation) |
| Coverage Duration | 1 year |
| Other Criteria | Adult T-Cell Leukemia/Lymphoma- approve if the patient has chronic/smoldering subtype and this medication is used as first-line therapy. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Adult T-Cell Leukemia/Lymphoma |
| Part B Prerequisite | No |

TASIGNA

Products Affected

- TASIGNA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis for which Tassigna is being used. For indication of CML and ALL, the Philadelphia chromosome (Ph) status of the leukemia must be reported. For indication of gastrointestinal stromal tumor (GIST) and melanoma, cutaneous, prior therapies tried. For melanoma, cutaneous, KIT mutation status. |
| Age Restrictions | ALL/GIST/Myeloid/lymphoid neoplasms/melanoma, cutaneous-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months. |
| Other Criteria | Patients new to therapy with Acute lymphoblastic leukemia, philadelphia chromosome positive or chronic myeloid leukemia- approve if the patient has tried Sprycel and had an inadequate response or significant intolerance or have a contraindication or are not a candidate for Sprycel. For GIST, approve if the patient has tried two of the following: imatinib, avapritinib, sunitinib, dasatinib, regorafenib or ripretinib. Myeloid/lymphoid neoplasms with eosinophilia-approve if the tumor has an ABL1 rearrangement. Pigmented villonodular synovitis/tenosynovial giant cell tumor-approve if the patient has tried Turalio or cannot take Turalio, according to the prescriber. For melanoma, cutaneous - approve if the patient has metastatic or unresectable disease AND has an activating KIT mutation AND has tried at least one systemic regimen. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Philadelphia positive Acute Lymphoblastic Leukemia (ALL) and Gastrointestinal Stromal Tumor (GIST), Pigmented villonodular synovitis/tenosynovial giant cell tumor, Myeloid/Lymphoid neoplasms with Eosinophilia, melanoma cutaneous. |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

TAZVERIK

Products Affected

- TAZVERIK

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | Epithelioid Sarcoma-16 years and older, Follicular Lymphoma-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Epithelioid Sarcoma-approve if the patient has metastatic or locally advanced disease and the patient is not eligible for complete resection. Follicular Lymphoma-approve if the patient has relapsed or refractory disease and there are no appropriate alternative therapies or the patient has tried at least two prior systemic therapies. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TEPMETKO

Products Affected

- TEPMETKO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | NSCLC-approve if the patient has advanced or metastatic disease and the tumor is positive for mesenchymal-epithelial transition (MET) exon 14 skipping mutations or patient has high-level MET amplification, as detected by an approved test. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Non-small cell lung cancer with high-level MET amplification. |
| Part B Prerequisite | No |

TERIPARATIDE

Products Affected

- *teriparatide subcutaneous pen injector 20 mcg/dose (600mcg/2.4ml)*
- TERIPARATIDE SUBCUTANEOUS PEN INJECTOR 20 MCG/DOSE (620MCG/2.48ML)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use with other medications for osteoporosis |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | High risk for fracture-2 yrs, Not high risk-approve a max of 2 yrs of therapy (total)/lifetime. |
| Other Criteria | Treatment of PMO, approve if pt has tried one oral bisphosphonate OR pt cannot take an oral bisphosphonate because the pt cannot swallow or has difficulty swallowing or the pt cannot remain in an upright position post oral bisphosphonate administration or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried an IV bisphosphonate (ibandronate or zoledronic acid), OR pt has severe renal impairment (creatinine clearance less than 35 mL/min) or CKD or pt has had an osteoporotic fracture or fragility fracture. Increase bone mass in men (a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression) with primary or hypogondal osteoporosis/Treatment of GIO, approve if pt tried one oral bisphosphonate OR pt cannot take an oral bisphosphonate because the patient cannot swallow or has difficulty swallowing or the patient cannot remain in an upright position post oral bisphosphonate administration or has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried zoledronic acid (Reclast), OR pt has severe renal impairment (CrCL less than 35 mL/min) or has |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | CKD or has had an osteoporotic fracture or fragility fracture. Patients who have already taken teriparatide for 2 years - approve if the patient is at high risk for fracture. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TETRABENAZINE

Products Affected

- *tetrabenazine*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | For treatment of chorea associated with Huntington's disease, Tourette syndrome or related tic disorders, hyperkinetic dystonia, or hemiballism, must be prescribed by or after consultation with a neurologist. For TD, must be prescribed by or after consultation with a neurologist or psychiatrist. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Chorea associated with Huntington's Disease-approve if the diagnosis of Huntington's Disease is confirmed by genetic testing. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Tardive dyskinesia (TD). Tourette syndrome and related tic disorders. Hyperkinetic dystonia. Hemiballism. |
| Part B Prerequisite | No |

THALOMID

Products Affected

- THALOMID

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | MM, myelofibrosis-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | Erythem Nodosum Leprosum-approve. Multiple Myeloma-approve. Discoid lupus erythematosus or cutaneous lupus erythematosus, approve if the patient has tried at least two other therapies (eg, corticosteroids [oral, topical, intralesional], hydroxychloroquine, tacrolimus [Protopic], methotrexate, dapsone, acitretin [Soriatane]). Myelofibrosis, approve if according to the prescriber the patient has anemia and has serum erythropoietin levels greater than or equal to 500 mU/mL or if the patient has serum erythropoietin level less than 500 mU/mL and experienced no response or loss of response to erythropoietic stimulating agents. Prurigo nodularis, approve. Recurrent aphthous ulcers or aphthous stomatitis, approve if the patient has tried at least two other therapies (eg, topical or intralesional corticosteroids, systemic corticosteroids, topical anesthetics/analgesics [eg, benzocaine lozenges], antimicrobial mouthwashes [eg, tetracycline], acyclovir, colchicine). Kaposi's Sarcoma-approve if the patient has tried at least one regimen or therapy and has relapsed or refractory disease. Castleman's disease-approve if the patient has multicentric Castleman's disease, is negative for the human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |

| PA Criteria | Criteria Details |
|----------------------------|--|
| Off-Label Uses | Discoid lupus erythematosus or cutaneous lupus erythematosus, Myelofibrosis, Prurigo nodularis, Recurrent aphthous ulcers or aphthous stomatitis, Kaposi's Sarcoma, Castleman's Disease. |
| Part B Prerequisite | No |

TIBSOVO

Products Affected

- TIBSOVO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, IDH1 Status |
| Age Restrictions | All diagnoses (except chondrosarcoma)-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | AML- approve if the disease is isocitrate dehydrogenase-1 (IDH1) mutation positive, as detected by an approved test. Cholangiocarcinoma-approve if the disease is isocitrate dehydrogenase-1 (IDH1) mutation positive and has been previously treated with at least one chemotherapy regimen (Part B before Part D Step Therapy - applies only to beneficiaries enrolled in an MA-PD plan). Chondrosarcoma-approve if the disease is isocitrate dehydrogenase-1 (IDH1) mutation positive. Central nervous system cancer-approve if the patient has recurrent or progressive disease, AND patient has World Health Organization (WHO) grade 2 or 3 oligodendroglioma, OR Patient has WHO grade 2 astrocytoma. Myelodysplastic Syndrome-approve if patient has isocitrate dehydrogenase-1 (IDH1) mutation-positive disease AND relapsed or refractory disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Chondrosarcoma, Central nervous system cancer |
| Part B Prerequisite | No |

TOLVAPTAN

Products Affected

- SAMSCA ORAL TABLET 15 MG
- *tolvaptan*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with Jynarque. |
| Required Medical Information | Serum sodium less than 125 mEq/L at baseline or less marked hyponatremia, defined as serum sodium less than 135 mEq/L at baseline, that is symptomatic (eg, nausea, vomiting, headache, lethargy, confusion). |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 30 days |
| Other Criteria | Hyponatremia - Pt must meet ONE of the following: 1. serum sodium less than 125 mEq/L at baseline, OR 2. marked hyponatremia, defined as less than 135 mEq/L at baseline, that is symptomatic (eg, nausea, vomiting, headache, lethargy, confusion), OR 3. patient has already been started on tolvaptan and has received less than 30 days of therapy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TOPICAL AGENTS FOR ATOPIC DERMATITIS

Products Affected

- ELIDEL
- *pimecrolimus*
- *tacrolimus topical*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months. |
| Other Criteria | Authorize use in patients who have tried a prescription strength topical corticosteroid (brand or generic) for the current condition. Dermatologic condition on or around the eyes, eyelids, axilla, or genitalia, authorize use without a trial of a prescription strength topical corticosteroid. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TOPICAL RETINOID PRODUCTS

Products Affected

- *tretinoin*
- *tretinoin microspheres*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Coverage is not provided for cosmetic use. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TOPIRAMATE/ZONISAMIDE

Products Affected

- EPRONTIA
- TOPAMAX
- *topiramate oral capsule, sprinkle*
- *topiramate oral capsule, extended release 24hr*
- *topiramate oral tablet*
- TROKENDI XR
- ZONISADE
- *zonisamide*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Coverage is not provided for weight loss or smoking cessation. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TRANSMUCOSAL FENTANYL DRUGS

Products Affected

- *fentanyl citrate buccal lozenge on a handle*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months. |
| Other Criteria | For breakthrough pain in patients with cancer if patient is unable to swallow, has dysphagia, esophagitis, mucositis, or uncontrollable nausea/vomiting OR patient is unable to take 2 other short-acting narcotics (eg, oxycodone, morphine sulfate, hydromorphone, etc) secondary to allergy or severe adverse events AND patient is on or will be on a long-acting narcotic (eg, Duragesic), or the patient is on intravenous, subcutaneous, or spinal (intrathecal, epidural) narcotics (eg, morphine sulfate, hydromorphone, fentanyl citrate). Clinical criteria incorporated into the quantity limit edits for all transmucosal fentanyl drugs require confirmation that the indication is breakthrough cancer pain (ie, FDA labeled use) prior to reviewing for quantity exception. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TRELSTAR

Products Affected

- TRELSTAR INTRAMUSCULAR
SUSPENSION FOR RECONSTITUTION

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a oncologist or urologist |
| Coverage Duration | 1 year |
| Other Criteria | Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TRIENTINE

Products Affected

- CUVRIOR
- *trientine oral capsule 250 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, medication history, pregnancy status, disease manifestations (all as described in Other Criteria) |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant physician. |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | For Wilson's Disease, approve if the patient meets A and B: A) Diagnosis of Wilson's disease is confirmed by ONE of the following (i or ii): i. Genetic testing results confirming biallelic pathogenic ATP7B mutations (in either symptomatic or asymptomatic individuals), OR ii. Confirmation of at least two of the following (a, b, c, or d): a. Presence of Kayser-Fleischer rings, OR b. Serum ceruloplasmin levels less than 20mg/dL, OR c. Liver biopsy findings consistent with Wilson's disease, OR d. 24-hour urinary copper greater than 40 micrograms/24 hours, AND B) Patient meets ONE of the following: 1) Patient has tried a penicillamine product and per the prescribing physician the patient is intolerant to penicillamine therapy, OR 2) Per the prescribing physician, the patient has clinical features indicating the potential for intolerance to penicillamine therapy (ie, history of any renal disease, congestive splenomegaly causing severe thrombocytopenia, autoimmune tendency), OR 3) Per the prescribing physician, the patient has a contraindication to penicillamine therapy, OR 4) The patient has neurologic manifestations of Wilson's disease, OR 5) The patient is pregnant, OR 6) the patient has been started on therapy with trientine. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

TRIKAFTA

Products Affected

- TRIKAFTA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Patients with unknown CFTR gene mutations. Combination therapy with Orkambi, Kalydeco or Symdeko. |
| Required Medical Information | Diagnosis, specific CFTR gene mutations, concurrent medications |
| Age Restrictions | 2 years of age and older |
| Prescriber Restrictions | Prescribed by or in consultation with a pulmonologist or a physician who specializes in CF |
| Coverage Duration | 1 year |
| Other Criteria | CF - must have at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive to the requested medication. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TRUQAP

Products Affected

- TRUQAP

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Breast Cancer-Approve if the patient meets the following (A, B, C, D and E): A) Patient has locally advanced or metastatic disease, AND B) Patient has hormone receptor positive (HR+) disease, AND C) Patient has human epidermal growth factor receptor 2 (HER2)-negative disease, AND D) Patient has at least one phosphatidylinositol 3-kinase (PIK3CA), serine/threonine protein kinase (AKT1), or phosphatase and tensin homolog (PTEN)-alteration, AND E) Patient meets one of the following (i or ii): i. Patient has had progression with at least one endocrine-based regimen in the metastatic setting (Note: Examples of endocrine therapy include anastrozole, exemestane, and letrozole.) OR ii. Patient has recurrence on or within 12 months of completing adjuvant endocrine therapy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TUKYSA

Products Affected

- TUKYSA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, prior therapies |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Breast Cancer-approve if the patient has recurrent or metastatic human epidermal growth factor receptor 2 (HER2)-positive disease, has received at least one prior anti-HER2-based regimen in the metastatic setting and Tukysa is used in combination with trastuzumab and capecitabine. Colon/Rectal Cancer-approve if the requested medication is used in combination with trastuzumab, patient has unresectable or metastatic disease, human epidermal growth factor receptor 2 (HER2)-positive disease, AND Patient's tumor or metastases are wild-type RAS (KRAS wild-type and NRAS wild-type). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TURALIO

Products Affected

- TURALIO ORAL CAPSULE 125 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Tenosynovial Giant Cell Tumor (Pigmented Villonodular Synovitis)-approve if, according to the prescriber, the tumor is not amenable to improvement with surgery. Histiocytic Neoplasms-approve if the patient has a colony stimulating factor 1 receptor (CSF1R) mutation AND has one of the following conditions (i, ii, or iii): i. Langerhans cell histiocytosis OR ii. Erdheim-Chester disease OR iii. Rosai-Dorfman disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Histiocytic Neoplasms |
| Part B Prerequisite | No |

TYMLOS

Products Affected

- TYMLOS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concomitant use with other medications for osteoporosis (eg, denosumab [Prolia], bisphosphonates, calcitonin nasal spray [Fortical], Forteo), Evenity, except calcium and Vitamin D. Previous use of Tymlos for a combined total no greater than 2 years duration during a patient's lifetime. |
| Required Medical Information | Previous medications tried, renal function |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 2 years of total therapy over a patient's lifetime |
| Other Criteria | Treatment of PMO and treatment of osteoporosis in men, approve if the patient meets ONE of the following criteria: patient has tried one oral bisphosphonate or cannot take an oral bisphosphonate because the patient cannot swallow or has difficulty swallowing or patient cannot remain in an upright position post oral bisphosphonate administration or patient has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR patient has tried an IV bisphosphonate (ibandronate or zoledronic acid), OR patient has severe renal impairment or CKD, OR patient has had an osteoporotic fracture or fragility fracture. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TYSABRI

Products Affected

- TYSABRI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use of other disease-modifying agents used for MS. Concurrent use with immunosuppressants (eg, 6-mercaptopurine, azathioprine, cyclosporine, methotrexate) in Crohn's disease (CD) patient |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 and older (initial and continuation) |
| Prescriber Restrictions | MS: prescribed by, or in consultation with, a neurologist or a physician who specializes in the treatment of MS. (initial and continuation) CD: prescribed by, or in consultation with, a gastroenterologist (initial and continuation) |
| Coverage Duration | MS-Authorization will be for 1 year.CD, initial-6 mo. CD, cont therapy-1 year. |
| Other Criteria | Adults with a relapsing form of MS-initial. Patient has had an inadequate response to, or is unable to tolerate, one disease modifying agent used for MS: (eg, interferon beta-1a (Avonex, Rebif), interferon beta-1b (Betaseron, Extavia), glatiramer acetate (Copaxone/Glatopa), Plegridy, fingolimod (Gilenya), Tecfidera, Lemtrada, daclizumab (Zinbryta), Aubagio, Mavenclad, Mayzent, Vumerity, Lemtrada, Ocrevus) OR the patient has highly active or aggressive disease according to the prescribing physician by meeting one of the following-the patient has demonstrated rapidly-advancing deterioration(s) in physical functioning (e.g., loss of mobility/or lower levels of ambulation, severe changes in strength or coordination OR disabling relapse(s) with suboptimal response to systemic corticosteroids OR magnetic resonance imaging (MRI) findings suggest highly-active or aggressive multiple sclerosis (e.g., new, enlarging, or a high burden of T2 lesions or gadolinium lesions) OR manifestation of multiple sclerosis-related cognitive impairment. Adults with CD, initial. Patient has moderately to severely active CD and patient has tried two biologics for CD. CD, continuation therapy. Patient has had a response to Tysabri, as determined by the prescribing physician. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |

| PA Criteria | Criteria Details |
|----------------------------|--|
| Off-Label Uses | Patients already started on Tysabri for a Covered Use. |
| Part B Prerequisite | No |

TZIELD

Products Affected

- TZIELD

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Diagnosis of clinical type 1 diabetes (i.e., Stage 3 type 1 diabetes) or type 2 diabetes |
| Required Medical Information | Patient meets ALL of the following (A, B, C and D): A) has tested positive for at least TWO of the following type 1 diabetes-related autoantibodies on two separate occasions: anti-glutamic acid decarboxylase 65 (anti-GAD65), anti-islet antigen-2 (anti-IA-2), islet-cell autoantibody (ICA), micro insulin, or anti-zinc transporter 8 (anti-ZnT8). B) Patient meets both of the following (i and ii): i. Patient has taken an oral glucose tolerance test within the preceding 2 months AND ii. The results of the oral glucose tolerance test indicated dysglycemia by meeting at least one of the following (a, b, or c): a) Fasting plasma glucose level greater than or equal to 110 to less than 126 mg/dL OR b) 2-hour postprandial plasma glucose level greater than or equal to 140 to less than 200 mg/dL OR c) Intervening postprandial glucose level at 30, 60, or 90 minutes greater than 200 mg/dL. C) At baseline (prior to the initiation of Tzield), patient does NOT have evidence of hematologic compromise, as defined by meeting the following (i, ii, iii, and iv): i. Lymphocyte count greater than or equal to 1,000 lymphocytes/mcL AND ii. Hemoglobin greater than or equal to 10 g/dL AND iii. Platelet count greater than or equal to 150,000 platelets/mcL AND iv. Absolute neutrophil count greater than or equal to 1,500 neutrophils/mcL AND D) At baseline (prior to the initiation of Tzield), patient does NOT have evidence of hepatic compromise, as defined by meeting the following (i, ii, and iii): i. Alanine aminotransferase (ALT) greater than or equal to 2 times the upper limit of normal (ULN) AND ii. Aspartate aminotransferase (AST) greater than or equal to 2 times the ULN AND iii. Bilirubin greater than or equal to 1.5 times the ULN. |
| Age Restrictions | 8 years and older |
| Prescriber Restrictions | Prescribed by or in consultation with an endocrinologist |
| Coverage Duration | 14 days |

| PA Criteria | Criteria Details |
|----------------------------|--|
| Other Criteria | Patient meets all the following (A, B and C): A) has at least one biological relative with a diagnosis of type 1 diabetes B) According to the prescriber, the patient does NOT have any of the following (i, ii, or iii): i. Laboratory or clinical evidence of acute infection with Epstein-Barr Virus or cytomegalovirus OR ii. Active serious infection OR iii. Chronic active infection (other than localized skin infection) AND C) Patient has NOT received Tzield in the past |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

UPTRAVI

Products Affected

- UPTRAVI ORAL

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent Use with Other Inhaled or Parenteral Prostacyclin Agents Used for Pulmonary Hypertension. |
| Required Medical Information | Confirmation of right heart catheterization, medication history. |
| Age Restrictions | N/A |
| Prescriber Restrictions | PAH must be prescribed by, or in consultation with, a cardiologist or a pulmonologist. |
| Coverage Duration | 1 year |
| Other Criteria | Must have PAH (WHO Group 1) and had a right heart catheterization to confirm the diagnosis of PAH (WHO Group 1). Patient new to therapy must meet a) OR b): a) tried one or is currently taking one oral therapy for PAH for 30 days, unless patient has experienced treatment failure, intolerance, or oral therapy is contraindicated: PDE5 inhibitor (eg, sildenafil, Revatio), endothelin receptor antagonist (ERA) [eg, Tracleer, Letairis or Opsumit], or Adempas, OR b) receiving or has received in the past one prostacyclin therapy for PAH (eg, Orenitram, Ventavis, or epoprostenol injection). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VALCHLOR

Products Affected

- VALCHLOR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | Cutaneous lymphoma-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Cutaneous Lymphomas (Note-includes mycosis fungoides/Sezary syndrome, primary cutaneous B-cell lymphoma, primary cutaneous CD30+ T-cell lymphoproliferative disorders)-approve. Adult T-Cell Leukemia/Lymphoma-approve if the patient has chronic/smoldering subtype of adult T-cell leukemia/lymphoma. Langerhans cell histiocytosis-approve if the patient has unifocal Langerhans cell histiocytosis with isolated skin disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Adults with T-cell leukemia/lymphoma, Langerhans Cell Histiocytosis |
| Part B Prerequisite | No |

VALTOCO

Products Affected

- VALTOCO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, other medications used at the same time |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist |
| Coverage Duration | 1 year |
| Other Criteria | Intermittent Episodes of Frequent Seizure Activity (i.e., seizure clusters, acute repetitive seizures)-approve if the patient is currently receiving maintenance antiseizure medication(s). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VANCOMYCIN

Products Affected

- *vancomycin oral capsule*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 2 weeks |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VANFLYTA

Products Affected

- VANFLYTA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Acute Myeloid Leukemia: approve if the patient has FLT3-ITD mutation-positive disease as detected by an approved test and this medication is being used for induction, re-induction, consolidation, or maintenance treatment. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VENCLEXTA

Products Affected

- VENCLEXTA
- VENCLEXTA STARTING PACK

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, prior therapy |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | AML-approve if used in combination with azacitidine, decitabine, or cytarabine. CLL/SLL- approve. Mantle Cell Lymphoma- approve if the patient has tried at least one systemic regimen. Multiple Myeloma- approve if the patient has t (11,14) translocation AND has tried at least one systemic regimen for multiple myeloma AND Venclexta will be used in combination with dexamethasone. Systemic light chain amyloidosis-approve if the patient has t (11, 14) translocation and has tried at least one systemic regimen. Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma-approve if the patient has tried at least one systemic regimen. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Mantle Cell Lymphoma, waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma, multiple myeloma, systemic light chain amyloidosis |
| Part B Prerequisite | No |

VENTAVIS

Products Affected

- VENTAVIS

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | B vs D coverage determination |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VERQUVO

Products Affected

- VERQUVO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | Patient has symptomatic chronic heart failure, an ejection fraction less than 45% and for new starts, has had either a hospitalization for heart failure within the last six months or has needed outpatient IV diuretics within the last three months. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VERZENIO

Products Affected

- VERZENIO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Breast cancer: HR status, HER2 status, previous medications/therapies tried, concomitant therapy, menopausal status |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | <p>Breast Cancer, Early-Approve if pt meets (A,B,C and D): A)Pt has HR+disease, AND B)Pt has HER2-negative breast cancer, AND C)Pt has node-positive disease at high risk of recurrence AND D)Pt meets ONE of the following (i or ii): i.Verzenio will be used in combo w/anastrozole, exemestane, or letrozole AND pt meets one of the following (a,b, or c): a)Pt is a postmenopausal woman, OR b)Pt is a pre/perimenopausal woman and meets one of the following 1 or 2:1-Pt is receiving ovarian suppression/ablation with a gonadotropin-releasing hormone (GnRH) agonist, OR 2-Pt has had surgical bilateral oophorectomy or ovarian irradiation, OR c)Pt is a man and pt is receiving a GnRH analog, OR ii.Verzenio will be used in combo with tamoxifen AND pt meets one of the following (a or b): a)Pt is a postmenopausal woman or man OR b)Pt is a pre/perimenopausal woman and meets one of the following 1 or 2:1-Pt is receiving ovarian suppression/ablation with a GnRH agonist, OR 2-Patient has had surgical bilateral oophorectomy or ovarian irradiation. Breast Cancer-Recurrent or Metastatic in Women-Approve if pt meets (A, B, C and D): A) Pt has HR+ disease, AND B)Pt has HER2-negative breast cancer, AND C)Pt meets ONE of the following criteria (i or ii): i.Pt is a postmenopausal woman, OR ii.Pt is a pre/perimenopausal woman and meets one of the following (a or b): a)Pt is receiving ovarian suppression/ablation with a GnRH agonist, OR b)Pt has had surgical bilateral oophorectomy or ovarian irradiation, AND D)Pt meets ONE of the</p> |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | <p>following criteria (i, ii, or iii): i.Verzenio will be used in combo with anastrozole, exemestane, or letrozole, OR ii.Verzenio will be used in combo with fulvestrant, OR iii.pt meets the following conditions (a, b, and c): a)Verzenio will be used as monotherapy, AND b)Pt's breast cancer has progressed on at least one prior endocrine therapy, AND c)Pt has tried chemotherapy for metastatic breast cancer.Breast Cancer-Recurrent or Metastatic in Men-Approve if pt meets the following criteria (A,B and C): A)Pt has HR+ disease, AND B)Pt has HER2-negative breast cancer, AND C)Pt meets ONE of the following criteria (i, ii, or iii): i.Pt meets BOTH of the following conditions (a and b): a)Pt is receiving a GnRH analog, AND b)Verzenio will be used in combo with anastrozole, exemestane, or letrozole, OR ii.Verzenio will be used in combo with fulvestrant, OR iii.Pt meets the following conditions (a, b, and c): a)Verzenio will be used as monotherapy, AND b)Pt's breast cancer has progressed on at least one prior endocrine therapy, AND c)Pt has tried chemotherapy for metastatic breast cancer. Endometrial cancer- approve if pt meets all of (A, B, And C): A) pt has recurrent or metastatic disease, and B) pt has estrogen receptor (ER)-positive tumors, and C) pt will be using in combination with letrozole.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Endometrial cancer |
| Part B Prerequisite | No |

VIBERZI

Products Affected

- VIBERZI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis of irritable bowel syndrome with diarrhea. |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | The patient must have a history of failure, contraindication or intolerance to one antidiarrheal drug. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VITRAKVI

Products Affected

- VITRAKVI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, NTRK gene fusion status |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Solid tumors - approve if the tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion AND the tumor is metastatic or surgical resection of tumor will likely result in severe morbidity. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VIZIMPRO

Products Affected

- VIZIMPRO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, EGFR status, exon deletions or substitutions |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | NSCLC-approve if the patient has advanced or metastatic disease, has sensitizing EGFR mutation-positive NSCLC as detected by an approved test. Note: Examples of sensitizing EGFR mutation-positive NSCLC include the following mutations: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S7681. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VONJO

Products Affected

- VONJO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Myelofibrosis (MF), including primary MF, post-polycythemia Vera MF, and Post-Essential Thrombocythemia MF-approve if the patient meets either (A, or B, or C): (A) the patient has a platelet count of less than $50 \times 10^9 /L$ (less than 50,000/mcL) and meets one of the following criteria (a or b): a) Patient has intermediate-risk or high-risk disease and is not a candidate for transplant, Patient has lower-risk disease OR (B) Patient has a platelet count of greater than or equal to $50 \times 10^9 /L$ (greater than or equal to 50,000/mcL) and meets all of the following criteria (a, b and c): a) Patient has high-risk disease, AND b) Patient is not a candidate for transplant, AND c) Patient has tried Jakafi (ruxolitinib tablets) or Inrebic (fedratinib capsules) OR (C) patient has myelofibrosis-associated anemia with symptomatic splenomegaly and/or constitutional symptoms. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VOSEVI

Products Affected

- VOSEVI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Genotype, prescriber specialty, other medications tried or used in combination with requested medication |
| Age Restrictions | 18 years or older |
| Prescriber Restrictions | Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician |
| Coverage Duration | Will be c/w AASLD guidance and inclusive of treatment already received for the requested drug |
| Other Criteria | Criteria will be applied consistent with current AASLD/IDSA guidance. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Indications consistent with current AASLD/IDSA guidance |
| Part B Prerequisite | No |

VOTRIENT

Products Affected

- *pazopanib*
- VOTRIENT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | <p>Soft tissue sarcoma other than GIST-approve if the patient has advanced or metastatic disease and has ONE of the following: alveolar soft part sarcoma, angiosarcoma, desmoid tumors (aggressive fibromatosis, dermatofibrosarcoma protuberans with fibrosarcomatous transformation, non-adipocytic sarcoma or pleomorphic rhabdomyosarcoma.</p> <p>Differentiated (ie, papillary, follicular, Hurthle) thyroid carcinoma, approve if the patient is refractory to radioactive iodine therapy. Uterine sarcoma, approve if the patient has recurrent or metastatic disease. Renal Cell Carcinoma, Clear Cell or non-Clear Cell histology-approved if the patient has relapsed or advanced disease or VonHippel-Lindau disease. Ovarian Cancer (ie, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer) - approve if the patient has persistent or recurrent disease. GIST - approve if the patient has succinate dehydrogenase (SDH)-deficient GIST OR the patient has tried TWO of the following: Gleevec, Ayvakit, Sutent, Sprycel, Qinlock or Stivarga. Medullary Thyroid Carcinoma, approve if the patient has tried at least one systemic therapy. Bone cancer-approve if the patient has chondrosarcoma and has metastatic widespread disease.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Differentiated (ie, papillary, follicular, Hurthle cell) thyroid carcinoma. Uterine sarcoma, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal |

| | |
|----------------------------|--|
| PA Criteria | Criteria Details |
| | Cancer, Gastrointestinal Stromal Tumor (GIST), Medullary thyroid carcinoma, bone cancer. |
| Part B Prerequisite | No |

VUMERITY

Products Affected

- VUMERITY

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with other disease-modifying agents used for multiple sclerosis (MS) |
| Required Medical Information | Relapsing form of Multiple Sclerosis (MS), to include, clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of MS. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Cont tx-approve if the patient has been established on Vumerity. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

WELIREG

Products Affected

- WELIREG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Renal Cell Carcinoma- approve if pt has advanced disease AND has tried at least one programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor AND has tried at least one a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). [Note: Examples of PD-1 inhibitor or PD-L1 inhibitor include: Keytruda (pembrolizumab intravenous infusion), Opdivo (nivolumab intravenous infusion), and Bavencio (avelumab intravenous infusion). Examples of VEGF-TKI include Cabometyx (cabozantinib tablets), Lenvima (lenvatinib capsules), Inlyta (axitinib tablets), Fotivda (tivozanib capsules), pazopanib, sunitinib, and sorafenib.] Van Hippel-Lindau Disease-approve if the patient meets the following (A, B, and C): A) Patient has a von Hippel-Lindau (VHL) germline alteration as detected by genetic testing, B) Does not require immediate surgery and C) Patient requires therapy for ONE of the following conditions (i, ii, iii, or iv): i. Central nervous system hemangioblastomas, OR ii. Pancreatic neuroendocrine tumors, OR iii. Renal cell carcinoma, OR iv. Retinal hemangioblastoma. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XALKORI

Products Affected

- XALKORI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | Anaplastic large cell lymphoma/IMT-patients greater than or equal to 1 year of age. All other diagnoses-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Metastatic non-small cell lung cancer-approve if the patient has anaplastic lymphoma kinase (ALK)-positive disease, as detected by an approved test and patients new to therapy must have a trial of Alecensa prior to approval of Xalkori. Metastatic non-small cell lung cancer, approve if the patient has ROS1 rearrangement positive disease, as detected by an approved test. Anaplastic Large Cell Lymphoma-approve if the patient has anaplastic lymphoma kinase (ALK)-positive disease AND (i or ii): (i) the medication is used for palliative-intent therapy, or (ii) pt has received at least one prior systemic treatment. Histiocytic neoplasm-approve if the patient has ALK rearrangement/fusion-positive disease and meets one of the following criteria (i, ii, or iii): (i. Patient has Langerhans cell histiocytosis, OR ii. Patient has Erdheim-Chester disease OR iii. Patient has Rosai-Dorfman disease. NSCLC with MET mutation-approve if the patient has high level MET amplification or MET exon 14 skipping mutation. Inflammatory Myofibroblastic Tumor-approve if the patient has ALK positive disease and the patient has advanced, recurrent or metastatic disease or the tumor is inoperable. Melanoma, cutaneous-approve if the patient has ALK fusion disease or ROS1 fusion disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |

| PA Criteria | Criteria Details |
|----------------------------|---|
| Off-Label Uses | NSCLC with high level MET amplification or MET Exon 14 skipping mutation, Histiocytic neoplasms, melanoma, cutaneous. |
| Part B Prerequisite | No |

XATMEP

Products Affected

- XATMEP

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XCOPRI

Products Affected

- XCOPRI 100MG X1), 350 MG/DAY (200 MG X1-
- XCOPRI MAINTENANCE PACK ORAL 150MG X1)
- TABLET 250MG/DAY(150 MG X1- • XCOPRI TITRATION PACK

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | Approve if the patient has tried one other anticonvulsant therapy (eg, carbamazepine, divalproex sodium, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, topiramate, valproic acid). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XDEMVY

Products Affected

- XDEMVY

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 6 weeks |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XELJANZ

Products Affected

- XELJANZ
- XELJANZ XR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with biologic therapy or targeted synthetic DMARD. |
| Required Medical Information | Diagnosis, concurrent medications, previous therapies tried. |
| Age Restrictions | N/A |
| Prescriber Restrictions | RA, JIA/JRA, Ankylosing spondylitis, prescribed by or in consultation with a rheumatologist. PsA prescribed by or in consultation with a rheumatologist or a dermatologist. UC-prescribed by or in consultation with a gastroenterologist. |
| Coverage Duration | End of the plan year |
| Other Criteria | Initial - patient has tried a TNF blocker for at least 3 months. Continuation-approve if the patient has had a response as determined by the prescriber. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XENICAL

Products Affected

- *orlistat*
- XENICAL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | For hyperlipidemia, the patient is on a maximally tolerated statin and a secondary cholesterol lowering drug. Patients intolerant to statins as demonstrated by experiencing statin-associated rhabdomyolysis to one statin OR has tried 2 statins (any combination of high or moderate intensity statins) and has experienced skeletal muscle related symptoms on both agents, no concurrent statin use required. Xenical can be approved with a non-D authorization for the indication of weight loss if the EGWP customer has the weight loss buy-up. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XERMELO

Products Affected

- XERMELO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, previous therapy, concomitant therapy |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Initial therapy - approve if the patient meets ALL of the following criteria: 1) patient has been on long-acting somatostatin analog (SSA) therapy (eg, Somatuline Depot [lanreotide for injection]) AND 2) while on long-acting SSA therapy (prior to starting Xermelo), the patient continues to have at least four bowel movements per day, AND 3) Xermelo will be used concomitantly with a long-acting SSA therapy. Continuation therapy - approve if the patient is continuing to take Xermelo concomitantly with a long-acting SSA therapy for carcinoid syndrome diarrhea. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XGEVA

Products Affected

- XGEVA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XIAFLEX

Products Affected

- XIAFLEX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Retreatment (i.e., treatment beyond eight injections for Peyronie's Disease). |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | Dupuytren's Contracture-administered by a healthcare provider experienced in injection procedures of the hand and in the treatment of Dupuytren's contracture. Peyronie's Disease -administered by a healthcare provider experienced in the treatment of male urological diseases. |
| Coverage Duration | Dupuytren's Contracture-3 months, Peyronie's Disease-6 months |
| Other Criteria | Dupuytren's Contracture-at baseline (prior to initial injection of Xiaflex), the patient had contracture of a metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint of at least 20 degrees AND the patient will not be treated with more than a total of three injections (maximum) per affected cord as part of the current treatment course. Peyronie's Disease-the patient meets ONE of the following (i or ii): i. at baseline (prior to use of Xiaflex), the patient has a penile curvature deformity of at least 30 degrees OR in a patient who has received prior treatment with Xiaflex, the patient has a penile curvature deformity of at least 15 degrees AND the patient has not previously been treated with a complete course (8 injections) of Xiaflex for Peyronie's disease. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XIFAXAN

Products Affected

- XIFAXAN

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | Hepatic encephalopathy, irritable bowel syndrome - 18 years of age or older. Traveler's diarrhea - 12 years of age or older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | Hepatic Encephalopathy-6 months, IBS with diarrhea-14 days, Traveler's diarrhea-3 days |
| Other Criteria | For IBS with diarrhea - customers are limited to 3 courses |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XOLAIR

Products Affected

- XOLAIR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with another monoclonal antibody therapy. |
| Required Medical Information | Moderate to severe persistent asthma, baseline IgE level of at least 30 IU/mL. For asthma, patient has a baseline positive skin test or in vitro testing (ie, a blood test for allergen-specific IgE antibodies such as an enzyme-linked immunoabsorbant assay (eg, immunoCAP, ELISA) or the RAST) for 1 or more perennial aeroallergens (eg, house dust mite, animal dander [dog, cat], cockroach, feathers, mold spores) and/or for 1 or more seasonal aeroallergens (grass, pollen, weeds). CIU - must have urticaria for more than 6 weeks (prior to treatment with Xolair), with symptoms present more than 3 days/wk despite daily non-sedating H1-antihistamine therapy (e.g., cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine). |
| Age Restrictions | Moderate to severe persistent asthma-6 years and older. CIU-12 years and older. Polyps-18 years and older. Food Allergy-1 yr and older |
| Prescriber Restrictions | Moderate to severe persistent asthma if prescribed by, or in consultation with an allergist, immunologist, or pulmonologist. CIU if prescribed by or in consultation with an allergist, immunologist, or dermatologist. Polyps-prescribed by or in consult with an allergist, immunologist, or otolaryngologist. Food allergy- allergist or immunologist |
| Coverage Duration | asthma/CIU-Initial tx 4 months, Polyps-initial-6 months, continued tx 12 months, Food allergy-1 yr |
| Other Criteria | Moderate to severe persistent asthma approve if pt meets criteria 1 and 2: 1) pt has received at least 3 months of combination therapy with an inhaled corticosteroid and at least one additional asthma controller or asthma maintenance medication (Examples: LABA, LAMA, leukotriene receptor antagonist, monoclonal antibody therapies for asthma) and 2)patient's asthma is uncontrolled or was uncontrolled prior to receiving Xolair or another monoclonal antibody therapy for asthma as defined by ONE of the following (a, b, c, d, or e): a) The patient experienced two or more asthma exacerbations requiring treatment with systemic corticosteroids in the previous year OR b) The patient experienced one or more asthma exacerbation requiring hospitalization, urgent care visit or an Emergency |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | <p>Department (ED) visit in the previous year OR c) Patient has a forced expiratory volume in 1 second (FEV1) less than 80% predicted OR d) Patient has an FEV1/forced vital capacity (FVC) less than 0.80 OR e) The patient's asthma worsens upon tapering of oral corticosteroid therapy</p> <p>NOTE: An exception to the requirement for a trial of one additional asthma controller/maintenance medication can be made if the patient has already received anti-IL-4/13 therapy (Dupixent) used concomitantly with an ICS.</p> <p>For continued Tx for asthma - patient has responded to therapy as determined by the prescribing physician and continues to receive therapy with one inhaled corticosteroid or inhaled corticosteroid containing combination product. For CIU cont tx - have responded to therapy as determined by the prescribing physician.</p> <p>Nasal Polyps Initial-Approve if the patient has a baseline (defined as prior to receiving any treatment with Xolair or another monoclonal antibody therapy that may lower IgE) IgE level greater than or equal to 30 IU/ml, patient is experiencing significant rhinosinusitis symptoms such as nasal obstruction, rhinorrhea, or reduction/loss of smell and patient is currently receiving therapy with an intranasal corticosteroid. Nasal polyps continuation-approve if the patient continues to receive therapy with an intranasal corticosteroid and has responded to therapy.</p> <p>IgE-Mediated Food Allergy-approve if pt meets (A, B, C and D): (A) baseline IgE greater than or equal to 30 IU/mL, and (B) positive skin prick test to one or more foods and positive in vitro test for IgE to one or more foods, and (C) history of allergic reaction that met all of the following: pt demonstrated signs and symptoms of a significant systemic allergic reaction, and reaction occurred within a short period of time following a known ingestion of the food, and prescriber deemed this reaction significant enough to require a prescription for an epinephrine auto-injector, and (D) pt has been prescribed an epinephrine auto-injector.</p> |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XOSPATA

Products Affected

- XOSPATA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, FLT3-mutation status |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | AML - approve if the patient has relapsed or refractory disease AND the disease is FLT3-mutation positive as detected by an approved test. Lymphoid, Myeloid Neoplasms-approve if the patient has eosinophilia and the disease is FLT3-mutation positive as detected by an approved test. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Lymphoid, Myeloid Neoplasms |
| Part B Prerequisite | No |

XPOVIO

Products Affected

- XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (40 MG X 1), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80MG TWICE WEEK (160 MG/WEEK)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, prior therapies |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | <p>Multiple Myeloma-Approve if the patient meets the following (A and B):</p> <p>A) The medication will be taken in combination with dexamethasone AND</p> <p>B) Patient meets one of the following (i, ii, or iii): i. Patient has tried at least four prior regimens for multiple myeloma OR ii. Patient meets both of the following (a and b): a) Patient has tried at least one prior regimen for multiple myeloma AND b) The medication will be taken in combination with bortezomib OR iii. Patient meets both of the following (a and b): a) Patient has tried at least one prior regimen for multiple myeloma AND b) The medication will be taken in combination with Darzalex (daratumumab infusion), Darzlaex Faspro (daratumumab and hyaluronidase-fihj injection), or Pomalyst (pomalidomide capsules). Note: Examples include bortezomib/Revlimid (lenalidomide capsules)/dexamethasone, Kyprolis (carfilzomib infusion)/Revlimid/dexamethasone, Darzalex (daratumumab injection)/bortezomib or Kyprolis/dexamethasone, or other regimens containing a proteasome inhibitor, immunomodulatory drug, and/or anti-CD38 monoclonal antibody. Diffuse large B-cell lymphoma Note:this includes patients with histologic transformation of indolent lymphomas to diffuse large B-cell lymphoma)-approve if the patient has been treated with at least two prior systemic therapies.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |

| PA Criteria | Criteria Details |
|----------------------------|--|
| Off-Label Uses | Treatment of multiple myeloma in combination with daratumumb or pomalidomide |
| Part B Prerequisite | No |

XTANDI

Products Affected

- XTANDI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis for which Xtandi is being used. |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Prostate cancer-castration-resistant [Metastatic or Non-metastatic] and Prostate cancer-metastatic, castration sensitive-approve if Xtandi will be used concurrently with a gonadotropin-releasing hormone (GnRH) agonist or the medication is concurrently used with Firmagon or if the patient has had a bilateral orchiectomy. Prostate cancer- Non-Metastatic, Castration-Sensitive - approve if pt has biochemical recurrence and is at high risk for metastasis. [Note: High-risk biochemical recurrence is defined as prostate-specific antigen (PSA) doubling time less than or equal to 9 months.] |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XYREM

Products Affected

- SODIUM OXYBATE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use with Xywav, Wakix or Sunosi |
| Required Medical Information | Medication history (as described in Other Criteria field) |
| Age Restrictions | 7 years and older |
| Prescriber Restrictions | Prescribed by a sleep specialist physician or a Neurologist |
| Coverage Duration | 12 months. |
| Other Criteria | For Excessive daytime sleepiness (EDS) in patients with narcolepsy, 18 years and older - approve if the patient has tried one CNS stimulant (e.g., methylphenidate, dextroamphetamine), modafinil, or armodafinil and narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT). For EDS in patients with narcolepsy, less than 18 years old-approve if the patient has tried one CNS stimulant (e.g., methylphenidate, dextramphetamine) or modafinil and narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT). Cataplexy treatment in patients with narcolepsy-approve if narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ZARXIO

Products Affected

- ZARXIO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Cancer/AML, MDS, ALL, oncologist or a hematologist. Cancer patients receiving BMT and PBPC, prescribed by or in consultation with an oncologist, hematologist, or a physician who specializes in transplantation. Radiation-expertise in acute radiation. SCN, AA - hematologist. HIV/AIDS neutropenia, infectious disease (ID) physician (MD), hematologist, or MD specializing in HIV/AIDS. |
| Coverage Duration | chemo/SCN/AML-6mo.HIV/AIDS-4mo.MDS-3mo.PBPC,Drug induce A/N,AA,ALL,BMT-3mo.Radi-1mo. Other-12mo. |
| Other Criteria | Cancer patients receiving chemotherapy, approve if the patient meets one of the following conditions: patient is receiving myelosuppressive anti-cancer medications that are associated with a high risk of febrile neutropenia (the risk is at least 20 percent based on the chemotherapy regimen), patient is receiving myelosuppressive anti-cancer medications that are associated with a risk of febrile neutropenia but the risk is less than 20 percent based on the chemotherapy regimen and the patient has one or more risk factors for febrile neutropenia (eg, aged greater than or equal to 65 years, prior chemotherapy or radiation therapy, persistent neutropenia, bone marrow involvement by tumor, recent surgery and/or open wounds, liver and/or renal dysfunction, poor performance status, or HIV infection), patient has had a neutropenic complication from prior chemotherapy and did not receive prophylaxis with a colony stimulating factor (eg, Leukine, filgrastim products, pegfilgrastim products) and a reduced dose or frequency of chemotherapy may compromise treatment, patient has received chemotherapy has febrile neutropenia and has at least one risk factor (eg, sepsis syndrome, aged greater than 65 years, severe neutropenia |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | [absolute neutrophil account less than 100 cells/mm ³], neutropenia expected to be greater than 10 days in duration, invasive fungal infection). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Neutropenia associated with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS). Treatment of myelodysplastic syndromes (MDS). Drug induced agranulocytosis or neutropenia. Aplastic anemia (AA). Acute lymphocytic leukemia (ALL). Radiation Syndrome (Hematopoietic Syndrome of Acute Radiation Syndrome). |
| Part B Prerequisite | No |

ZEJULA

Products Affected

- ZEJULA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Ovarian, fallopian tube, or primary peritoneal cancer, maintenance therapy - approve if the patient is in complete or partial response after platinum-based chemotherapy regimen and if the patient is in complete or partial response to first-line primary treatment or if the patient has recurrent disease and a BRCA mutation. Uterine leiomyosarcoma-approve if the patient has BRCA2 mutation and has tried one systemic regimen. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Uterine Leiomyosarcoma |
| Part B Prerequisite | No |

ZELBORAF

Products Affected

- ZELBORAF

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | BRAFV600 mutation status required. |
| Age Restrictions | All diagnoses (except CNS cancer)-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Melanoma, patient new to therapy must have BRAFV600 mutation for approval AND have unresectable, advanced or metastatic melanoma. HCL - must have tried at least one other systemic therapy for hairy cell leukemia OR is unable to tolerate purine analogs and Zelboraf will be used in combination with Gazyva (obinutuzumab intravenous infusion) as initial therapy. Thyroid Cancer-patient has disease that is refractory to radioactive iodine therapy. Erdheim-Chester disease, in patients with BRAF V600 mutation-approve. Central Nervous System Cancer-approve if the patient has BRAF V600 mutation-positive disease AND medication is being used for one of the following situations (i, ii, or iii): i. Adjuvant treatment of one of the following conditions (a, b, or c): a) Pilocytic astrocytoma OR b) Pleomorphic xanthoastrocytoma OR c) Ganglioglioma OR ii. Recurrent or progressive disease for one of the following conditions (a or b): a) glioma OR b) Glioblastoma OR iii. Melanoma with brain metastases AND the medication with be taken in combination with Cotellic (cobimetinib tablets). Histiocytic Neoplasm-approve if the patient has Langerhans cell histiocytosis and one of the following (i, ii, or iii): i. Multisystem disease OR ii. Pulmonary disease OR iii. Central nervous system lesions AND the patient has BRAF V600-mutation positive disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |

| PA Criteria | Criteria Details |
|----------------------------|---|
| Off-Label Uses | Patients with Hairy Cell Leukemia, Non-Small Cell Lung Cancer (NSCLC) with BRAF V600E Mutation, Differentiated thyroid carcinoma (i.e., papillary, follicular, or Hurthle cell) with BRAF-positive disease, Central Nervous System Cancer, Histiocytic Neoplasm |
| Part B Prerequisite | No |

ZEPOSIA

Products Affected

- ZEPOSIA
- ZEPOSIA STARTER KIT (28-DAY)
- ZEPOSIA STARTER PACK (7-DAY)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | MS-Concurrent use with other disease-modifying agents used for multiple sclerosis. UC- Concurrent Use with a Biologic or with a Targeted Synthetic Disease-modifying Antirheumatic Drug (DMARD) for Ulcerative Colitis |
| Required Medical Information | Diagnosis |
| Age Restrictions | UC-18 years and older |
| Prescriber Restrictions | MS-Prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis. UC-Prescribed by or in consultation with a gastroenterologist |
| Coverage Duration | 1 year |
| Other Criteria | MS-approve. Ulcerative Colitis, initial-approve if the patient has tried a preferred adalimumab product. Note-a trial of Simponi SC, a non-preferred adalimumab product or infliximab would also count). Cont tx-approve if the patient has been established on Zeposia. Please Note: preferred adalimumab products include Humira (NDCs starting with -00074), Cyltezo, Hyrimoz (NDCs starting with -61314), adalimumab-adaz, adalimumab-adbm. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ZIEXTENZO

Products Affected

- ZIEXTENZO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Cancer patients receiving chemotherapy, if prescribed by or in consultation with an oncologist or hematologist. PBPC-prescribed by or in consultation with an oncologist, hematologist, or physician that specializes in transplantation |
| Coverage Duration | Cancer pts receiving chemo-6 mo. PBPC-1 mo |
| Other Criteria | Cancer patients receiving chemotherapy, approve if-the patient is receiving myelosuppressive anti-cancer medications that are associated with a high risk of febrile neutropenia (the risk is at least 20 percent based on the chemotherapy regimen), OR the patient is receiving myelosuppressive anti-cancer medications that are associated with a risk of febrile neutropenia but the risk is less than 20 percent based on the chemotherapy regimen) and the patient has one or more risk factors for febrile neutropenia according to the prescribing physician (eg, aged greater than or equal to 65 years, prior chemotherapy or radiation therapy, persistent neutropenia, bone marrow involvement by tumor, recent surgery and/or open wounds, liver and/or renal dysfunction, poor performance status or HIV infection, OR the patient has had a neutropenic complication from prior chemotherapy and did not receive prophylaxis with a colony stimulating factor and a reduced dose or frequency of chemotherapy may compromise treatment. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients undergoing PBPC collection and therapy |
| Part B Prerequisite | No |

ZOLINZA

Products Affected

- ZOLINZA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Cutaneous T-Cell Lymphoma including Mycosis Fungoides/Sezary Syndrome-approve. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ZTALMY

Products Affected

- ZTALMY

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 2 years and older |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist |
| Coverage Duration | 1 year |
| Other Criteria | Seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder-approve if the patient has a molecularly confirmed pathogenic or likely pathogenic mutation in the CDKL5 gene and patient has tried or is concomitantly receiving two other antiepileptic drugs. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ZURZUVAE

Products Affected

- ZURZUVAE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Previous treatment with Zurzuvae during the current episode of postpartum depression |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | Prescribed by or in consultation with a psychiatrist or an obstetrician-gynecologist |
| Coverage Duration | 14 days |
| Other Criteria | Postpartum depression-approve if the patient meets the following (A, B and C): A.Patient meets BOTH of the following (i and ii): i. Patient has been diagnosed with severe depression, AND ii. Symptom onset began during the third trimester of pregnancy or up to 4 weeks post-delivery, AND B. Patient is less than or equal to 12 months postpartum, AND C. Patient is not currently pregnant. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ZYDELIG

Products Affected

- ZYDELIG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be 1 year |
| Other Criteria | CLL/SLL-approve if the patient has tried at least one systemic regimen. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | small lymphocytic lymphoma |
| Part B Prerequisite | No |

ZYKADIA

Products Affected

- ZYKADIA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Erdheim-Chester Disease-approve if the patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease. NSCLC, ALK positive-approve if the patient has advanced or metastatic disease that is ALK positive as detected by an approved test and for patients new to therapy must have a trial of Alecensa prior to approval of Zykadia. NSCLC, ROS1 Rearrangement-approve if the patient has advanced or metastatic disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Inflammatory Myofibroblastic Tumor (IMT) with ALK Translocation. Patients with NSCLC with ROS1 Rearrangement. Erdheim-Chester disease. |
| Part B Prerequisite | No |

ZYPREXA RELPREVV

Products Affected

- ZYPREXA RELPREVV

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Dementia-related psychosis |
| Required Medical Information | N/A |
| Age Restrictions | Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply. |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ZYTIGA

Products Affected

- *abiraterone*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | <p>Prostate Cancer-Metastatic, Castration-Resistant (mCRPC)-Approve if abiraterone is being used in combination with prednisone or dexamethasone and the medication is used concurrently used with a gonadotropin-releasing hormone (GnRH) agonist, or the medication is concurrently used with Firmagon or the patient has had a bilateral orchiectomy. Prostate cancer-metastatic, castration-sensitive (mCSPC)-approve if the medication is used in combination with prednisone and the medication is concurrently used with a gonadotropin-releasing hormone agonist or concurrently used with Firmagon or the patient has had a bilateral orchiectomy. Prostate Cancer - Regional Risk Group - Approve if the patient meets all of the following criteria (A, B, and C): A) abiraterone is used in combination with prednisone AND B) Patient has regional lymph node metastases and no distant metastases AND C) Patient meets one of the following criteria (i, ii or iii): i. abiraterone with prednisone is used in combination with gonadotropin-releasing hormone (GnRH) agonist OR ii. Patient has had a bilateral orchiectomy OR iii. the medication is used in combination with Firmagon. Prostate cancer-very-high-risk-group-approve if according to the prescriber the patient is in the very-high-risk group, the medication will be used in combination with prednisone, the medication will be used in combination with external beam radiation therapy and the patient meets one of the following criteria (i, ii or iii): i. abiraterone is used in combination with gonadotropin-releasing hormone (GnRH) agonist OR</p> |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | ii. Patient has had a bilateral orchiectomy OR iii. the medication is used in combination with Firmagon. Prostate cancer-radical prostatectomy-approve if the medication is used in combination with prednisone, the patient has prostate specific antigen (PSA) persistence or recurrence following radical prostatectomy, patient has pelvic recurrence, the medication will be used concurrently with GnRH agonist, Firmagon or the patient has had a bilateral orchiectomy. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Prostate Cancer-Regional Risk Group, Prostate cancer-very-high-risk group, Prostate cancer-radical prostatectomy |
| Part B Prerequisite | No |

PART B VERSUS PART D

Products Affected

- *acetylcysteine*
- *acyclovir sodium intravenous solution*
- ADRIAMYCIN INTRAVENOUS RECON SOLN 50 MG
- *albuterol sulfate inhalation solution for nebulization*
- *amiodarone intravenous solution*
- *aprepitant*
- *arformoterol*
- *arsenic trioxide*
- ASCENIV
- ASTAGRAF XL
- ATGAM
- *azacitidine*
- AZASAN
- *azathioprine*
- *azathioprine sodium*
- BELEODAQ
- *bendamustine*
- BENDEKA
- BIVIGAM
- *bleomycin*
- BLINCYTO INTRAVENOUS KIT
- BROVANA
- *budesonide inhalation*
- *busulfan*
- *carboplatin intravenous solution*
- *carmustine intravenous recon soln 100 mg*
- CELLCEPT
- *cisplatin intravenous solution*
- *cladribine*
- CLINIMIX 5%/D15W SULFITE FREE
- CLINIMIX 4.25%/D10W SULF FREE
- CLINIMIX 4.25%/D5W SULFIT FREE
- CLINIMIX 5%-D20W(SULFITE-FREE)
- CLINIMIX 6%-D5W (SULFITE-FREE)
- CLINIMIX 8%-D10W(SULFITE-FREE)
- CLINIMIX 8%-D14W(SULFITE-FREE)
- CLINIMIX E 4.25%/D10W SUL FREE
- CLINISOL SF 15 %
- *clofarabine*
- COSMEGEN
- *cromolyn inhalation*
- *cyclophosphamide intravenous recon soln*
- CYCLOPHOSPHAMIDE INTRAVENOUS SOLUTION 200 MG/ML
- *cyclophosphamide intravenous solution 500 mg/ml*
- *cyclophosphamide oral*
- *cyclosporine intravenous*
- *cyclosporine modified*
- *cyclosporine oral capsule*
- *cytarabine*
- *cytarabine (pf)*
- *dacarbazine*
- *dactinomycin*
- *daunorubicin*
- *decitabine*
- *docetaxel*
- *doxorubicin intravenous recon soln 50 mg*
- *doxorubicin intravenous solution*
- *doxorubicin, peg-liposomal*
- *dronabinol*
- EMEND ORAL SUSPENSION FOR RECONSTITUTION
- ENGERIX-B (PF)
- ENGERIX-B PEDIATRIC (PF)
- ENVARSUS XR
- *epirubicin intravenous solution*
- ERBITUX
- ETOPOPHOS
- *etoposide intravenous*
- *everolimus (immunosuppressive)*
- FIRMAGON KIT W DILUENT SYRINGE
- FLEBOGAMMA DIF
- *floxuridine*
- *fludarabine*
- *fluorouracil intravenous*
- FOLOTYN
- *formoterol fumarate*
- *fulvestrant*
- GAMMAGARD LIQUID
- GAMMAGARD S-D (IGA < 1 MCG/ML)
- GAMMAKED

- GAMMAPLEX (WITH SORBITOL)
- GAMMAPLEX INTRAVENOUS SOLUTION 10 %
- GAMUNEX-C
- *gemcitabine intravenous recon soln*
- *gemcitabine intravenous solution 1 gram/26.3 ml (38 mg/ml), 2 gram/52.6 ml (38 mg/ml), 200 mg/5.26 ml (38 mg/ml)*
- GEMCITABINE INTRAVENOUS SOLUTION 100 MG/ML
- *gengraf*
- *granisetron hcl oral*
- HEPLISAV-B (PF)
- *hizentra subcutaneous solution 1 gram/5 ml (20 %)*
- HIZENTRA SUBCUTANEOUS SOLUTION 10 GRAM/50 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %)
- HIZENTRA SUBCUTANEOUS SYRINGE
- *idarubicin*
- *ifosfamide*
- INFUGEM
- INFUMORPH P/F
- INTRALIPID INTRAVENOUS EMULSION 20 %, 30 %
- *ipratropium bromide inhalation*
- *ipratropium-albuterol*
- *irinotecan*
- IXEMPRA
- JEVTANA
- KABIVEN
- *kemoplat*
- KYPROLIS
- *levalbuterol hcl*
- MEDROL ORAL TABLET 2 MG
- *melphalan*
- *melphalan hcl*
- *mesna*
- *methotrexate sodium (pf)*
- *methotrexate sodium injection*
- *methylprednisolone oral tablet*
- *mitomycin intravenous*
- *mitoxantrone*
- *mycophenolate mofetil*
- *mycophenolate mofetil (hcl)*
- *mycophenolate sodium*
- MYFORTIC
- *nelarabine*
- NEORAL
- NIPENT
- *nitroglycerin intravenous*
- NULOJIX
- NUTRILIPID
- OCTAGAM
- ONCASPAR
- *ondansetron*
- *ondansetron hcl oral solution*
- *ondansetron hcl oral tablet 4 mg, 8 mg*
- *oxaliplatin*
- *paclitaxel*
- PANZYGA
- *pentamidine inhalation*
- PERFOROMIST
- PERIKABIVEN
- *plenamine*
- *plerixafor*
- PORTRAZZA
- PRALATREXATE
- *prednisolone sodium phosphate oral tablet, disintegrating*
- PREHEVBRIO (PF)
- PREMASOL 10 %
- PRIVIGEN
- PROGRAF
- PROSOL 20 %
- PULMICORT
- PULMOZYME
- RAPAMUNE
- RECOMBIVAX HB (PF)
- RYLAZE
- SANDIMMUNE ORAL SOLUTION
- SIMULECT
- *sirolimus*
- *tacrolimus oral*
- TEMODAR INTRAVENOUS
- *temsirolimus*
- TICE BCG
- *tobramycin in 0.225 % nacl*
- *topotecan*
- TPN ELECTROLYTES

- TRAVASOL 10 %
- TREANDA
- TROPHAMINE 10 %
- TYVASO
- TYVASO INSTITUTIONAL START KIT
- TYVASO REFILL KIT
- TYVASO STARTER KIT
- *valrubicin*
- *vinblastine*
- *vincristine*
- *vinorelbine*
- VYXEOS
- YUPELRI
- ZALTRAP
- ZANOSAR
- ZOLADEX
- *zoledronic acid intravenous solution*
- *zoledronic acid-mannitol-water*
- *zoledronic ac-mannitol-0.9nacl*
- ZORTRESS ORAL TABLET 1 MG

Details

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

Index

A

ABELCET..... 17
abiraterone..... 353, 354
ABRAXANE 18, 19
ABRYSVO 1
acetylcysteine..... 355
ACTHAR 2
ACTIMMUNE..... 3
acyclovir sodium intravenous solution ... 355
ADALIMUMAB-ADAZ 125, 126
ADALIMUMAB-ADB1 125, 126
ADALIMUMAB-ADB1(CF) PEN
CROHNS 125, 126
ADALIMUMAB-ADB1(CF) PEN PS-UV
..... 125, 126
ADCETRIS 18, 19
ADEMPAS 4
ADRIAMYCIN INTRAVENOUS RECON
SOLN 50 MG..... 355
adstiladrin..... 18, 19
AFINITOR 86, 87
AFINITOR DISPERZ..... 86, 87
AIMOVIG AUTOINJECTOR..... 5
AJOVY AUTOINJECTOR 6
AJOVY SYRINGE..... 6
AKEEGA 7
albuterol sulfate inhalation solution for
nebulization..... 355
ALDURAZYME..... 8
ALECENSA..... 9
ALIQOPA 18, 19
alosetron 10
ALUNBRIG 12
alyq..... 215
ambrisentan 13
amikacin injection solution 1,000 mg/4 ml,
500 mg/2 ml 14, 15
amiodarone intravenous solution 355
amphotericin b 17
amphotericin b liposome..... 17
ampicillin sodium..... 14, 15
ampicillin-sulbactam..... 14, 15
aprepitant..... 355
ARALAST NP 11

ARANESP (IN POLYSORBATE)
INJECTION SOLUTION 100 MCG/ML,
200 MCG/ML, 25 MCG/ML, 40
MCG/ML, 60 MCG/ML 20
ARANESP (IN POLYSORBATE)
INJECTION SYRINGE..... 20
ARCALYST 21
AREXVY (PF)..... 22
arformoterol 355
ARIKAYCE..... 23, 24
armodafinil 25
arsenic trioxide..... 355
ASCENIV 355
ascomp with codeine..... 120
ASTAGRAF XL 355
ATGAM..... 355
AUBAGIO 27
AUGTYRO 28
AUSTEDO..... 29
AUSTEDO XR 29
AUSTEDO XR TITRATION KT(WK1-4)
..... 29
AVONEX..... 30
AVSOLA 139, 140
AYVAKIT 31
azacitidine 355
AZASAN 355
azathioprine..... 355
azathioprine sodium 355
azithromycin intravenous..... 14, 15
aztreonam 14, 15
B
BALVERSA 32
BAVENCIO 18, 19
BELEODAQ..... 355
bendamustine 355
BENDEKA 355
BENLYSTA..... 33, 34
benztropine oral 114
BESPONSA 18, 19
BESREMI 35
BETASERON SUBCUTANEOUS KIT .. 36
bexarotene 37, 275
BICILLIN L-A..... 14, 15

BIVIGAM..... 355
 BLENREP..... 18, 19
 bleomycin..... 355
 BLINCYTO INTRAVENOUS KIT 355
 BORTEZOMIB INJECTION RECON
 SOLN 1 MG, 2.5 MG 18, 19
 bortezomib injection recon soln 3.5 mg... 18,
 19
 BORTEZOMIB INTRAVENOUS RECON
 SOLN 18, 19
 bosentan 38
 BOSULIF..... 39
 BOTOX..... 40, 41
 BRAFTOVI..... 42
 BRIUMVI 43
 BROVANA..... 355
 BRUKINSA 44
 budesonide inhalation 355
 busulfan..... 355
 butalbital-acetaminop-caf-cod 120
 butalbital-acetaminophen oral tablet..... 120
 butalbital-acetaminophen-caff 120
 butalbital-aspirin-caffeine oral capsule... 120
 BYDUREON BCISE 106
 BYETTA..... 106
C
 CABOMETYX 45
 CALQUENCE 46
 CALQUENCE (ACALABRUTINIB MAL)
 46
 CAPRELSA 47
 CARBAGLU..... 48
 carboplatin intravenous solution 355
 carglumic acid..... 48
 carisoprodol..... 115
 carmustine intravenous recon soln 100 mg
 355
 caspofungin 16
 CAYSTON..... 49
 CEFEPIME INTRAVENOUS..... 14, 15
 cefoxitin 14, 15
 cefoxitin in dextrose, iso-osm 14, 15
 ceftazidime 14, 15
 cefuroxime sodium injection recon soln 750
 mg 14, 15
 cefuroxime sodium intravenous 14, 15

CELLCEPT..... 355
 CEREZYME INTRAVENOUS RECON
 SOLN 400 UNIT..... 50
 CHEMET 51
 chlorzoxazone oral tablet 500 mg..... 123
 CHORIONIC GONADOTROPIN,
 HUMAN INTRAMUSCULAR 52
 CIALIS ORAL TABLET 2.5 MG, 5 MG. 53
 CIMZIA 54
 CIMZIA POWDER FOR RECONST 54
 CIMZIA STARTER KIT 54
 ciprofloxacin in 5 % dextrose 14, 15
 cisplatin intravenous solution 355
 cladribine..... 355
 CLINDAMYCIN IN 0.9 % SOD CHLOR
 14, 15
 clindamycin in 5 % dextrose..... 14, 15
 clindamycin phosphate injection..... 14, 15
 CLINIMIX 5%/D15W SULFITE FREE 355
 CLINIMIX 4.25%/D10W SULF FREE . 355
 CLINIMIX 4.25%/D5W SULFIT FREE 355
 CLINIMIX 5%-D20W(SULFITE-FREE)
 355
 CLINIMIX 6%-D5W (SULFITE-FREE) 355
 CLINIMIX 8%-D10W(SULFITE-FREE)
 355
 CLINIMIX 8%-D14W(SULFITE-FREE)
 355
 CLINIMIX E 4.25%/D10W SUL FREE 355
 CLINISOL SF 15 %..... 355
 clobazam 55
 clofarabine..... 355
 clomiphene citrate 56
 colistin (colistimethate na)..... 14, 15
 COLUMVI..... 18, 19
 COMETRIQ..... 57
 COPAXONE SUBCUTANEOUS
 SYRINGE 58
 COPIKTRA..... 59
 CORLANOR ORAL TABLET 60
 COSMEGEN..... 355
 COTELLIC 61
 CRINONE VAGINAL GEL 8 % 62
 cromolyn inhalation 355
 CUVRIOR..... 292, 293
 cyclobenzaprine oral tablet 116, 123

cyclophosphamide intravenous recon soln
 355
 CYCLOPHOSPHAMIDE INTRAVENOUS
 SOLUTION 200 MG/ML 355
 cyclophosphamide intravenous solution 500
 mg/ml 355
 cyclophosphamide oral 355
 cyclosporine intravenous 355
 cyclosporine modified 355
 cyclosporine oral capsule 355
 CYLTEZO(CF) 125, 126
 CYLTEZO(CF) PEN 125, 126
 CYLTEZO(CF) PEN CROHN'S-UC-HS
 125, 126
 CYLTEZO(CF) PEN PSORIASIS-UV . 125,
 126
 CYRAMZA 18, 19
 CYSTARAN 63
 cytarabine 355
 cytarabine (pf) 355
D
 dacarbazine 355
 dactinomycin 355
 dalfampridine 64
 DANYELZA 18, 19
 DARZALEX 18, 19
 DARZALEX FASPRO 18, 19
 daunorubicin 355
 DAURISMO 65
 decitabine 355
 deferiprone 66
 diclofenac sodium topical solution in
 metered-dose pump 68
 dimethyl fumarate 69
 docetaxel 355
 DOPTELET (10 TAB PACK) 70
 DOPTELET (15 TAB PACK) 70
 DOPTELET (30 TAB PACK) 70
 doxorubicin intravenous recon soln 50 mg
 355
 doxorubicin intravenous solution 355
 doxorubicin, peg-liposomal 355
 doxy-100 14, 15
 doxycycline hyclate intravenous 14, 15
 dronabinol 355
 droxidopa 71

DUAVEE 72
 DUPIXENT PEN 73, 74
 DUPIXENT SYRINGE 73, 74
E
 ELAPRASE 75
 ELIDEL 287
 ELIGARD 107, 108
 ELIGARD (3 MONTH) 107, 108
 ELIGARD (4 MONTH) 107, 108
 ELIGARD (6 MONTH) 107, 108
 ELREXFIO 18, 19
 ELZONRIS 18, 19
 EMEND ORAL SUSPENSION FOR
 RECONSTITUTION 355
 EMLICITI 18, 19
 ENBREL MINI 76, 77
 ENBREL SUBCUTANEOUS SOLUTION
 76, 77
 ENBREL SUBCUTANEOUS SYRINGE 76,
 77
 ENBREL SURECLICK 76, 77
 ENDARI 78
 ENGERIX-B (PF) 355
 ENGERIX-B PEDIATRIC (PF) 355
 ENHERTU 18, 19
 ENVARUS XR 355
 EPCLUSA 79
 EPIDIOLEX 80
 epirubicin intravenous solution 355
 EPKINLY 18, 19
 EPRONTIA 289
 ERBITUX 355
 ergoloid 119
 ERIVEDGE 83
 ERLEADA 84
 erlotinib 85
 ERYTHROCIN INTRAVENOUS RECON
 SOLN 500 MG 14, 15
 ETOPOPHOS 355
 etoposide intravenous 355
 everolimus (antineoplastic) 86, 87
 everolimus (immunosuppressive) 355
 EVOMELA 18, 19
 EXKIVITY 88
 EXTAVIA 89
 EYLEA 90

F

| | |
|---|--------|
| FANAPT | 26 |
| FARYDAK | 91 |
| FASENRA | 92, 93 |
| FASENRA PEN..... | 92, 93 |
| fentanyl citrate buccal lozenge on a handle | 290 |
| FERRIPROX..... | 66 |
| FERRIPROX (2 TIMES A DAY) | 66 |
| fingolimod..... | 94 |
| FINTEPLA..... | 95 |
| FIRDAPSE..... | 96 |
| FIRMAGON KIT W DILUENT SYRINGE | 355 |
| FLEBOGAMMA DIF..... | 355 |
| floxuridine..... | 355 |
| fluconazole in nacl (iso-osm)..... | 16 |
| fludarabine | 355 |
| fluorouracil intravenous | 355 |
| FOLOTYN..... | 355 |
| formoterol fumarate | 355 |
| FORTEO | 97, 98 |
| FOTIVDA..... | 99 |
| FRUZAQLA | 100 |
| fulvestrant | 355 |
| FYARRO | 18, 19 |
| G | |
| GAMMAGARD LIQUID..... | 355 |
| GAMMAGARD S-D (IGA < 1 MCG/ML) | 355 |
| GAMMAKED..... | 355 |
| GAMMAPLEX (WITH SORBITOL) | 356 |
| GAMMAPLEX INTRAVENOUS SOLUTION 10 % | 356 |
| GAMUNEX-C | 356 |
| GATTEX 30-VIAL..... | 101 |
| GATTEX ONE-VIAL | 101 |
| GAVRETO | 102 |
| GAZYVA..... | 18, 19 |
| gefitinib..... | 146 |
| gemcitabine intravenous recon soln..... | 356 |
| gemcitabine intravenous solution 1 gram/26.3 ml (38 mg/ml), 2 gram/52.6 ml (38 mg/ml), 200 mg/5.26 ml (38 mg/ml) | 356 |

GEMCITABINE INTRAVENOUS

| | |
|---|-----------|
| SOLUTION 100 MG/ML..... | 356 |
| gengraf | 356 |
| GENOTROPIN..... | 109, 110 |
| GENOTROPIN MINIQUICK | 109, 110 |
| gentamicin in nacl (iso-osm) intravenous piggyback 100 mg/100 ml, 60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml..... | 14, 15 |
| GENTAMICIN IN NAACL (ISO-OSM) INTRAVENOUS PIGGYBACK 100 MG/50 ML, 120 MG/100 ML | 14, 15 |
| gentamicin injection solution 40 mg/ml .. | 14, 15 |
| gentamicin sulfate (ped) (pf)..... | 14, 15 |
| GILENYA..... | 103 |
| GILOTRIF | 104 |
| GLASSIA..... | 11 |
| glatiramer | 105 |
| glatopa..... | 105 |
| glyburide | 121 |
| glyburide micronized | 121 |
| glyburide-metformin | 122 |
| granisetron hcl oral | 356 |
| H | |
| HAEGARDA | 111 |
| HALAVEN | 18, 19 |
| HARVONI | 112 |
| HEPLISAV-B (PF)..... | 356 |
| HETLIOZ..... | 113 |
| hizentra subcutaneous solution 1 gram/5 ml (20 %)...... | 356 |
| HIZENTRA SUBCUTANEOUS SOLUTION 10 GRAM/50 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %)...... | 356 |
| HIZENTRA SUBCUTANEOUS SYRINGE | 356 |
| HUMIRA PEN..... | 125, 126 |
| HUMIRA PEN CROHNS-UC-HS START | 125, 126 |
| HUMIRA PEN PSOR-UEVITS-ADOL HS | 125, 126 |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML | 125, 126 |
| HUMIRA(CF)..... | 125, 126 |

HUMIRA(CF) PEDI CROHNS STARTER
 125, 126
 HUMIRA(CF) PEN 125, 126
 HUMIRA(CF) PEN CROHNS-UC-HS. 125,
 126
 HUMIRA(CF) PEN PEDIATRIC UC... 125,
 126
 HUMIRA(CF) PEN PSOR-UV-ADOL HS
 125, 126
 HYRIMOZ PEN CROHN'S-UC STARTER
 125, 126
 HYRIMOZ PEN PSORIASIS STARTER
 125, 126
 HYRIMOZ(CF) 125, 126
 HYRIMOZ(CF) PEDI CROHN STARTER
 125, 126
 HYRIMOZ(CF) PEN..... 125, 126

I
 IBRANCE..... 127, 128
 icatibant..... 129
 ICLUSIG..... 130
 idarubicin 356
 IDHIFA 131
 ifosfamide 356
 imatinib 132, 133
 IMBRUVICA ORAL CAPSULE... 134, 135
 IMBRUVICA ORAL SUSPENSION... 134,
 135
 IMBRUVICA ORAL TABLET 140 MG,
 280 MG, 420 MG..... 134, 135
 IMFINZI 18, 19
 IMJUDO 18, 19
 INCRELEX..... 136
 INFLECTRA..... 137, 138
 INFUGEM 356
 INFUMORPH P/F 356
 INGREZZA..... 141
 INGREZZA INITIATION PACK 141
 INLYTA..... 142
 INQOVI 143
 INREBIC..... 144
 INTRALIPID INTRAVENOUS
 EMULSION 20 %, 30 % 356
 INTRAROSA..... 145
 ipratropium bromide inhalation 356
 ipratropium-albuterol 356

irinotecan..... 356
 ivermectin oral 147
 IWILFIN 148
 IXEMPRA..... 356

J
 JAKAFI..... 149, 150
 javygtor 244
 JAYPIRCA 151, 152
 JEMPERLI..... 18, 19
 JEVTANA..... 356

K
 KABIVEN..... 356
 KADCYLA 18, 19
 KALYDECO..... 153
 kemoplat..... 356
 KERENDIA 154
 KESIMPTA PEN 155
 KEYTRUDA..... 18, 19
 KIMMTRAK 18, 19
 KISQALI..... 156, 157
 KISQALI FEMARA CO-PACK 156, 157
 KORLYM 158
 KOSELUGO 159, 160
 KRAZATI..... 161
 KYPROLIS..... 356

L
 lapatinib..... 162, 163
 lenalidomide..... 164, 165
 LENVIMA 166, 167
 LEUPROLIDE (3 MONTH)..... 107, 108
 leuprolide subcutaneous kit..... 107, 108
 levalbuterol hcl..... 356
 levofloxacin in d5w..... 14, 15
 levofloxacin intravenous..... 14, 15
 LIBTAYO 18, 19
 lincomycin..... 14, 15
 linezolid in dextrose 5%..... 14, 15
 linezolid-0.9% sodium chloride 14, 15
 LONSURF 168
 LOQTORZI..... 169
 LORBRENA 170
 LUMAKRAS 171
 LUMIZYME 172
 LUNSUMIO 18, 19
 LUPRON DEPOT..... 107, 108
 LUPRON DEPOT (3 MONTH) 107, 108

LUPRON DEPOT (4 MONTH) 107, 108
 LUPRON DEPOT (6 MONTH) 107, 108
 LUPRON DEPOT-PED 107, 108
 LUPRON DEPOT-PED (3 MONTH) ... 107, 108
 LYBALVI 26
 LYNPARZA 173, 174
 LYTGABI 175
M
 MARGENZA 18, 19
 MAVYRET 176
 MEDROL ORAL TABLET 2 MG 356
 megestrol oral suspension 400 mg/10 ml (10 ml), 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml), 800 mg/20 ml (20 ml) 177
 megestrol oral tablet 177
 MEKINIST 178, 179
 MEKTOVI 180
 melphalan 356
 melphalan hcl 356
 memantine 188
 mesna 356
 metaxalone 123
 methocarbamol oral tablet 500 mg, 750 mg 123
 methotrexate sodium (pf) 356
 methotrexate sodium injection 356
 methylprednisolone oral tablet 356
 metro i.v. 14, 15
 metronidazole in nacl (iso-os) 14, 15
 metyrosine 214
 mifepristone oral tablet 300 mg 158
 mitomycin intravenous 356
 mitoxantrone 356
 modafinil 181
 MONJUVI 18, 19
 MOUNJARO 106
 MOXIFLOXACIN-SOD.ACE,SUL-WATER 14, 15
 moxifloxacin-sod.chloride(iso) 14, 15
 mycophenolate mofetil 356
 mycophenolate mofetil (hcl) 356
 mycophenolate sodium 356
 MYFORTIC 356
 MYLOTARG 18, 19

N
 nafcillin in dextrose iso-osm 14, 15
 nafcillin injection 14, 15
 nafcillin intravenous recon soln 2 gram... 14, 15
 NAGLAZYME 182
 NAMENDA TITRATION PAK 188
 NAMENDA XR ORAL CAPSULE,SPRINKLE,ER 24HR 188
 NAMZARIC 188
 NAYZILAM 183
 nelarabine 356
 NEORAL 356
 NERLYNX 184
 NEXAVAR 254, 255
 NEXLETOL 185
 NEXLIZET 186
 NINLARO 187
 NIPENT 356
 nitroglycerin intravenous 356
 NORTHERA 71
 NOVAREL INTRAMUSCULAR RECON SOLN 5,000 UNIT 52
 NUBEQA 189
 NUCALA SUBCUTANEOUS AUTO-INJECTOR 190, 191
 NUCALA SUBCUTANEOUS SYRINGE 190, 191
 NUEDEXTA 192
 NULOJIX 356
 NUPLAZID 193
 NURTEC ODT 194
 NUTRILIPID 356
 NUZYRA INTRAVENOUS 14, 15
O
 OCALIVA 195
 OCREVUS 196
 OCTAGAM 356
 octreotide acetate 197
 ODOMZO 198
 OFEV 199
 OJJAARA 200
 ONCASPAR 356
 ondansetron 356
 ondansetron hcl oral solution 356
 ondansetron hcl oral tablet 4 mg, 8 mg... 356

ONIVYDE 18, 19
 ONUREG 201
 OPDIVO 18, 19
 OPDUALAG 18, 19
 OPSUMIT 202
 ORBACTIV 14, 15
 ORENCIA 203
 ORENCIA CLICKJECT 203
 orenitram 204
 ORENITRAM MONTH 1 TITRATION KT
 204
 ORENITRAM MONTH 2 TITRATION KT
 204
 ORENITRAM MONTH 3 TITRATION KT
 204
 ORGOVYX 205
 ORKAMBI 206
 orlistat 328
 orphenadrine citrate oral 123
 ORSERDU 207
 OSPHENA 208
 OTEZLA 209
 OTEZLA STARTER ORAL
 TABLETS,DOSE PACK 10 MG (4)-20
 MG (4)-30 MG (47) 209
 oxacillin injection 14, 15
 oxaliplatin 356
 OXERVATE 210
 OZEMPIC SUBCUTANEOUS PEN
 INJECTOR 0.25 MG OR 0.5 MG (2
 MG/3 ML), 1 MG/DOSE (4 MG/3 ML),
 2 MG/DOSE (8 MG/3 ML) 106

P

paclitaxel 356
 PACLITAXEL PROTEIN-BOUND .. 18, 19
 PADCEV 18, 19
 paliperidone 26
 PANZYGA 356
 pazopanib 318, 319
 PEGASYS 211
 PEMAZYRE 212
 pemetrexed disodium intravenous recon soln
 18, 19
 penicillin g potassium 14, 15
 pentamidine inhalation 356
 PERFOROMIST 356

PERIKABIVEN 356
 PERJETA 18, 19
 pfizerpen-g 14, 15
 phenobarbital 118
 PHESGO 18, 19
 pimecrolimus 287
 PIQRAY 216
 pirfenidone oral tablet 217
 plenamine 356
 plerixafor 356
 POLIVY 18, 19
 polymyxin b sulfate 14, 15
 POMALYST 218
 PORTRAZZA 356
 POTELIGEO 18, 19
 PRALATREXATE 356
 prednisolone sodium phosphate oral
 tablet,disintegrating 356
 PREGNYL 52
 PREHEVBRIO (PF) 356
 PREMASOL 10 % 356
 PRIVIGEN 356
 PROCRIT 81, 82
 PROGRAF 356
 PROLASTIN-C 11
 PROMACTA 219, 220
 promethazine oral 117
 PROSOL 20 % 356
 PROVIGIL 181
 PULMICORT 356
 PULMOZYME 356
 pyrimethamine 221
 PYRUKYND 222

Q

QINLOCK 223
 QUILLICHEW ER 224
 quinine sulfate 225

R

RADICAVA 226
 RAPAMUNE 356
 REBIF (WITH ALBUMIN) 227
 REBIF REBIDOSE 227
 REBIF TITRATION PACK 227
 RECOMBIVAX HB (PF) 356
 REGRANEX 67
 REMICADE 228, 229

RENFLEXIS 139, 140
 REPATHA PUSHTRONEX..... 230, 231
 REPATHA SURECLICK..... 230, 231
 REPATHA SYRINGE..... 230, 231
 RETACRIT..... 81, 82
 RETEVMO 232
 REVLIMID..... 233, 234
 REZLIDHIA 235
 REZUROCK..... 236
 RINVOQ..... 237
 romidepsin intravenous recon soln 238
 ROMIDEPSIN INTRAVENOUS
 SOLUTION..... 238
 ROZLYTREK..... 239
 RUBRACA 240, 241
 RUXIENCE 18, 19
 RYBELSUS 106
 RYBREVANT 18, 19
 RYDAPT..... 242
 RYLAZE..... 356
S
 sajazir 129
 SAMSCA ORAL TABLET 15 MG 286
 SANDIMMUNE ORAL SOLUTION ... 356
 SANDOSTATIN LAR DEPOT
 INTRAMUSCULAR
 SUSPENSION,EXTENDED REL
 RECON..... 243
 sapropterin..... 244
 SARCLISA 18, 19
 SCEMBLIX 245
 SIGNIFOR 246
 sildenafil (pulm.hypertension) oral tablet 215
 SIMPONI 247
 SIMPONI ARIA 247
 SIMULECT..... 356
 sirolimus..... 356
 SIRTURO 248
 SIVEXTRO INTRAVENOUS 14, 15
 SKYRIZI INTRAVENOUS 249, 250
 SKYRIZI SUBCUTANEOUS PEN
 INJECTOR..... 249, 250
 SKYRIZI SUBCUTANEOUS SYRINGE
 150 MG/ML 249, 250
 SKYRIZI SUBCUTANEOUS WEARABLE
 INJECTOR..... 249, 250

SODIUM OXYBATE..... 339
 sodium phenylbutyrate..... 213
 SOMATULINE DEPOT..... 251, 252
 SOMAVERT..... 253
 sorafenib..... 254, 255
 SPRAVATO NASAL SPRAY, NON-
 AEROSOL 56 MG (28 MG X 2), 84 MG
 (28 MG X 3)..... 256, 257
 SPRYCEL..... 258
 STELARA SUBCUTANEOUS..... 259
 STIVARGA 260
 STREPTOMYCIN..... 14, 15
 SUCRAID 261
 sulfamethoxazole-trimethoprim intravenous
 14, 15
 sunitinib malate..... 262, 263
 SUTENT 262, 263
 SYMDEKO..... 264
 SYMLINPEN 120..... 265
 SYMLINPEN 60..... 265
 SYMPAZAN..... 55
 SYNAGIS 266
T
 TABRECTA 267
 tacrolimus oral 356
 tacrolimus topical..... 287
 tadalafil (pulm. hypertension)..... 215
 tadalafil oral tablet 2.5 mg, 5 mg 53
 TADLIQ..... 215
 TAFINLAR..... 269, 270
 TAGRISSO 271
 TALTZ AUTOINJECTOR..... 272, 273
 TALTZ SYRINGE..... 272, 273
 TALVEY..... 18, 19
 TALZENNA 274
 TARGRETIN TOPICAL 275
 TASIGNA 276, 277
 tasimelteon 113
 tazicef..... 14, 15
 TAZVERIK..... 278
 TECENTRIQ 18, 19
 TECVAYLI..... 18, 19
 TEFLARO..... 14, 15
 TEMODAR INTRAVENOUS 356
 temsirolimus..... 356
 tencon 120

| | | | |
|---|----------|--|----------|
| TEPMETKO | 279 | TYVASO | 357 |
| teriflunomide..... | 27 | TYVASO INSTITUTIONAL START KIT | 357 |
| teriparatide subcutaneous pen injector 20 mcg/dose (600mcg/2.4ml) | 280, 281 | TYVASO REFILL KIT | 357 |
| TERIPARATIDE SUBCUTANEOUS PEN INJECTOR 20 MCG/DOSE (620MCG/2.48ML)..... | 280, 281 | TYVASO STARTER KIT..... | 357 |
| tetrabenazine | 282 | TZIELD..... | 301, 302 |
| THALOMID | 283, 284 | U | |
| thiotepa..... | 18, 19 | UNITUXIN..... | 18, 19 |
| TIBSOVO | 285 | UPTRAVI ORAL | 303 |
| TICE BCG | 356 | V | |
| tigecycline..... | 14, 15 | VALCHLOR..... | 304 |
| TIVDAK | 18, 19 | valrubicin | 357 |
| tobramycin in 0.225 % nacl | 356 | VALTOCO | 305 |
| tobramycin sulfate..... | 14, 15 | vancomycin oral capsule..... | 306 |
| tolvaptan..... | 286 | VANFLYTA..... | 307 |
| TOPAMAX..... | 289 | VECTIBIX..... | 18, 19 |
| topiramate oral capsule, sprinkle | 289 | VENCLEXTA..... | 308 |
| topiramate oral capsule,extended release 24hr | 289 | VENCLEXTA STARTING PACK | 308 |
| topiramate oral tablet | 289 | VENTAVIS..... | 309 |
| topotecan | 356 | VERQUVO..... | 310 |
| TPN ELECTROLYTES..... | 356 | VERZENIO..... | 311, 312 |
| TRAVASOL 10 % | 357 | VIBERZI..... | 313 |
| TRAZIMERA | 18, 19 | VICTOZA 2-PAK..... | 106 |
| TREANDA | 357 | VICTOZA 3-PAK..... | 106 |
| TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION | 291 | vinblastine..... | 357 |
| tretinoin | 288 | vincristine..... | 357 |
| tretinoin microspheres..... | 288 | vinorelbine | 357 |
| trientine oral capsule 250 mg..... | 292, 293 | VITRAKVI..... | 314 |
| trihexyphenidyl | 124 | VIZIMPRO | 315 |
| TRIKAFTA..... | 294 | VONJO | 316 |
| TRIPTODUR | 107, 108 | voriconazole intravenous | 16 |
| TRODELVY | 18, 19 | VOSEVI..... | 317 |
| TROKENDI XR..... | 289 | VOTRIENT..... | 318, 319 |
| TROPHAMINE 10 % | 357 | VUMERITY | 320 |
| TRULICITY | 106 | VYNDAMAX..... | 268 |
| TRUQAP..... | 295 | VYNDAQEL | 268 |
| TUKYSA | 296 | VYXEOS | 357 |
| TURALIO ORAL CAPSULE 125 MG.. | 297 | W | |
| TYKERB..... | 162, 163 | WEGOVY..... | 106 |
| TYMLOS | 298 | WELIREG..... | 321 |
| TYTABRI | 299, 300 | X | |
| | | XALKORI..... | 322, 323 |
| | | XATMEP | 324 |
| | | XCOPRI..... | 325 |
| | | XCOPRI MAINTENANCE PACK ORAL TABLET 250MG/DAY(150 MG X1- | |

| | |
|---|----------|
| 100MG X1), 350 MG/DAY (200 MG X1-150MG X1)..... | 325 |
| XCOPRI TITRATION PACK..... | 325 |
| XDEMVIY..... | 326 |
| XELJANZ..... | 327 |
| XELJANZ XR..... | 327 |
| XENICAL..... | 328 |
| XERMELO..... | 329 |
| XGEVA..... | 330 |
| XIAFLEX..... | 331 |
| XIFAXAN..... | 332 |
| XOLAIR..... | 333, 334 |
| XOSPATA..... | 335 |
| XPROVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (40 MG X 1), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80MG TWICE WEEK (160 MG/WEEK)..... | 336, 337 |
| XTANDI..... | 338 |
| Y | |
| YERVOY..... | 18, 19 |
| YONDELIS..... | 18, 19 |
| YUPELRI..... | 357 |
| Z | |
| ZALTRAP..... | 357 |

| | |
|---|----------|
| ZANOSAR..... | 357 |
| ZARXIO..... | 340, 341 |
| ZEJULA..... | 342 |
| ZELBORAF..... | 343, 344 |
| ZEMAIRA..... | 11 |
| ZEPOSIA..... | 345 |
| ZEPOSIA STARTER KIT (28-DAY).... | 345 |
| ZEPOSIA STARTER PACK (7-DAY).. | 345 |
| ZEPZELCA..... | 18, 19 |
| ZIEXTENZO..... | 346 |
| ZIRABEV..... | 18, 19 |
| ZOLADEX..... | 357 |
| zoledronic acid intravenous solution..... | 357 |
| zoledronic acid-mannitol-water..... | 357 |
| zoledronic ac-mannitol-0.9nacl..... | 357 |
| ZOLINZA..... | 347 |
| ZONISADE..... | 289 |
| zonisamide..... | 289 |
| ZORTRESS ORAL TABLET 1 MG..... | 357 |
| ZTALMY..... | 348 |
| ZURZUVAE..... | 349 |
| ZYDELIG..... | 350 |
| ZYKADIA..... | 351 |
| ZYNLONTA..... | 18, 19 |
| ZYNYZ..... | 18, 19 |
| ZYPREXA RELPREVV..... | 352 |